Current landscape of innovative drug development and regulatory support in China.

Introduction

Innovative drug development has become a central focus of the global pharmaceutical industry, driven by advancements in biomedical technologies, regulatory innovations, and unmet medical needs. Across major global markets, such as the United States and Europe, significant advancements have been achieved in diverse areas of pharmaceutical innovation, encompassing novel therapeutic platforms, breakthroughs in precision medicine, and the integration of cutting-edge technologies, such as artificial intelligence, as well as the application of real-world evidence in drug development. 1 – 7 Leading regulatory agencies like the U.S. FDA and European Medicines Agency (EMA) have implemented innovative approaches, such as expedited approval pathways, to facilitate the development and commercialization of these therapies. 8 – 13 Additionally, both agencies have expanded their global influence through collaborations like Project Orbis, 14 which allows simultaneous reviews of cancer treatments by multiple regulatory bodies, 15 – 19 and the establishment of the African Medicines Agency (AMA), 20 based on the EMA’s model, which enhances regulatory capacity across Africa. 21 – 25 Simultaneously, emerging markets, such as China, have intensified their efforts to compete on a global scale, aligning regulatory frameworks with international standards and focusing on advancements in innovative pharmacological developments.

In parallel with global advancements, China has emerged as a pivotal player in the pharmaceutical industry, transitioning from a generics-focused market to one increasingly driven by innovation. 26 – 29 The evolution of China’s regulatory framework has been pivotal in facilitating this progress. Beginning with the establishment of the State Drug Administration (SDA) in 1998 30 , 31 and its transformation into the National Medical Products Administration (NMPA) in 2018, 31 , 32 China has progressively modernized its regulatory system. Guided by principles of scientific rigor and efficiency, NMAP has supported the China’s shift towards a more innovation-driven pharmaceutical industry. Major regulatory changes has been implemented to align with international standards, including streamlining its drug approval pathways and adopting International Council for Harmonisation (ICH) guidelines. 1 , 33 – 37 The NMPA has been central to the efforts and initiatives such as the “Major New Drug Development” National Science and Technology Project and the “Drug Regulatory Science Action Plan” which have provided strong support for innovative drug research and development. 38 , 39 These measures have not only accelerated the review and approval of new drugs but also fostered the development of advanced therapeutic approaches, such as cell and gene therapies, further integrating China into the global pharmaceutical ecosystem. 40 – 43

China’s progress in innovative drug development has been further driven by a combination of increased R&D investment, advancements in clinical trial efficiency, and the emergence of globally competitive therapies. Between 2019 and 2023, China’s pharmaceutical industry witnessed a significant rise in Investigational New Drug (IND) applications and New Drug Applications (NDA), reflecting a rapidly growing pipeline of innovative therapies. 44 , 45 Notably, the acceleration of clinical trial approvals and the increasing integration of China into global multicenter studies underscore the country’s expanding role in global pharmaceutical innovation. 30 , 45 This progress is complemented by a sharp increase in the number of first-in-class drugs, next-generation biologics, and novel technologies like cell and gene therapies. 40 , 41 These achievements highlight China’s dual focus on addressing domestic public health challenges while significantly enhancing its role in global pharmaceutical innovation.

Despite China’s remarkable advancements, the global landscape of innovative drug development remains highly dynamic and competitive, with regions such as the United States and Europe continuing to lead in several key areas. The United States, driven by well-established regulatory frameworks such as the FDA’s Breakthrough Therapy Designation and Accelerated Approval pathways, continues to excel in the development of innovative therapies. 8 , 11 Europe continues to be a global hub for clinical research, and the EMA has made significant strides in harmonizing regulatory frameworks across member states, facilitating multi-country trials and promoting innovation. 2 , 46 – 48 However, the region faces challenges such as extended approval timelines and intricate administrative requirements, which could impact its ability to remain competitive in the rapidly advancing global pharmaceutical sector. In comparison, China’s strengths lie in its rapidly increasing clinical trial efficiency, policy-driven innovation ecosystem, and significant advancements in biopharmaceutical manufacturing capabilities. This evolving dynamic highlights the global interconnectivity of pharmaceutical R&D and the need for continued international collaboration to address unmet medical needs and advance drug innovation.

Looking ahead, the continued evolution of China’s innovative drug landscape will depend on its ability to sustain global competitiveness while addressing key challenges, such as regulatory alignment, investment in R&D, and enhancing clinical trial efficiency. Strengthening alignment with international regulatory standards and fostering deeper collaboration with global pharmaceutical companies can further enhance China’s integration into the global ecosystem. Meanwhile, the country’s focus on emerging technologies positions it as a critical player in addressing global health priorities. By leveraging its growing expertise in clinical trial efficiency, innovative drug manufacturing, and policy-driven support, China has the potential to contribute significantly to the development of life-saving therapies worldwide, particularly in areas such as cell-based therapies, exemplified by CAR-T therapy for cancer treatment, and gene therapy, where advancements in treating genetic disorders like thalassemia and hemophilia have garnered global attention.

This review systematically examines China’s progress in innovative drug development and regulation from 2019 to 2023, placing it within a global context. The article explores key aspects such as Investigational New Drug (IND) and New Drug Application (NDA) processes, advances in clinical trials, and evaluations of cutting-edge technologies and therapies. Additionally, it provides an international comparison of regulatory efficiency, investment trends, and scientific innovation, with a focus on the United States and European Union. This review highlights China’s achievements and challenges within the global context, offering insights into the evolving pharmaceutical landscape. It serves as a resource for policymakers, researchers, and industry leaders aiming to advance innovation and address global health needs.

Current status of innovative drug development and approval in China within a global context

Definition and classification of innovative drugs

According to the “Drug Administration Law of the People’s Republic of China,” the “drugs” include TCM, chemical drugs, and biologics. 49 In August 2015, the State Council issued the “Opinions on Reforming the Review and Approval System for Drugs and Medical Devices,” which categorized drugs into innovative drugs and generic drugs. 50 In parallel, similar reforms have been implemented for medical devices, including the introduction of the “Special Approval Procedure for Innovative Medical Devices,” which accelerates the approval process for breakthrough devices with significant clinical value, further supporting innovation in this sector.

The definition of innovative drugs has been modified from the erstwhile criterion of “drugs not previously introduced to the Chinese market” to “drugs not yet introduced to the global market”. This alteration has broadened the scope of Chinese innovative drugs from being “novel to China” to being “novel to the world.” 50 To encourage new drug development, ensure rigorous review and approval processes, enhance drug quality, and promote industrial upgrades, the NMPA has proactively improved the drug registration classification system. Chemical drugs are now stratified into five categories, preventive or therapeutic biologics into three classes, and TCM into four classes. Category 1 drugs in each classification represent innovative drugs. 51 – 54 As illustrated in Table 1 , the precise definitions and classifications of Category 1 Innovative Drugs for TCM, chemical drugs, and biologics are delineated. Unless explicitly stated otherwise, the term “innovative drugs” in this paper typically denotes drugs recognized as Category 1 under the prevailing “Drug Registration Administrative Measures,” including TCM, chemical drugs, and biologics, distinguishing them from new drugs, which also include modified new drugs and other types. Table 1 Definitions and classifications of Category 1 innovative drugs in China Innovative drugs Definition Subcategories Category 1 chemical drugs Innovative drugs that have not been marketed domestically or internationally. These drugs contain new, structurally defined compounds with pharmacological activity and clinical value. 16 Category 1 preventive biological products (vaccines) Vaccines that have not been marketed domestically or internationally. 17 1.1 Vaccines for diseases with no effective preventive measures. 1.2 Vaccines developed from new antigen forms based on existing marketed vaccines. 1.3 Vaccines containing new adjuvants or novel adjuvant systems. 1.4 Multivalent or combined vaccines containing new antigens or new antigenic forms. 17 Category 1 therapeutic biological products Therapeutic biological products that have not been marketed domestically or internationally. 17 Category 1 traditional Chinese medicines (TCMs) New TCM formulations not included in the National Drug Standards, Drug Registration Standards, or the “Ancient Classical Formula Directory” issued by national TCM authorities. These formulations must have clinical value and not be marketed internationally. 18 1.1 TCM compound formulations. 1.2 Extracts and their preparations derived from single substances such as plants, animals, or minerals. 1.3 New medicinal materials and their preparations. 18

Expanding on this framework, it is important to compare China’s classification of innovative drugs with the standards established by international regulatory authorities such as the United States FDA and the EMA. In the U.S., according to the standards set by the FDA, innovative drugs encompass both New Molecular Entities (NMEs) and new products approved through a Biologics License Application (BLA). 55 – 61 NMEs refer to chemical or biological drugs that contain an active moiety never before approved by the FDA, emphasizing the novelty of the molecular structure or mechanism of action. 62 – 66 These drugs are evaluated under the New Drug Application (NDA) pathway. In addition to NMEs, biologics approved through BLAs, including monoclonal antibodies, therapeutic proteins, vaccines, gene therapies, and cell-based therapies, are also recognized as innovative drugs. 67 – 71 These biologics embody groundbreaking advancements in therapeutic development, offering targeted and highly specific mechanisms of action to address complex and unmet medical needs. By leveraging the intricacies of biological systems, biologics have revolutionized treatments for cancers, autoimmune diseases, genetic disorders, and infectious diseases, often providing solutions where traditional small-molecule drugs have limited efficacy. 72 – 78 Both NMEs and BLAs undergo rigorous FDA evaluations to ensure safety, efficacy, and manufacturing consistency. This dual framework reflects the FDA’s commitment to fostering innovation across a wide spectrum of pharmaceutical and biological products, providing a regulatory foundation for advancing treatments for unmet medical needs.

The EMA defines an innovative medicine as “a medicine that contains an active substance or combination of active substances that has not been authorized before.” 79 This definition emphasizes the novelty of the active components in the therapeutic product. 80 – 85 The EMA does not have a specific classification system for innovative drugs like the FDA’s NMEs. Instead, innovation is assessed through the potential therapeutic benefits, addressing unmet medical needs, and the clinical significance of the product. Drugs and therapies that meet these criteria can access EMA programs such as Priority Medicines Scheme (PRIME) 86 – 90 and Accelerated Assessment, 91 – 94 which are designed to support the development and authorization of innovative treatments. These efforts aim to foster the development of new treatments that address unmet medical needs within the European Union.

A key distinction between China’s regulatory framework and that of the FDA and EMA lies in their respective priorities and approaches to innovative drug classification. The NMPA’s system aims to align with international standards while simultaneously fostering domestic innovation by providing incentives for local entities to develop novel drugs that can compete globally. This dual emphasis ensures the integration of Chinese innovation into the global pharmaceutical landscape while fostering local research and development. In contrast, both the FDA and EMA adopt classification systems that focus on therapeutic and molecular uniqueness, independent of the drug’s origin. For instance, the FDA’s NMEs and EMA’s innovative drug evaluation system focus on the drug’s novelty and clinical benefits.

Another significant difference lies in the treatment of TCM. China’s framework explicitly integrates TCM within its classification of innovative drugs, recognizing its cultural and industrial significance. This approach is unique to China and highlights a region-specific priority not shared by Western systems. Neither the FDA nor EMA includes traditional or herbal medicines in their primary innovation frameworks, as their focus remains on molecularly defined and evidence-based therapeutic products. These differences underscore China’s efforts to balance its domestic priorities with international competitiveness, while the FDA and EMA adopt a more universal and origin-neutral approach to defining and regulating innovative drugs.

IND applications and approvals for innovative drugs: China’s role in the global landscape

As depicted in Fig. 1a , the number of INDs registration applications of innovative drug accepted by the NMPA has increased annually over the last five years. 95 – 99 The count of accepted applications from 688 in 2019 surged to 2298 in 2023, marking a compound annual growth rate (CAGR, calculated by dividing the ending value by the beginning value, then taking the result to the power of the reciprocal of the number of years, and finally subtracting 1) of 35.19% (Fig. 1a ). Similarly, the number of approvals of innovative drug IND applications also increased from 627 in 2019 to 1918 in 2023, with a CAGR of 32.25% (Fig. 1a ). In 2023, the NMPA accepted a total of 2997 new drug IND applications, covering 1650 products. Among these, 2298 applications were for innovative drugs, corresponding to 1257 products, which accounted for 76.18% of the total 1650 products (Fig. 1b ). In 2023, the NMPA also approved for 2461 IND applications (covering 1403 products), with 1918 being innovative drug INDs (covering 1089 products), accounting for 77.62% of the total IND product count (Fig. 1c ). Fig. 1 Overview of IND applications and approvals for innovative drugs in China from 2019 to 2023. a Number of innovative drug IND applications and approvals from 2019 to 2023, along with their respective growth rates. b Number and proportion of innovative drug varieties within the total drug varieties in IND applications of 2023. The groups are classified as: all drugs, chemical drugs, preventive biologics (vaccine), therapeutic biologics (TB), and TCM. c Number and proportion of innovative drug varieties within the total drug varieties in IND approvals of 2023. d Number of chemical drug, vaccine, TB and TCM among innovative drug IND applications from 2019 to 2023. e Number of chemical drug, vaccine, TB, and TCM among approved innovative drug INDs from 2019 to 2023. Data for this figure were derived from 2019 - 2023 Annual Drug Evaluation Reports published by CDE, NMPA. 95 – 99

Regarding the development of innovative chemical drugs, from 2019 to 2023, a total of 4821 innovative chemical drug IND applications were accepted (552; 721; 1134; 1,046; and 1368 per annum, respectively) (Fig. 1d ). In 2023, 1368 innovative chemical drug IND applications (covering 600 products) were accepted, representing a 30.78% year-on-year increase compared to the previous year, constituting 72.38% of all chemical drug IND products that year (Fig. 1b ). From 2019 to 2023, 4342 innovative chemical drug INDs were approved/suggested for approval (493; 694; 994; 1014; and 1147 per annum, respectively) (Fig. 1e ). In 2023, 1147 innovative chemical drug INDs (513 products) were approved/suggested for approval, representing a year-on-year increase of 13.12% compared to the previous year, accounting for 75% of all approved chemical drug IND products that year (Fig. 1c ).

Regarding innovative preventive biologics (vaccine), from 2019 to 2023, 95 innovative preventive biologics IND applications were accepted (2; 5; 26; 21; and 43 per annum, respectively) (Fig. 1d ). In 2023, 43 innovative preventive biologics IND applications (34 products) were accepted, representing a year-on-year increase of 104.76% compared to the previous year, accounting for 60.71% of all preventive biologics IND products that year (Fig. 1b ). From 2019 to 2023, 89 innovative preventive biologics INDs were approved/suggested for approval (5; 4; 24; 18; and 31 per annum, respectively) (Fig. 1e ). In 2023, 31 innovative preventive biologics INDs (27 products) were approved/suggested for approval, representing a year-on-year increase of 72.22% compared to the previous year, accounting for 58.70% of all approved preventive biologics IND products that year (Fig. 1c ).

Regarding innovative therapeutic biologics, from 2019 to 2023, 2350 innovative therapeutic biologics IND applications were accepted (119; 273; 617; 627; and 833 per annum, respectively) (Fig. 1d ). In 2023, 833 innovative therapeutic biologics IND applications (576 products) were accepted, representing a year-on-year increase of 32.85% compared to the previous year, accounting for 82.64% of all therapeutic biologics IND products that year (Fig. 1b ). From 2019 to 2023, 1761 innovative therapeutic biologics INDs were approved/suggested for approval (115; 221; 513; 553; and 695 per year, respectively) (Fig. 1e ). In 2023, 695 innovative therapeutic biologics INDs (510 products) were approved/suggested for approval, representing a year-on-year increase of 25.68% compared to the previous year, accounting for 82.79% of all approved therapeutic biologics IND products in 2023 that year (Fig. 1c ).

Regarding innovative TCMs, from 2019 to 2023, 154 innovative TCM IND applications were accepted (15; 17; 44; 39; and 54 per year, respectively) (Fig. 1d ). In 2023, 54 innovative TCM IND applications (47 products) were accepted, representing a year-on-year increase of 38.46% compared to the previous year, accounting for 69.12% of all TCM IND products that year (Fig. 1b ). From 2019 to 2023, 127 innovative TCM INDs were approved/suggested for approval (14; 24; 28; 30; and 45 per year, respectively) (Fig. 1e ). In 2023, 45 innovative TCM INDs (39 products) were approved/suggested for approval, representing a year-on-year increase of 50.00% compared to the previous year, accounting for 68.42% of all approved TCM IND products in 2023 that year (Fig. 1c ).

The statistics presented above include both conventional medicines and TCMs, as TCMs play an integral role in China’s pharmaceutical innovation. However, it is important to note that TCMs are regulated separately under the NMPA and are not treated as a distinct category by the FDA or the EMA. These regulatory agencies do not specifically categorize TCMs in their drug approval processes. Therefore, the data reflects the progress of both conventional medicines and TCMs in China, with a clear distinction between the two. Therefore, when comparing statistics of China to those of its counterparts, the differing regulatory frameworks and conditions should be taken into account.

The substantial increase in the number of IND applications and approvals for innovative drugs in China reflects the country’s rapid advancements in pharmaceutical research and development. This growth demonstrates China’s emergence as a significant contributor to global drug innovation, with its IND process increasingly integrated into international clinical research efforts. The rising efficiency of IND applications and approvals, coupled with the volume of innovative drug submissions, positions China as a competitive player in the global pharmaceutical landscape.

China’s IND process has become increasingly streamlined, demonstrating a significant improvement in regulatory efficiency. In 2023, the NMPA accepted 2298 innovative drug IND applications, reflecting a substantial increase compared to previous years. Of these, 1918 INDs were approved, representing an approval-to-submission ratio exceeding 80%. This robust performance highlights China’s increasing capacity for supporting innovative drug development. When compared globally, the U.S. FDA typically receives about 1500 new IND submissions annually, with around 91% of applications allowed to proceed without clinical holds. 100 – 102 Although the EMA does not have a direct IND system like the FDA or NMPA, its Clinical Trial Application (CTA) process receives significant volumes annually, with strong approval rates in line with global norms. 103 – 105 The sheer volume of IND applications accepted and approved by the NMPA highlights China’s rapidly expanding pharmaceutical ecosystem.

China’s increasing IND activity has also positioned it as a competitive hub for global clinical research. According to the ClinicalTrials.gov database which includes clinical studies involving human participants conducted worldwide, China has significantly increased its presence in global clinical trials, with 57,667 trials conducted as of 2023, accounting for 12.7% of global clinical trials, compared to the United States’ 162,523 trials (35.9%). 106 , 107 This marks a substantial rise for China, which had only conducted 702 trials as of 2003, representing just 3.2% of global trials at the time, compared to the United States’ 11,915 trials (54.7%). 106 , 107 By 2013, the gap had begun to narrow, with China conducting 16,122 trials (9.5% of global trials), while the United States conducted 73,634 trials (43.4%). 106 , 107 While the U.S. remains the dominant force, its global share has steadily declined as countries like China have emerged as key players. Unlike the U.S., which benefits from a long-established infrastructure and strong R&D investments, China’s growth has been driven by streamlined regulatory processes, government incentives, and an expanding clinical trial ecosystem.

China has surpassed Europe in clinical trial activity, reflecting its rapid growth and increasing global competitiveness. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA) and IQVIA, Europe’s share of commercially sponsored clinical trials dropped from 22% in 2013 to 12% in 2023, 108 – 110 reflecting a sharp decline over the past decade. The reduction may be due to fragmented regulatory frameworks following Brexit and the relocation of the EMA from the UK to Holland, which has caused disharmonization in clinical trials across European countries. 111 Additionally, the COVID-19 pandemic has further exacerbated these challenges by disrupting trial operations, approval processes, and patient recruitment. 112

New strategies to address the challenges brought about by the disharmonisation of clinical trials following Brexit, the relocation of the EMA, and the impact of COVID are being developed, with promising results aimed at improving the regulatory environment and ensuring more efficient trial operations in Europe. 113 In contrast, China has significantly expanded its share of commercially sponsored clinical trials, increasing from 9% in 2018 to 18% in 2023. 108 – 110 This shift is further supported by collaborative efforts between multinational pharmaceutical companies and Chinese research institutions, leveraging the country’s streamlined IND processes and expanding R&D capabilities.

NDA applications and approvals for innovative drugs in China and international markets

As illustrated own in Fig. 2 , over the past five years, the number of New Drug Applications (NDAs) of innovative drug accepted by the NMPA has significantly increased. 114 – 117 The annual number of accepted applications has escalated from 30 in 2019 to 133 in 2023, with a CAGR of 45.11% (Fig. 2a ). The number of approved innovative drugs also significantly uptick, with the annual number of approvals rising from 20 in 2019 to 66 in 2023 (Fig. 2a ). In terms of variety number of drugs, 138 innovative drug varieties were approved in total over the 5-year period, with the annual number of approvals increasing from 10 products in 2019 to 40 products in 2023, resulting in a CAGR of 41.42% (Fig. 2c ). Fig. 2 Overview of NDA applications and approvals for innovative drugs in China from 2019 to 2023. a Number of innovative drug NDA applications and approvals from 2019 to 2023, along with their respective growth rates. b Number of NDA applications for chemical drugs, biological products (BP), and TCM among innovative drug NDA applications from 2019 to 2023, along with their respective growth rates. c Number of drug varieties of chemical drugs, BP, and TCM among innovative drug NDAs approved from 2019 to 2023, along with their respective growth rates. The total number of approved drug varieties each year is indicated by yellow-marked symbols and numbers. d Number and growth rate of out-licensing deals of Chinese innovative drugs. Data for this figure were derived from 2020 - 2023 Annual Report on the Progress of Clinical Trials for New Drug Registration in China published by CDE, NMPA. 114 – 117

The most notable increase in innovative drug registrations over the past five years was observed in biologics, which had a CAGR of 66% (Fig. 2b ). Biologics also experienced a significant increase in approved innovative drugs, exhibiting a CAGR of 68% (Fig. 2c ). In 2023, a total of 40 innovative drug varieties were approved for marketing, including 19 chemical drugs, 16 biologics, and 5 traditional Chinese medicines (Fig. 2c ). In terms of marketing authorization holder (MAH) status, 90.0% were held by domestic entities. From the perspective of therapeutic areas, the most prevalent among innovative drugs approved in 2023 was anti-cancer drugs, with 14 products, double the number approved in 2022. This was followed by anti-infective drugs, with 6 products. Additionally, two TCM products for dermatology and otorhinolaryngology were approved, along with one product each in the fields of gastroenterology, respiratory medicine, and neuropsychiatry. 95

A comprehensive inventory of Category 1 innovative drugs approved by the NMPA from 2018 to 2023 is shown in Table S1 . In the first half of 2024 (January to June), according to data from the NMPA, 26 new drugs were approved, including 15 chemical drugs, 8 biologics, and 3 TCM products (Table S2). This represents an increase from the corresponding period in 2023 (24 drugs).

The rapid growth in NDA applications and approvals for innovative drugs in China underscores the significant strides made in the country’s pharmaceutical sector over the past five years. Biologics have emerged as the leading category driving this growth, with a remarkable annual growth rate. Additionally, oncology drugs dominate the therapeutic focus of approved NDAs, reflecting global trends in prioritizing high-burden and unmet medical needs. This aligns with China’s broader strategy of fostering domestic innovation to meet public health challenges, while also position China as a growing force in the global pharmaceutical landscape.

The FDA consistently led the global regulatory agencies in approving innovative drugs throughout the five-year period. As shown by Fig. 2d , starting with 48 approvals in 2019, 118 the number steadily increased, reaching 55 approvals in 2023. 1 , 119 , 120 This highlights the FDA’s robust capacity for drug evaluation and approval, maintaining its position as the leading regulatory body globally. Additionally, the FDA’s integration of programs like Breakthrough Therapy Designation 121 – 126 and Accelerated Approval 8 , 127 – 131 pathways continues to incentivize the rapid development of treatments targeting unmet medical needs, particularly in areas such as oncology and rare diseases. 132 – 138

Despite its leadership, the FDA faces challenges in sustaining approval growth. The relatively flat trajectory in innovative drug approvals may reflect constraints in the R&D ecosystem, including the high costs of drug development, and the lengthy timelines required for clinical trials. The FDA’s emphasis on robust clinical evidence reflects its commitment to ensuring the safety and efficacy of approved therapies. 139 While this approach minimizes risk, it may also extend the timeline for novel therapies seeking approval compared to more flexible regulatory frameworks emerging in other regions. The FDA’s focus on global therapeutic impact, however, continues to position it as the gold standard in regulatory, and its emphasis on post-marketing surveillance ensures safety while supporting innovation.

The EMA has shown a moderate performance in innovative drug approvals compared to the FDA, with approvals fluctuating between 30 in 2019 and peaking at 54 in 2021, before falling to 39 in 2023 (Fig. 2d ). 2 , 140 This variability reflects the challenges within Europe’s regulatory framework, where diverse national systems, extended timelines, and intricate clinical trial requirements can sometimes hinder timely access to the market. Unlike the FDA, which operates under a centralized model, the EMA’s coordination across 27 member states introduces additional layers of complexity, potentially deterring global pharmaceutical companies from prioritizing the European Union (EU) as a primary launch market for new drugs. 140 , 141 The impact of Brexit on the EMA functionality has led to considerable changes in its operational structure. As a result of the United Kingdom’s departure from the European Union, the EMA has faced increased challenges in regulatory coordination, particularly in terms of the alignment of approval timelines for medicines. The relocation of the EMA’s headquarters from London to Amsterdam has further compounded these difficulties, leading to delays in decision-making processes and disruptions in the approval of new drugs. These changes have necessitated new frameworks for regulatory cooperation among EU member states, thereby adding additional complexities to the approval system. 142 The EMA in 2024 focused on accelerating approvals, conditional marketing authorizations, and international collaboration to facilitate the timely market entry of innovative medicines while ensuring their safety and effectiveness, particularly in addressing public health needs and rare diseases. 143

However, the EMA is generally more restrictive than the FDA in drug approvals, as seen in cases like Aducanumab 144 – 149 and Lecanemab . 150 – 155 While the FDA often utilizes accelerated approval pathways based on surrogate endpoints, the EMA requires more robust clinical evidence demonstrating clear patient benefits. For example, the FDA approved Aducanumab despite concerns over its efficacy, whereas the EMA rejected it due to insufficient proof of meaningful clinical improvement. 156 Similarly, the EMA has taken a more cautious approach with Lecanemab , 157 emphasizing a thorough risk-benefit analysis before approval. This reflects the EMA’s stricter regulatory standards and focus on long-term safety.

In terms of evidence requirements, the NMPA tends to follow a regulatory approach that shares some similarities with the FDA, especially in regard to expedited approval pathways. This can sometimes involve using surrogate endpoints or more limited clinical data, particularly in areas like oncology and rare diseases. At the same time, the NMPA is also gradually refining its regulatory processes, which may involve placing greater emphasis on clinical data and safety assessments, somewhat in line with practices seen in the EMA. However, it’s worth noting that the approach of the NMPA can vary depending on the specific therapeutic area or drug under consideration. In general, while the NMPA’s regulatory approach may reflect aspects of both the FDA and EMA, it is continuously evolving to adapt to the changing landscape of drug approval and patient safety.

Building on the observations above, the comparative trends in drug approvals across China, the FDA, and the EMA reflect broader shifts in global pharmaceutical dynamics. China’s focus on biologics and oncology reflects alignment with global trends prioritizing high-burden therapeutic areas and addressing unmet medical needs. The rapid increase in innovative drug approvals by the NMPA demonstrates the impact of regulatory changes aimed at enhancing efficiency and fostering domestic innovation. These efforts have included the integration of international standards to align with global best practices while maintaining a focus on addressing the specific healthcare needs of China’s population. This dual strategy highlights China’s commitment to advancing pharmaceutical innovation and improving public health outcomes, with a growing emphasis on strengthening its role in the global regulatory landscape.

Overall, these trends indicate an intensely competitive global landscape where regulatory frameworks are increasingly required to balance the dual imperatives of fostering innovation and ensuring patient safety. China’s rapid ascent reflects its growing ambition to play a more prominent role in the global regulatory ecosystem, while the FDA and EMA face pressures to address emerging inefficiencies to sustain their established positions as benchmarks for drug evaluation and approval. These developments underscore the importance of international harmonization and collaboration in maintaining a balanced and innovative pharmaceutical ecosystem.

Looking ahead, improving regulatory processes and enhancing efficiency will be crucial for adapting to the evolving pharmaceutical landscape. For China, expanding its focus beyond the volume of approvals to include a higher proportion of globally novel, first-in-class therapies would reinforce its position as a leader in both regulatory efficiency and pharmaceutical innovation. For the FDA and EMA, continued modernization of their regulatory frameworks will be important to maintain their competitiveness, particularly in addressing the increasing complexity of biologics, gene therapies, and precision medicine. These efforts will play a critical role in shaping the future of global drug development and ensuring equitable access to groundbreaking therapies.

As global drug development becomes increasingly complex, regulatory systems must adapt to ensure timely access to new therapies. Regulatory reliance refers to the practice where smaller or developing regulatory agencies depend on the review standards and approval decisions of larger, more experienced institutions, such as the FDA and EMA, during the drug approval process. This approach not only enhances approval efficiency and avoids redundant reviews but also ensures that drugs can rapidly reach the market, especially in complex areas such as biologics, gene therapies, and precision medicine. Many countries and regions, particularly developing nations, have started to adopt this model. 158

In the global drug regulatory system, the FDA and EMA are key leaders. They establish rigorous standards and processes, driving the standardization of global drug approvals. The review results and approval standards set by these two agencies are often used as references by other national regulatory bodies. For instance, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), after Brexit, has further strengthened its cooperation with the FDA and EMA, thereby promoting the trend of regulatory reliance and ensuring smooth drug approval processes. 159

In China, the NMPA has gradually absorbed the advanced experiences of the FDA and EMA in its drug approval process, particularly in modernizing the drug review and approval procedures. The NMPA has also strengthened its collaboration with international regulatory agencies to improve the efficiency of drug approvals and ensure the safety and efficacy of medications. As the NMPA’s position in the global drug regulatory system continues to grow, it may further enhance its cooperation with other regulatory bodies in the future, adopting regulatory reliance models to accelerate the drug approval process and improve patient access to treatments.

In summary, regulatory reliance, as an international collaboration model, is becoming widely adopted in the global drug regulatory field. It not only facilitates efficient approval processes but also plays a crucial role in ensuring the timely market availability of innovative therapies and equitable access for patients worldwide.

Progress and global positioning of China’s pharmaceutical innovation

R&D investment, new technologies, and new targets in China compared to global trends

The R&D investment, pipeline layouts, and development trends of innovative drug development in China over the past five years are shown in Fig. 3 . The pharmaceutical industry’s R&D investment in China has been continuously increasing. 160 In 2019, 2020, and 2021, the internal R&D expenditures of the pharmaceutical manufacturing industry amounted to 60.96 billion yuan (approximately 9.5 billion USD), 78.46 billion yuan (approximately 12.1 billion USD), and 94.24 billion yuan (approximately 14.5 billion USD), respectively, representing a growth of 54.59% from 2019 to 2021 160 (Fig. 3a ). The R&D investment intensity of the pharmaceutical industry consistently exceeded the national average R&D investment intensity over these three years and continued to increase. Additionally, in 2022–2023, three Chinese companies, Sinopharm, Hengrui Medicine, and BeiGene, were ranked among the top 25 global pharmaceutical companies by pipeline size, demonstrating China’s emergence in global drug innovation. 160 Fig. 3 R&D investment, new technologies, and new targets in China’s innovative drugs. a Internal R&D expenditure in China’s pharmaceutical manufacturing industry from 2019 to 2021, along with the year-on-year growth rates. 160 b Comparison of the number and growth rates of First-in-Class (FIC), Fast-Follower (FF), Me-Too and all drugs under development in China in 2021 and 2024. c Number and proportion of various drug types under development in China in 2021 (inner ring) and 2024 (outer ring). 44 d Number of drug pipelines in China and globally from 2019 to 2023, along with annual growth rates. 177 , 178

As of July 1, 2021, Chinese pharmaceutical companies had 2251 drugs under development across all therapeutic areas, including small molecules, monoclonal antibodies, recombinant proteins, vaccines, and next-generation drugs which encompass cell therapies, gene therapies, antibody-drug conjugates (ADCs), bispecific/multispecific antibodies, and nucleic acid-based products (Figs. 3b and c ). 44 By January 1, 2024, the number of innovative products in development by Chinese pharmaceutical companies had nearly doubled from 2251 in 2021 to 4391 161 (Fig. 3b ). Next-generation products grew rapidly, increasing from 613 to 1709 (179% growth), raising their share of the total pipeline from 27% in 2021 to 39% in 2024, surpassing the proportion of small-molecule drugs (Fig. 3c ).

Based on their level of innovation, these drugs were categorized as First-in-Class (FIC), Fast-Follower (FF), or Me-Too, following internationally recognized conventions. FIC drugs refer to those that introduce a completely novel therapeutic mechanism or target, offering groundbreaking advancements in treatment and addressing unmet medical needs. FF drugs are developed after FIC drugs, leveraging similar mechanisms of action but with modifications or improvements, such as enhanced efficacy, safety, or patient convenience. Me-Too drugs, on the other hand, share the same mechanism of action as existing drugs but generally replicate these with minor modifications, focusing on market competition rather than significant innovation. 162 – 174

Among the 2251 drugs, 418 were FIC, 473 were FF, and 923 were Me-Too 44 (Fig. 3b ). The growth rate of FIC drugs (increasing from 418 to 836, 100% growth) and FF drugs (increasing from 473 to 1053, 123% growth) outpaced that of Me-Too drugs (increasing from 923 to 1803, 95% growth) 161 (Fig. 3b ). Next-generation products now account for the majority of FF pipelines and FIC pipelines. Within next-generation products, cell therapies continue to dominate, while bispecific/multispecific antibodies and ADCs are the second and third largest categories. 161 , 175 , 176 Oncology was the most active therapeutic area, accounting for 55% of all drugs, followed by infectious diseases, which made up 11%. Among FIC drugs, oncology accounted for 67% of the total. 44

Regarding new targets and target combinations, the number of targets increased by 295 from 375 in 2021 to 670 in 2024. The integration of new technologies has also propelled a significant rise in multi-target combinations, which expanded from 207 in 2021 to 454 by 2024. 161 An analysis of the top 10 oncology targets in 2021 and 2024 reveals that seven targets remained consistently present in both lists, with CD19 and HER2 maintaining their positions as the top two targets. 161 A closer examination of the top ten oncology targets in these years reveals that seven of them (CD19, HER2, BCMA, PD-1, EGFR, PD-L1, CD19/CD22) have remained consistent, with CD19 and HER2 continuing to hold the top spots. Furthermore, the advent of novel therapeutic targets such as CLDN18.2, CD7, and CD276 (B7-H3) is largely propelled by the progress of cutting-edge technologies, encompassing cell therapies and ADCs. In the field of non-oncological diseases, there has been a persistent increase in candidate drugs targeting SARS-CoV-2 associated targets. Additionally, drugs targeting GLP1R, GIPR, and GCGR are progressively demonstrating promise in improving the first generation of drugs. 161

According to Pharmaprojects data from Citeline in April 2023, 177 , 178 China currently has 5402 drug pipelines (drug candidates in development), a 23.22% increase from 2022, far exceeding the global growth rate of 5.88% (Fig. 3d ). Meanwhile, China is also catching up in the development of innovative drug candidates, with 1457 candidates in 2022, ranking second globally. During the same year, 73 new drugs were launched worldwide, including 74 New Active Substances (NAS). As of March 2022, China’s share of NAS is steadily increasing, with 16 NAS launched, 177 , 178 accounting for 21.6% of the total new drugs.

The rapid growth in R&D investment, pipeline expansion, and technological advancements in China’s pharmaceutical sector over the past five years highlights the country’s accelerating role in global drug innovation. With R&D spending outpacing national averages and a significant increase in innovative products under development, China has emerged as a strong contender in pharmaceutical innovation. The shift towards next-generation products, such as cell therapies, ADCs, and bispecific antibodies, has reshaped the drug development landscape in China, 44 , 179 – 186 with these cutting-edge modalities accounting for a growing share of the overall pipeline. The focus on oncology as the dominant therapeutic area, alongside the rise in FIC and fast-follower FF drugs, underscores China’s alignment with global priorities of addressing high-burden and unmet medical needs.

The significant increase in new targets and multi-target combinations further demonstrates the integration of advanced technologies into China’s drug discovery efforts. The emergence of novel targets such as CLDN18.2 and CD276, coupled with advancements in fields like antibody-based therapies and nucleic acid drugs, reflects the country’s capability to compete in the rapidly evolving pharmaceutical landscape. Furthermore, China’s contribution to the global launch of NAS is steadily increasing, accounting for 21.6% of NAS in 2022, which underscores its growing influence in introducing globally relevant therapies.

Globally, the United States continues to lead global pharmaceutical R&D, driven by its well-established infrastructure, significant private-sector investment, and focus on cutting-edge innovation. According to IQVIA’s report on global R&D trends, as of 2022, U.S.-based companies accounted for over 40% of global R&D pipelines, 187 maintaining their dominance over the past 15 years. This leadership extends to new therapeutic modalities, with the U.S. consistently spearheading advancements in cell and gene therapies, as well as next-generation biologics, such as mRNA vaccines and ADCs. Moreover, the United States has shown resilience in sustaining investment levels despite the global economic slowdown. While total life sciences investment in the U.S. decreased by 39% from its 2021 peak, the 2022 investment level still exceeded pre-pandemic benchmarks by 25%, reflecting the sustained confidence in the country’s pharmaceutical ecosystem. 187

In terms of innovative drug development, the United States also leads in the approval of first-in-class drugs and biologics, underpinned by regulatory pathways such as the FDA’s Breakthrough Therapy Designation and Accelerated Approval programs. 8 , 127 – 131 These frameworks encourage the rapid development of treatments targeting unmet medical needs, particularly in areas such as oncology and rare diseases, which remain the focus of nearly half of the U.S. R&D pipeline. 8 , 121 , 123 , 188 – 195 However, while the U.S. excels in fostering innovation and regulatory efficiency, the high costs of drug development and the increasing complexity of clinical trials remain challenges for its R&D productivity. Despite these barriers, the U.S. continues to set the benchmark for pharmaceutical innovation, reflecting its global influence in shaping the direction of drug discovery and development.

Europe’s position in global pharmaceutical R&D and innovation has faced increasing challenges, particularly in maintaining its competitive edge. Over the past decade, Europe’s share of global R&D pipelines has steadily declined, with its proportion falling from 31% in 2007 to 23% in 2022. 187 Although the absolute number of active R&D pipelines in Europe increased from 1327 in 2007 to 1655 in 2022, this growth has been outpaced by regions such as the United States and China, where significant investments and innovation-driven policies have expanded their respective shares. 187 This growth occurred post-Brexit, and the loss of infrastructure, such as EMA relocation from London to Amsterdam, may have had an impact on this trend. 196 China’s share of global R&D pipelines has increased significantly over the past 15 years, rising from 2% in 2007 to 15% in 2022, 187 demonstrating the rapid advancements made in China’s pharmaceutical R&D landscape. In addition, Europe’s average pharmaceutical investment in 2022 was approximately half of its peak in 2020. Despite some success in collaborative research initiatives and multi-country clinical trials, fragmented regulatory systems and slower processes than the U.S. 197 have hindered Europe’s ability to compete effectively on a global scale.

In addition to the declining share of global R&D pipelines, Europe faces ongoing challenges in maintaining its competitive position in pharmaceutical innovation. While the region remains active in therapeutic areas such as oncology and rare diseases, its pipelines include a relatively smaller proportion of first-in-class therapies compared to those of the United States and China, reflecting differences in innovation focus and development strategies. Furthermore, Europe’s longer regulatory timelines and fragmented approval processes have slowed the development of next-generation therapies, including cell and gene therapies, which have experienced significant growth in the U.S. and China. At the same time, China’s progress in pharmaceutical innovation has been bolstered by increasing investments, streamlined regulatory frameworks, and an active focus on cutting-edge technologies, enabling the country to expand its global R&D presence and challenge traditional leaders in the field.

Overall, China’s pharmaceutical R&D ecosystem has experienced significant growth, marked by increases in investment, pipeline expansion, and the rapid adoption of next-generation technologies. This progress has allowed China to emerge as an important player in global drug development, particularly in innovative modalities such as cell and gene therapies, ADCs, and bispecific antibodies. While the United States continues to lead the global landscape with its well-established infrastructure, strong focus on first-in-class therapies, and dominance in advanced therapeutic areas, China’s dynamic trajectory highlights its growing capacity to reshape global innovation. In contrast, Europe, despite its historical strengths in key areas like oncology and rare diseases, faces challenges from slower regulatory timelines and fragmented systems, which have limited its competitiveness against rapidly advancing regions. 197 These developments underline a rebalancing in global pharmaceutical R&D, as China increasingly asserts itself as a critical force shaping the future of drug innovation.

Advances in clinical trials for new drug registration: local progress and international participation

Registered clinical trials for new drugs

Over the past three years, the number of new drug clinical trials (NDCTs) and bioequivalence (BE) trials in China has grown year-on-year. 114 – 117 In 2023, the annual number of drug clinical trial registrations in China surpassed 4000 for the first time, reaching 4300, representing a 26.1% increase compared to 2022 (Fig. 4a ). In 2023, 2323 new drug clinical trials were registered (54.0%), representing an increase of approximately 17.7% compared to 2022 (1974 trials). Meanwhile, 1977 BE trials were registered (46.0%), an increase of approximately 37.7% compared to 2022 (1436 trials) (Fig. 4a ). Fig. 4 Clinical trials for new drug registration in China. a Number and growth rate of new drug clinical trials (NDCT) and bioequivalence (BE) trials in China from 2019 to 2023. b Proportion of Category 1 innovative drugs in NDCT in 2023 (left pie chart) and the proportion of chemical drugs, biological products, and TCM among Category 1 innovative drugs (right pie chart). c Time to initiate subject recruitment in NDCT from 2021 to 2023. d Time required for market approval for innovative drugs. The time to market is analyzed based on the date of the first clinical trial approval to the date of the market approval. The inner ring and outer ring of the combined ring chart represent the time to market of innovative drugs that approved for market release in 2022 and 2023, respectively. Data for this figure were derived from 2020 - 2023 Annual Report on the Progress of Clinical Trials for New Drug Registration in China published by CDE, NMPA. 114 – 117

Drug types, registration categories, varieties, and clinical trial phases

In 2023, among the registered new drug clinical trials, 1294 were dedicated to chemical drugs, 953 to biologics, and 76 to TCMs. 116 , 117 These figures align with trends from previous years, with a slight increase in TCM trials compared to 2022. Over recent years, chemical drugs and biologics have dominated new drug clinical trials, with chemical drugs comprising over half of the total, and biologics approximately 40%. The proportion of TCM trials in 2023 was 3.3%, mirroring the percentage from 2022 (3.1%).

In terms of registration categories, a total of 1606 trials were registered for Category 1 innovative drugs in 2023, accounting for 69.1% of the overall trials (1606/2323). Chemical drugs dominated with 53.7% (862/1,606) of the registered innovative drug trials (Fig. 4b ). Furthermore, there was a marked increase in the registration of clinical trials for cell and gene therapy (CGT) products, which rose to 81 in 2023, a nearly twofold increase from the 46 trials registered in 2022. These trials were predominantly concentrated on domestic Phase I anti-cancer drugs. The number of clinical trials for medical imaging drugs reached 14, the highest in recent years.

Regarding varieties and indications, clinical trials for Category 1 innovative drugs were predominantly aimed at oncology, accounting for 40.6% of the total (652/1606). As for innovative TCMs trials, they were primarily focused on five indication areas: respiratory, dermatology and otorhinolaryngology, cardiovascular, gastrointestinal, and neuropsychiatric disorders, accounting for approximately 80.3% of all TCM clinical trials. Encouraged by supportive policies for innovation, research into drugs for children, rare diseases, and niche areas such as medical imaging and radiopharmaceuticals has become more active. In terms of clinical trial phases, in 2023, there were 978 Phase I trials, 440 Phase II trials, 489 Phase III trials, and 62 Phase IV trials. 116 , 117 The proportion of trials in each phase remained consistent with 2022.

Over the past three years, China’s clinical trial landscape has experienced significant growth, with a notable increase in both NDCTs and BE studies. In 2023, the total number of registered drug clinical trials in China exceeded 4000 for the first time, marking a 26.1% rise compared to 2022. 198 This upward trend reflects China’s commitment to advancing pharmaceutical research and development. This expansion encompasses a diverse range of drug types, including chemical drugs, biologics, and TCMs. Innovative drug trials, particularly those in Category 1, have seen substantial growth, accounting for a significant portion of the overall trials. Additionally, there has been a marked increase in clinical trials for CGT products, indicating China’s dedication to pioneering advanced therapeutic modalities.

Globally, the clinical trial landscape has been evolving, with regions such as North America and China experiencing growth in trial activity. China’s share of global clinical trial activity reached 27.7% by 2022, reflecting its increasing prominence in the field. 199 – 201 This shift underscores the dynamic nature of global clinical research and the varying regional focuses on different therapeutic areas and phases of clinical development.

When comparing China’s clinical trial growth to global trends, several key distinctions emerge. China has experienced a significant increase in early-phase trials, particularly Phase I studies, underscoring its commitment to innovative drug development. This expansion is largely driven by domestic sponsors, who accounted for 91.7% of new registrations in 2023. 198 China’s increasing participation in global multicenter studies reflects its deeper integration into the international clinical research community. This involvement contributes to the diversification and globalization of clinical data, enhancing the robustness and applicability of research outcomes worldwide.

In summary, China’s clinical trial landscape has experienced significant growth, with a notable increase in both new drug clinical trials and bioequivalence studies. This growth positions China as a significant player in the global clinical trial landscape, contributing to the diversification and globalization of clinical data. However, challenges remain, including the acceptability of clinical trials conducted solely in China by regulatory authorities in the USA and Europe. For instance, Sintilimab, a PD-1 inhibitor, was approved in China but faced rejection by the FDA due to the reliance on data from the ORIENT-11 trial, which was conducted exclusively in China. 202 This case highlights the need for more diverse, multiregional clinical trials to meet international regulatory standards. Addressing these challenges will be crucial for China’s continued advancement in global clinical research.

Efficiency of clinical trial registration, review, and implementation

Clinical trial initiation and execution in China have demonstrated a marked improvement in efficiency. During the years 2021, 2022, and 2023, over half of the new drug clinical trials initiated subject recruitment within a six-month timeframe. In 2023, the proportion of trials that commenced subject recruitment within six months slightly increased to 56.3%, exhibiting a slightly upward trend from the 51.4% in 2021 (Fig. 4c ). An analysis of the geographical distribution of clinical trial sites revealed that trials conducted in areas with a higher density of leading sites exhibited a longer initiation period.

Upon analyzing the initiation of subject recruitment in the same year as the trial approval, 2023 exhibited a further reduction in initiation time compared to 2022, with an average time of 3.0 months (down from 3.3 months in 2022). The proportion of trials that initiated recruitment within six months then increased to 93.4% in 2023 (from 91.5% in 2022).

Analyzing upon examination of the interval from the initial approval of domestic clinical trials to the ultimate grant of marketing authorization for innovative drugs, the average time to market for innovative drugs approved in 2022 was 7.6 years, and in 2023 was 7.2 years. Among the innovative drugs approved for marketing in 2022, 10 products (47.6%) were brought to market within five years. In 2023, 21 innovative drugs (52.5%) were marketed within five years (Fig. 4d ). These findings suggest a trend towards accelerated drug development and regulatory processes, facilitating faster patient access to novel therapeutics.

China has made significant strides in enhancing the efficiency of its clinical trial processes. Recent changes have streamlined the approval timelines for clinical trial applications (CTAs). Previously, obtaining CTA approval could take two to three years; however, with the implementation of a 60-working-day “silent approval” mechanism, 30 , 203 – 205 applications are now approved by default if no response is received within this period. This acceleration has led to a notable increase in the number of innovative drugs entering the market.

The U.S. FDA has established review timelines for NDAs. Standard reviews are typically completed within 10 months, while priority reviews are expedited to a six-month timeframe. 206 , 207 The FDA offers expedited programs, such as Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review, to facilitate the development and review of drugs addressing unmet medical needs. 8 , 208 These programs can significantly reduce the time to market for critical therapies.

The EMA follows a centralized procedure for marketing authorization applications, with a standard review timeline of up to 210 active days, excluding clock stops when applicants prepare responses to questions. 209 The EU’s Clinical Trials Regulation, which came into application on 31 January 2022, aims to harmonize the assessment and supervision processes for clinical trials throughout the EU via the Clinical Trials Information System (CTIS). 105 , 210 This regulation seeks to streamline procedures and improve the environment for conducting clinical research across member states.

China’s recent changes have led to notable improvements in the efficiency of clinical trial processes, with reduced approval times and quicker trial initiations. The FDA maintains structured and predictable review timelines, with mechanisms to expedite reviews for priority medicines. The EMA’s centralized procedure offers a harmonized approach across EU member states, though its standard review timeline is longer compared to the FDA’s priority review process. While the FDA and EMA have established expedited pathways for critical therapies, China’s implementation of the “silent approval” mechanism represents a distinctive approach to accelerating clinical trial approvals.

In summary, each region has developed regulatory strategies to balance the need for timely access to new therapies with the imperative of ensuring safety and efficacy. China’s recent changes reflect a commitment to enhancing efficiency in clinical trial processes, positioning it as an increasingly significant player in the global pharmaceutical landscape.

Notable innovative drugs in China and international market

As delineated in Table 2 , the past 5 years have seen the inaugural approvals and continuous updates, including new indications, improved formulations, and line extensions, of therapeutic drugs in the fields of major public health diseases, malignant tumors, and other life-threatening or quality-of-life-impacting conditions. This has continuously driven the launch of new and high-quality drugs in the fields of rare diseases and pediatric medicine, meeting the clinical medication needs of patients. Notably, the number of vaccine products has significantly increased, ensuring diversity and coverage through a variety of technological approaches, including inactivated vaccines, adenovirus vector vaccines, and recombinant protein vaccines, providing effective prevention against diseases with significant public health impacts. Important breakthroughs have also been made in other vaccine areas, such as rotavirus and influenza vaccines, enriching the domestic vaccine portfolio and technological pathways, thereby enhancing public health prevention and control capabilities. Table 2 Notable innovative drugs approved in China in the past five years Product name Time of approval Manufacturer Indication Remark Chemical and Biotherapeutic Drugs Benvitimod Cream 05/31/2019 Guangdong Zhonghao Mild to moderate stable plaque psoriasis in adults Approved through the priority review and approval process. Ormutivimab Injection 01/25/2022 North China Pharmaceutical Passive immunization for adults exposed to rabies virus Approved through the priority review and approval process; First recombinant human anti-rabies monoclonal antibody in China. Tafolecimab Injection 08/16/2023 Innovent Biologics (Suzhou) Primary hypercholesterolemia and mixed dyslipidemia in adults First domestically developed PCSK9 monoclonal antibody inhibitor in China. Surufatinib Capsules (SULANDA) 12/30/2020 Hutchison Medipharma (Shanghai) Neuroendocrine tumors Approved through the priority review and approval process. Narlumosbart Injection 09/06/2023 Shanghai JMT Giant cell tumor of bone in adults Conditionally approved; First domestically developed RANKL-targeted drug. Sunvozertinib Tablets 08/23/2023 Dizal (Jiangsu) Locally advanced or metastatic non-small cell lung cancer in adults Conditionally approved; First domestic tyrosine kinase inhibitor targeting EGFR exon 20 mutations. Simnotrelvir Tablets/Ritonavir Tablets (co-packaged) 01/29/2023 Simcere (Hainan) Mild to moderate COVID-19 in adults Emergency review and conditional approval; Meets dynamic needs of China’s COVID-19 prevention efforts. Deuremidevir Hydrobromide Tablets 01/29/2023 Shanghai Wangshi Mild to moderate COVID-19 in adults Emergency review and conditional approval; Supports China’s COVID-19 prevention efforts. Leritrelvir Tablets 03/23/2023 Guangdong Zhongsheng Ruichuang Mild to moderate COVID-19 in adults Conditionally approved; First 3CL protease inhibitor approved in China. Coblopasvir Hydrochloride Capsules 02/12/2020 Beijing Kain-Gelin Chronic hepatitis C virus (HCV) infection in adults Approved through the priority review and approval process; First domestically developed broad-spectrum anti-HCV drug. Ainuovirine 06/23/2021 Jiangsu Hansoh Chronic hepatitis B in adults Approved through the priority review and approval process; First domestically developed small-molecule anti-hepatitis B drug. Ainomeptide Tablets 01/04/2023 Jiangsu Aide HIV-1 infection in treatment-naïve adults First domestically developed novel anti-HIV combination therapy. Spesolimab-sbzo Injection 12/14/2022 Boehringer Ingelheim International GmbH Generalized pustular psoriasis in adults Approved through the priority review process; Global simultaneous development and launch. Ritlecitinib Tosylate Capsules 10/19/2023 Pfizer Severe alopecia areata in adolescents and adults (12 years and older) Approved through the priority review process; First drug in China for adolescent alopecia areata; global simultaneous development and launch. Risdiplam Oral Solution 06/17/2021 Roche Spinal muscular atrophy (SMA) in patients 2 months and older Approved through the priority review process; Global simultaneous development and launch; First oral treatment for SMA. Siponimod Tablets 05/11/2020 Novartis Pharma AG Relapsing multiple sclerosis in adults Approved through the priority review process; Global simultaneous development and launch. Vericiguat Tablets 05/19/2022 Bayer Chronic heart failure in adults Approved through the priority review process; Global simultaneous development and launch. Pralsetinib Capsules 03/24/2021 Blueprint Medicines Corporation Locally advanced or metastatic non-small cell lung cancer in adults (NSCLC) Conditionally approved through the priority review process; RET (Rearranged during Transfection) inhibitor. Glofitamab Injection 11/08/2023 Roche Pharma (Schweiz) AG Relapsed or refractory diffuse large B-cell lymphoma in adults Conditionally approved through the priority review process; First bispecific CD3/CD20 antibody approved in China; globally co-developed and launched. Vaccines Inactivated COVID-19 Vaccine (Vero Cell) 12/30/2020 Sinopharm CNBG Beijing Prevention of COVID-19 Emergency review and conditional approval; First domestically approved inactivated COVID-19 vaccine. Inactivated COVID-19 Vaccine (Vero Cell) 02/05/2021 Sinovac Biotech (Beijing) Prevention of COVID-19 Emergency review and conditional approval; Second domestically approved COVID-19 vaccine. Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) 02/25/2021 CanSino Biologics Prevention of COVID-19 Emergency review and conditional approval; First domestically approved adenovirus vector COVID-19 vaccine. Inactivated COVID-19 Vaccine (Vero Cell) 02/25/2021 Sinopharm CNBG Wuhan Prevention of COVID-19 Emergency review and conditional approval. Recombinant COVID-19 Protein Vaccine (CHO Cell) 03/01/2022 Anhui Zhifei Longcom Prevention of COVID-19 Emergency review and conditional approval; First globally approved recombinant protein COVID-19 vaccine; First overseas clinical trial inspected by Chinese regulators. Oral Trivalent Live Attenuated Rotavirus Vaccine (Vero Cell) 04/17/2023 Sinopharm CNBG Lanzhou Prevention of infant diarrhea caused by rotavirus (types G1, G2, G3, G4, G9) First domestically developed trivalent rotavirus vaccine. Quadrivalent Influenza Virus Subunit Vaccine 05/12/2023 Jiangsu Zhonghui Yuantong Influenza virus infection in individuals aged 3 years and older First domestically developed quadrivalent influenza virus subunit vaccine. Cell and Gene Therapy Relmacabtagene Autoleucel Injection 09/01/2021 Shanghai, JW Therapeutics Relapsed or refractory large B-cell lymphoma in adults First domestically developed and approved Category 1 cell therapy product in China. Inaticabtagene Autoleucel Injection 11/07/2023 Tianjin Juventas Cell Therapy Relapsed or refractory B-cell acute lymphoblastic leukemia in adults Conditionally approved through the priority review process. Equecabtagene Autoleucel Injection 06/30/2023 Nanjing IASO Bio Relapsed or refractory multiple myeloma in adults Conditionally approved through the priority review process. TCM Innovative Drugs Ramulus Mori (Sangzhi) alkaloids tablets 03/27/2020 Beijing Wehand-Bio Type 2 diabetes First anti-diabetic TCM drug approved in the last decade. Icariin Soft Capsules 01/10/2022 Beijing Shenogen Hepatocellular carcinoma Conditionally approved through the priority review process; Class 1.2 TCM innovative drug. Yiqi Tongqiao Pills 09/14/2021 Tianjin Dongfang Huakang Seasonal allergic rhinitis (lung and spleen qi deficiency syndrome) TCM compound preparation based on clinical experience.

CGT products have emerged as innovative therapeutic options for an array of refractory and rare diseases. Several domestically developed CGT products have been approved for market, marking significant breakthroughs in this frontier field in China. The national regulatory framework, through the priority review and approval process, has facilitated the earlier market entry and clinical utilization of CAR-T products for the treatment of relapsed/refractory adult acute lymphoblastic leukemia and relapsed/refractory multiple myeloma to enter the market and clinical application earlier, allowing patients to benefit sooner.

China’s drug approvals are increasingly aligned with those in the US and Europe due to the adoption of international standards, accelerated approval pathways for globally approved drugs, and participation in global clinical trials. Simultaneous or near-simultaneous approvals are becoming more common, reflecting China’s integration into the global regulatory landscape. Additionally, local innovation is now influencing global markets, while regulatory reforms have reduced the need for duplicative trials, enabling greater reliance on global data. 211 , 212

In this section, we will focus on China’s recent advancements in pharmaceutical innovation, emphasizing key breakthroughs across various drug categories, including chemical drugs, therapeutic biologics, cell and gene therapies, and vaccines. These categories are further subdivided into therapeutic areas, such as oncology, cardiovascular diseases, public health diseases, and rare diseases. We will explore China’s progress in each area, providing a comprehensive overview of its achievements in drug development. In parallel, we will also discuss notable innovations from global markets, primarily focusing on advancements in the U.S. and Europe. This allows us to highlight not only China’s pharmaceutical progress but also the global context in which these advancements are unfolding. The section will culminate in a comparative analysis between China and the leading global players, examining the similarities and differences in drug development approaches, regulatory processes, and innovations.

For each of the categories mentioned, we will present a selection of significant drugs that showcase both China’s innovations and global advancements. These drugs were chosen based on their innovative mechanisms, their ability to address critical medical needs, and their regulatory achievements, such as being first-in-class or receiving expedited approvals. By highlighting these examples, we aim to emphasize the diversity and global nature of pharmaceutical progress, illustrating how innovations in China are aligned with and contribute to global healthcare. The selected drugs reflect key challenges and accomplishments in drug development, offering insight into the evolving landscape of pharmaceutical R&D across various regions. The diseases or conditions involved below are characterized by the emergence of novel therapeutic options, the potential for significant clinical benefit, or a large unmet medical need. This approach allows for a comprehensive comparison of the most impactful developments in the pharmaceutical sector, both in China and globally.

China’s highlights in innovative drugs

Chemical drugs

Psoriasis Treatment

First, in the field of psoriasis treatment, China has pioneered the approval of Benvitimod Cream (Table 2 ), the world’s first topical treatment for plaque psoriasis in nearly 20 years on a global scale. This drug is a Category 1 innovative drug of Chinese origin, characterized by a novel structure and mechanism of action, with independent intellectual property and multiple patents. 213 – 218 Initially approved in China, its approval journey highlights the effectiveness of China’s regulatory pathways. The drug underwent a priority review by the NMPA, which expedited its evaluation process due to its innovative nature and the unmet medical need it addressed. After receiving approval in China, it was subsequently approved by the FDA in the United States three years later, marking an important milestone in international recognition. This regulatory process not only underscores the NMPA’s alignment with global standards but also demonstrates China’s ability to facilitate the approval of novel drugs that meet rigorous international criteria. The successful regulatory approval in both China and the U.S. further emphasizes Benvitimod ’s role as a safe, effective treatment for psoriasis, fulfilling the critical gap in treatment options and showcasing China’s growing influence in global pharmaceutical innovation.

Cardiovascular Disease Management

Tafolecimab Injection , approved in 2023, was selected as a key example due to its innovative nature as the first domestically developed PCSK9 monoclonal antibody inhibitor in China. This drug addresses significant unmet medical needs in the management of dyslipidemia and its related complications, particularly in patients who struggle to achieve desired lipid levels with conventional treatments. 219 – 224 Tafolecimab’s innovative mechanism of action, targeting PCSK9, provides a more effective approach to controlling LDL-C levels, a major risk factor for atherosclerotic cardiovascular disease (ASCVD). The drug’s approval is a reflection of China’s increasing ability to develop first-in-class therapies, and it has been selected for its clinical relevance, regulatory milestone, and potential impact on public health. Moreover, Tafolecimab’s dosing regimen, requiring only a subcutaneous injection every 6 weeks, significantly improves patient compliance, making it a practical and accessible treatment option for a broader patient population. This combination of clinical efficacy and regulatory success exemplifies China’s growing leadership in innovative drug development.

Oncology

In the realm of oncology, Surufatinib Capsules represent a novel, oral multi-targeted, anti-angiogenic small-molecule tyrosine kinase inhibitor (TKI), and the first innovative drug approved in China for the treatment of unresectable locally advanced or metastatic, progressive, well-differentiated (G1, G2), non-pancreatic neuroendocrine tumors. This product has demonstrated significant efficacy, markedly reducing disease progression and mortality risk in these patients, filling a treatment gap in this disease area upon its approval. 225 – 235 Surufatinib is highlighted for its novel mechanism and ability to address a significant unmet need in a challenging disease area.

Sunvozertinib Tablets were conditionally approved in 2023 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions, who have experienced disease progression during or after platinum-based chemotherapy, or who are intolerant to platinum-based chemotherapy. 236 – 246 Approximately 2% of NSCLC patients carry EGFR exon 20 insertion mutations. The predominant clinical treatment for these patients is platinum-based chemotherapy, however, the pursuit of enhanced therapeutic outcomes remains a critical area of focus. 247 This innovation not only expands the therapeutic landscape for NSCLC patients with this specific genetic aberration but also underscores the ongoing commitment to improving the efficacy and accessibility of targeted therapies for this patient population (Table 2 ). Sunvozertinib is highlighted due to its targeted precision for a specific mutation and its potential to improve outcomes for patients with limited treatment options.

Pralsetinib Capsules were approved in 2021 for the treatment of adult patients with RET fusion-positive locally advanced or metastatic NSCLC who have previously undergone platinum-based chemotherapy. This product is a receptor tyrosine kinase RET (Rearranged during Transfection) inhibitor that selectively inhibits RET kinase activity and dose-dependently inhibits RET and its downstream molecular phosphorylation, effectively suppressing the proliferation of cells expressing RET (both wild-type and various mutant types). 248 – 254 The approval of this drug provides a new treatment option for patients. Pralsetinib is highlighted for its targeted action on RET fusions, a key genetic driver of NSCLC, offering a novel solution to patients with otherwise limited treatment options.

COVID-19 Therapies

In response to the global public health emergency caused by COVID-19, three domestically developed Class 1 innovative drugs have been approved: Simnotrelvir Tablets/Ritonavir Tablets (co-packaged) , 255 – 261 Deuremidevir Hydrobromide Tablets , 255 , 262 – 264 and Leritrelvir Tablets , 265 – 268 all intended for the treatment of mild to moderate COVID-19 in adult patients. These drugs are highlighted for their innovative mechanisms of action, addressing the urgent need for effective treatments during the COVID-19 pandemic. They offer supportive data showing sensitivity to current circulating variants, meeting the dynamic needs of China’s pandemic prevention efforts. Notably, Leritrelvir Tablets is the first domestically approved single-drug 3CL protease inhibitor in China. Its rapid approval has significantly alleviated the limitations of 3CL protease inhibitors that require combination therapy, providing more treatment options for elderly patients on concomitant medications and those with high-risk factors.

Public Health Diseases

To address unmet clinical needs in major public health diseases in China, the NMPA has also approved four drugs for the treatment of chronic hepatitis C virus (HCV) infection, three drugs for HIV infection, and one drug for chronic hepatitis B, all of which are domestically developed Class 1 innovative drugs. Among them, Coblopasvir Hydrochloride Capsules 269 – 272 is the first domestically developed broad-spectrum anti-HCV drug, Tenofovir Amibufenamide Tablets 273 – 280 is the first domestically developed small-molecule anti-HBV drug, and Ainuovirine 281 – 288 is the first domestically developed novel anti-HIV combination therapy, providing patients with more treatment options. These drugs are highlighted here for their groundbreaking roles in addressing critical public health needs. Their approval processes were expedited through the NMPA’s priority review and approval pathways, allowing for faster access to these much-needed therapies and enhancing their availability to patients in China.

Therapeutic biologics

Rabies Prevention

In the prevention and control of rabies, Ormutivimab Injection was approved in 2022 for passive immunization in patients exposed to the rabies virus. Rabies, caused by the rabies virus, has an almost 100% fatality rate and is a major public health threat in China (Table 2 ). According to the WHO consensus, passive immunization for rabies is primarily aimed at patients with suspected rabies virus exposure (Category III). Existing passive immunization agents, such as immunoglobulins or sera, have limited supply, high costs, potential risks of serum sickness, and blood-borne disease transmission. 289 – 293 Ormutivimab is highlighted for being the first recombinant human anti-rabies monoclonal antibody developed domestically in China, offering a critical alternative to traditional passive immunization agents that are limited by supply, cost, and safety risks. The approval of Ormutivimab followed a rigorous evaluation process, with the NMPA granting it Category 1 innovative drug status due to its novel therapeutic approach. The expedited approval was facilitated by the drug’s potential to address a public health crisis, ensuring rapid availability for patients exposed to the rabies virus.

Oncology

Narlumosbart Injection received conditional approval in 2023 for adult patients with giant cell tumor of bone (GCTB) that is unresectable or where resection could result in severe functional impairment. 294 , 295 GCTB is an aggressive tumor characterized by osteolytic destruction, heavily enriched with receptor activator of nuclear factor kappa-B ligand (RANKL), leading to bone destruction, deformity, and disability. 296 Surgery is the main treatment for GCTB, but some cases are considered “difficult to operate on (resection may cause severe functional impairment or complications)” or “unresectable,” leading to significant unmet clinical needs. This product is the first domestically developed RANKL-targeted drug, which blocks the interaction between RANKL and its receptor RANK, inhibiting osteoclast development and suppressing bone resorption. The introduction of Narlumosbart Injection has expanded the therapeutic armamentarium for GCTB, offering an alternative treatment option for patients who may not be candidates for surgery.

Glofitamab Injection has been granted conditional approval in 2023 for the treatment of adult patients diagnosed with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have received at least systemic therapy regimens. DLBCL is the most common subtype of B-cell-derived non-Hodgkin lymphoma, with an estimated 40% of patients experiencing R/R, and there are currently no effective treatment options available. The clinical demand for alternative therapies is significant. This product, submitted for approval in parallel in China, the US, and Europe, is the first CD3 and CD20 bispecific antibody approved in China. It functions by binding to CD20 expressed on the surface of target B cells and the CD3ε chain (CD3ε) on effector T cells, thereby inducing T cell activation, proliferation, cytokine release, and tumor cell lysis, providing a new treatment option for R/R DLBCL patients. 297 – 306

Rare Diseases

Spesolimab-sbzo Injection was approved in 2022 for the treatment of Generalized Pustular Psoriasis (GPP) in adults. GPP is a life-threatening disease with no effective treatment and has been included in China’s list of rare diseases. The rapid and sustained clearance of pustules and improvement in skin symptoms by this product met urgent patient needs. 307 – 310

Ritlecitinib Tosylate Capsules was approved in 2023 for the treatment of severe alopecia areata in adolescents aged 12 and older, as well as in adults. Alopecia areata is a specific autoimmune disease with a rising prevalence, especially among younger populations. The incidence rate among children and adolescents is as high as 12.8%. Although the condition is not life-threatening, long-term hair loss can severely affect a patient’s psychological health and quality of life, particularly in adolescents. This drug has shown significant efficacy in improving the severity of hair loss and overall patient response. 311 – 315 It is the first medication approved in China for the treatment of alopecia areata in adolescents, addressing an urgent need in this patient group. The drug was developed and launched simultaneously on a global scale.

Risdiplam Oral Solution was approved in 2021 for the treatment of spinal muscular atrophy (SMA) in patients aged 2 months and older. SMA is listed in the “First Batch of Rare Disease Lists” published by China’s National Health Commission. The disease typically manifests before 6 months of age, with a life expectancy often not exceeding 2 years. This product is the first oral medication for SMA, enabling patients to achieve unsupported sitting, reach motor milestones, significantly improve survival, and avoid permanent mechanical ventilation. 316 – 321 Developed and launched globally simultaneously, this drug meets the urgent needs of pediatric SMA patients in China.

Siponimod Tablets were approved in 2020 for the treatment of adult relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Multiple sclerosis has been included in the “First Batch of Rare Disease Lists” published by China’s National Health Commission, with a high rate of disability and mortality. This product offers a new treatment option for patients with relapsing forms of multiple sclerosis in China and was developed and launched globally simultaneously. 322 – 331

Heart Failure

Vericiguat Tablets were approved in 2022 for the treatment of adult patients with symptomatic chronic heart failure with reduced ejection fraction (ejection fraction <45%) who are stabilized after recent decompensation requiring intravenous therapy, to reduce the risk of heart failure hospitalization or the need for emergency intravenous diuretic treatment. Symptomatic chronic heart failure with reduced ejection fraction severely affects the daily functioning and quality of life of patients, with a heavy economic burden and high mortality rate. This product was developed and launched globally simultaneously, providing a new treatment option for heart failure patients in China. 248 , 332 – 339

Cell and gene therapy products

Cell and gene therapies (CGT) have emerged as a major focus in global biopharmaceutical innovation, offering transformative solutions for previously untreatable and rare diseases. 340 Internationally, regions like the United States and Europe have led advancements in CGT, with numerous products receiving accelerated approvals, reflecting the increasing prioritization of these therapies. Similarly, China has made significant strides in this domain, leveraging policy-driven innovation and expedited regulatory pathways to foster the development of groundbreaking CGT products. This progress underscores China’s growing integration into the global CGT landscape, demonstrating its capacity to contribute to and compete within the international biopharmaceutical ecosystem.

The development of products related to CGT is currently a key area of focus in international medical frontiers, offering new options and hope for the treatment of various diseases, particularly for difficult-to-treat and rare conditions. Relmacabtagene Autoleucel Injection (Table 2 ) is the first domestically developed Category 1 cell therapy product approved for market in China. It is used to treat adult patients with relapsed or refractory large B-cell lymphoma (including diffuse large B-cell lymphoma not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and diffuse large B-cell lymphoma from follicular lymphoma) who have previously received at least two lines of systemic therapy. 341 – 345 Relmacabtagene Autoleucel Injection is an autologous immune cell injection, prepared from autologous CD19-targeted CAR-T cells genetically modified by a lentiviral vector carrying the CD19 CAR gene. The approval of this product fills a gap in domestically developed Category 1 cell therapy products, providing a new treatment option for adult patients with relapsed or refractory large B-cell lymphoma after second-line or higher systemic treatments.

In 2023, China also approved two additional domestically developed CAR-T products, namely Inaticabtagene Autoleucel Injection and Equecabtagene Autoleucel Injection . Inaticabtagene Autoleucel Injection is used to treat relapsed/refractory B-cell acute lymphoblastic leukemia in adults while Equecabtagene Autoleucel Injection is indicated for the treatment of adult patients with relapsed/refractory multiple myeloma. 346 – 350 The market launch of these two CAR-T cell therapy products not only enhances the cure rates for these advanced hematological malignancies and significantly improves patient outcomes but, more importantly, represents a major breakthrough in the approval of domestically developed CAR-T products in China. This achievement holds milestone significance in the research and industrialization of this cutting-edge field of biopharmaceuticals.

The national regulatory approval system has played a crucial role in promoting the development and market entry of CGT products. Both Inaticabtagene Autoleucel Injection and Equecabtagene Autoleucel Injection were conditionally approved through the priority review and approval process, which accelerated the evaluation and approval of these innovative drugs, shortening their time to market. This allowed these CAR-T products to enter the market earlier and be applied clinically, offering new treatment options for patients. Additionally, the NMPA has provided policy support and guidance, helping domestic companies overcome various challenges in research, development, and approval processes, promoting the rapid advancement of domestically developed products. These measures have collectively driven innovation and progress in the field of CGT, accelerating the clinical application of new therapies and benefiting more patients.

Vaccine

China’s COVID-19 vaccine products have demonstrated significant advancements, with vaccines developed along five different technical routes having received approval for market release. 351 – 354 As shown in Table 2 , the NMPA granted conditional approval for the Sinopharm CNBG Beijing inactivated COVID-19 vaccine (Vero cells) on December 30, 2020, through an emergency review and approval process. This vaccine was the first Chinese-made inactivated COVID-19 vaccine to receive approval. 355 – 357 The second vaccine to be approved for market release was the CoronaVac inactivated vaccine (Vero cells) from Sinovac. 358 – 361 This vaccine is currently the most exported COVID-19 vaccine from China, having been granted emergency use or conditional market approval in over 50 countries, and is listed on the WHO Emergency Use Listing (EUL). It is the only domestically produced COVID-19 vaccine supplied to the Hong Kong region and has been recognized by Hong Kong authorities in comparative studies with the Pfizer mRNA COVID-19 vaccine. The recombinant adenovirus type 5 vector COVID-19 vaccine (CanSino) was the first domestically produced adenovirus vector COVID-19 vaccine to receive approval. 362 – 365

Since May 2021, the above three vaccines have been successively certified by the WHO and included in the EUL. The Sinopharm Wuhan COVID-19 inactivated vaccine (Vero cells) also received conditional approval through an emergency review and approval process. The Anhui Zhifei Longcom recombinant protein COVID-19 vaccine (CHO cells) was the first recombinant protein COVID-19 vaccine to be approved globally and the first in China to be approved for use in children aged 3–17. 366 – 368 Additionally, this vaccine was the first and so far the only one to undergo overseas clinical trial site inspection by Chinese regulatory authorities.

Moreover, other vaccine products have also received approval. As shown On April 17, 2023, the oral trivalent rotavirus attenuated live vaccine (Vero cells) developed by Sinopharm Lanzhou was approved. This marks China’s first domestically developed polyvalent rotavirus vaccine, verified for safety and efficacy through protective efficacy trials, and currently the only one available on the market in China. 369 , 370 The rotavirus vaccine is a WHO priority prequalification (PQ) vaccine, and globally, there are only two other polyvalent rotavirus vaccines in production, by Merck and in India. Additionally, in May 2023, the quadrivalent influenza virus subunit vaccine from Jiangsu Zhonghui Yuantong was approved, becoming the first domestically produced quadrivalent influenza virus subunit vaccine in China. 371 It is intended for the prevention of influenza caused by the virus types included in the vaccine for children aged three years and above and adults, adding diversity to the technical routes of influenza vaccines available in China and expanding the range of vaccination options.

In summary, there has been substantial progress in China regarding the research and approval of vaccine products, attributed to its continuously improving innovative drug research capabilities and the support and facilitation provided by the national regulatory and approval systems. Through a diverse range of COVID-19 vaccine technologies, including inactivated vaccines, adenovirus vector vaccines, and recombinant protein vaccines, China has ensured the diversity and coverage of its vaccine products. 372 Several vaccines have gained global recognition, with some being the first of their kind to receive approval worldwide, showcasing China’s innovation capacity and international influence in the biopharmaceutical sector. 372 , 373

The NMPA’s special approval procedures have accelerated the emergency review and approval of COVID-19 vaccines, ensuring that they are prioritized and made available quickly in urgent situations. China’s regulatory agencies have also conducted overseas clinical trial inspections, enhancing the international credibility of these vaccines. Beyond COVID-19 vaccines, China has developed a diverse range of vaccine products, with increasing focus on innovation and enhancing domestic public health prevention. Advancements in vaccine research and approval processes in China have been observed in the biopharmaceutical field. These developments have been aligned with both domestic public health needs and global public health initiatives.

Global highlights in innovative drugs

Chemical drugs

Oncology

In 2021, Sotorasib became the first KRAS G12C inhibitor to gain approval, revolutionizing the treatment of NSCLC. 374 – 393 The KRAS gene had long been considered an “undruggable” target, and the approval of Sotorasib marked a significant milestone in precision medicine, offering hope in an area previously deemed unattainable.

Approved by the FDA in 2020 under the accelerated approval pathway, Lurbinectedin provides a novel treatment option for small cell lung cancer (SCLC). 394 – 413 Its unique mechanism of action targets transcriptional pathways, addressing the critical unmet needs of patients with relapsed SCLC.

Cardiovascular Disease Management

Inclisiran, approved in the U.S. and Europe in 2021, is the first cholesterol-lowering drug based on RNA interference (RNAi) technology. 414 – 432 By reducing LDL-C levels with a twice-yearly subcutaneous injection, Inclisiran offers unparalleled convenience and efficacy, setting a new standard for lipid-lowering therapies.

Infectious Diseases

Approved in 2019, Pretomanid is a groundbreaking therapy for multidrug-resistant tuberculosis (MDR-TB). Its use in combination regimens significantly shortens treatment duration while improving efficacy, representing a crucial breakthrough in global TB management. 433 – 452

Therapeutic biologics

Oncology

A standout global innovation in oncology is Tebentafusp (Kimmtrak), approved in 2022, which represents a paradigm shift in the treatment of uveal melanoma, a rare but aggressive cancer. Leveraging a novel T-cell receptor (TCR) platform, Tebentafusp targets Gp100 antigens expressed in melanoma cells. This marks a groundbreaking step in immunotherapy, addressing a patient population with historically poor outcomes and limited options, thereby setting a new standard for rare oncology indications. 453 – 472

Rare Diseases

In rare diseases, Avalglucosidase Alfa (Nexviazyme), approved in 2021 for Pompe disease, exemplifies innovation in enzyme replacement therapy (ERT). This therapy enhances receptor binding and cellular uptake, significantly improving the treatment’s efficacy compared to earlier options. 473 – 491 Avalglucosidase Alfa not only advances outcomes for patients with this lysosomal storage disorder but also underscores the continuous evolution of therapies targeting rare metabolic diseases.

Cardiovascular Diseases

Evinacumab, approved in 2021, is a first-in-class monoclonal antibody targeting ANGPTL3. This biologic is specifically indicated for patients with homozygous familial hypercholesterolemia (HoFH), a severe and rare genetic condition. By lowering LDL cholesterol levels independently of LDL receptors, Evinacumab provides a much-needed alternative for patients unresponsive to conventional therapies. 492 – 508

Infectious Diseases

Approved in Europe in 2021, Regdanvimab is a monoclonal antibody therapy developed for the treatment of COVID-19. It has shown efficacy in preventing severe illness in high-risk patients, making it a critical addition to the global fight against the pandemic.

Cell and gene therapy products

Globally, the field of CGT has seen remarkable progress between 2019 and 2023, marking significant strides in addressing complex and rare diseases. Notable advancements include the approval of Zynteglo (betibeglogene autotemcel) in the United States in 2022 for transfusion-dependent beta-thalassemia (TDT). This gene therapy uses autologous hematopoietic stem cells modified with a functional beta-globin gene, offering a potentially curative option for patients. 509 – 516 Similarly, Roctavian (valoctocogene roxaparvovec) was approved as the first licensed hemophilia A gene therapy that was conditionally approved in Europe in 2022 and approved in the United States in 2023, for utilizing an AAV5 vector to deliver a functional factor VIII gene, significantly reducing bleeding episodes in patients. 517 – 523

In the domain of CAR-T cell therapies, Breyanzi (lisocabtagene maraleucel), approved in 2021, introduced a new generation of CAR-T therapies targeting CD19 for large B-cell lymphoma, offering enhanced efficacy and safety profiles compared to earlier products. 524 – 544 Additionally, Abecma (idecabtagene vicleucel) was approved in 2021 as the first CAR-T cell therapy for relapsed or refractory multiple myeloma, addressing unmet needs in hematologic malignancies. 545 – 563

Vaccine

Globally, significant strides have been made in vaccine development between 2019 and 2023, with groundbreaking advancements in both technology and target diseases. The Pfizer-BioNTech mRNA COVID-19 vaccine, approved in 2020, was the first mRNA-based vaccine to receive regulatory authorization, setting a new benchmark for vaccine technology. Its rapid development and high efficacy against SARS-CoV-2 represented a major scientific milestone. 564 , 565 Similarly, Moderna’s mRNA vaccine (Spikevax), also authorized in 2020, expanded the use of mRNA technology, showcasing its scalability and adaptability to emerging viral threats. 564 – 574 Beyond COVID-19, Mosquirix (RTS,S/AS01), approved by the WHO in 2021, became the first vaccine for malaria, providing critical protection against a disease responsible for significant global morbidity and mortality. 575 – 581 This breakthrough in malaria prevention underscores the global commitment to addressing infectious diseases that disproportionately affect low-income regions.

Comparison between China and globe in innovative drugs

Chemical drugs

China and global leaders have taken distinct approaches to chemical drug innovation. While China has made substantial progress in addressing unmet clinical needs in oncology and public health diseases, global markets, particularly the U.S. and Europe, maintain leadership in groundbreaking and platform-based therapies.

Targeting “Undruggable” Pathways: The U.S.‘s approval of Sotorasib 374 – 393 for KRAS G12C mutations showcases its ability to tackle historically challenging drug targets. This marks a significant breakthrough in oncology, as KRAS mutations were long considered resistant to direct inhibition. In contrast, China’s advancements have predominantly focused on refining existing targets and expanding indications, such as through drugs like Surufatinib 225 – 235 and Sunvozertinib. 236 – 245 This strategy has led to the rapid development of next-generation inhibitors that improve upon existing treatments, addressing resistance and broadening patient eligibility.

The approval of Inclisiran, an RNAi-based therapy, highlights Western leadership in next-generation drug development platforms. In comparison, China is still in the early stages of adopting these technologies. Breakthrough therapies like Sotorasib and Pretomanid have leveraged extensive international multi-center trials to accelerate approval and global market entry. Conversely, China’s chemical drugs have primarily addressed domestic needs, with limited integration into international clinical research ecosystems.

China’s efforts in chemical drug innovation have demonstrated rapid progress, particularly in addressing domestic public health challenges and developing more accessible therapies. However, further advancements in cutting-edge technologies, global collaboration, and expansion into international markets will be pivotal for China to solidify its position as a global key player in pharmaceutical innovation.

Therapeutic biologics

China and the global landscape of innovative therapeutic biologics reveal both unique strengths and complementary priorities. Globally, significant strides have been made in addressing rare diseases, oncology, cardiovascular conditions, and infectious diseases through groundbreaking biologics such as Tebentafusp, Avalglucosidase Alfa, Evinacumab, and Regdanvimab. These innovations highlight a focus on precision medicine and meeting critical unmet needs in specific patient populations.

China, meanwhile, has demonstrated rapid progress in the development and approval of therapeutic biologics tailored to its unique healthcare landscape. Chinese innovations have increasingly focused on addressing high-burden diseases prevalent within the country, such as gastric and liver cancers, and expanding access to treatments for rare diseases. Examples include the approval of domestically developed biologics like Hunterase for Hunter syndrome and Risdiplam for spinal muscular atrophy. Additionally, China has prioritized biosimilars and collaborative efforts to enhance accessibility and affordability of biologics, aligning with its broader healthcare improvement goals.

The COVID-19 pandemic further underscored China’s capacity for rapid biologic innovation and large-scale manufacturing, as evidenced by the development and deployment of monoclonal antibodies like Etesevimab and JS016. These efforts complemented global advancements, such as Regdanvimab, in combating the pandemic.

In conclusion, while global efforts in therapeutic biologics often emphasize high-precision innovations targeting rare and complex conditions, China’s approach reflects a focus on broadening access, addressing local disease burdens, and building foundational capacities in biologic development. These complementary strategies collectively advance global healthcare innovation and improve patient outcomes worldwide.

Cell and gene therapy products

The regulatory landscape for CGT globally has also evolved to support these breakthroughs. Initiatives such as the FDA’s RMAT (Regenerative Medicine Advanced Therapy) 582 – 584 designation and Europe’s PRIME (PRIority MEdicines) scheme have facilitated expedited review processes, promoting faster access to these life-changing therapies. These advancements reflect the growing international emphasis on fostering innovation in CGT.

China’s CGT sector has made impressive progress during the same period, with approvals for several domestically developed CAR-T therapies, including Relmacabtagene Autoleucel Injection, Inaticabtagene Autoleucel Injection, and Equecabtagene Autoleucel Injection, which target hematological malignancies. While these therapies align with global trends in CAR-T innovation, China’s advancements are distinguished by the rapid pace of regulatory approval under priority review pathways, such as the NMPA’s Conditional Approval mechanism.

However, when compared to global CGT leaders like the United States and Europe, China’s CGT field faces challenges in international market penetration and harmonization with global regulatory standards. For instance, while globally approved therapies like Zynteglo and Roctavian have expanded into international markets, China’s CAR-T therapies remain primarily focused on domestic needs, with limited international collaboration or adoption.

China has established a robust CGT pipeline, achieving significant milestones in regulatory efficiency and clinical implementation. However, global leaders have set benchmarks in the areas of market penetration, international collaboration, and diversification of CGT applications beyond hematological malignancies. Bridging these gaps will require China to enhance global regulatory harmonization, expand partnerships, and focus on CGT therapies addressing broader indications. Nonetheless, China’s rapid progress in CGT demonstrates its potential to become a key global player in this transformative field.

Vaccine

Compared to global leaders, China has focused on establishing a diverse portfolio of vaccines leveraging established platforms like inactivated and adenoviral vector vaccines. While mRNA platforms remain underexplored in China, its achievements in large-scale production, rapid approval processes, and supply to multiple countries have positioned it as a key contributor to global vaccine equity. The comparative advantage of China lies in its robust manufacturing capabilities and rapid regulatory pathways, while areas such as adopting cutting-edge platforms like mRNA and multi-valent vaccine formulations offer room for further growth. Together, these global and Chinese advancements underscore the importance of complementary strategies to strengthen vaccine innovation and accessibility worldwide.

Both the FDA and the EMA used Emergency Use Authorizations (EUAs) to rapidly approve COVID-19 vaccines. 585 , 586 The FDA issued EUAs for the Pfizer-BioNTech and Moderna mRNA vaccines in December 2020, while the EMA followed with approvals shortly after. These mechanisms were put in place to speed up the approval process during the COVID-19 emergency, allowing the vaccines to be rolled out quickly despite some remaining uncertainties regarding long-term efficacy and safety. Both agencies used rolling reviews, where data from ongoing clinical trials were reviewed in stages, which helped expedite the decision-making process. In contrast, the NMPA also took steps to expedite the approval of COVID-19 vaccines in China, granting emergency use authorization for several vaccines. While NMPA also implemented expedited approval procedures for COVID-19 vaccines, including emergency use authorizations, the overall approval timeline may have been slightly longer compared to the FDA and EMA. However, the differences in approval times were often influenced by factors such as the availability of domestic data, regulatory requirements, and safety monitoring considerations.

The promotion of drug innovation

Regulatory support for innovative drug development in China

Following the discussion of individual disease areas, we now turn to the broader context of the promotion of innovative drug development and regulatory support, which provides essential context for understanding the environment in which these innovations are being developed. Regulatory support refers to the framework of policies, guidance, and resources provided by regulatory authorities to facilitate the efficient development, approval, and commercialization of pharmaceutical products, ensuring compliance with safety, efficacy, and quality standards.

In recent years, regulatory science research has been promoted by drug regulatory authorities in the U.S., the EU, Japan, China, and other countries, developing into a key strategic frontier discipline of the 21st century for global food and drug regulatory agencies. It has become an important battleground for influencing the next generation of the pharmaceutical industry on the international stage. While technological advancements in the 20 th century have addressed issues such as poverty, disease, and disability, they have also introduced new risks, exemplified by events like the 1937 Sulfanilamide disaster in the U. S., where a toxic solvent was used in the formulation of a liquid medicine, resulting in the deaths of over 100 people, including many children. 587 , 588 This tragedy highlighted the dire need for stricter drug safety regulations and served as a turning point in the development of modern regulatory frameworks.

The Sulfanilamide disaster directly led to the enactment of the 1938 Federal Food, Drug, and Cosmetic Act, which granted the U.S. FDA the authority to ensure the safety of drugs before they could be marketed. This marked a major milestone in the evolution of the FDA and modern drug regulation. The FDA’s origins, however, trace back earlier to the 1906 Pure Food and Drug Act, the first federal law to regulate food and drugs in the United States, introduced to address widespread concerns about unsafe products and false claims. Together, these milestones established the FDA as a cornerstone of public health protection, laying the foundation for the emergence of regulatory science as a discipline.

Modern society faces the challenges of managing risks brought by emerging technologies, necessitating new regulatory tools, methods, and models—thus marking the emergence of the concept of “regulatory science.” Although the idea of regulatory science was initially proposed by public policy scholars, it was not widely accepted for a long time. In 1970, Alan Moghissi from the U.S. Environmental Protection Agency (EPA) first introduced the term “regulatory science” to describe the science used by the agency to formulate regulations. Alan Moghissi from the U.S. EPA first introduced the term “regulatory science“ 589 Since then, it has evolved through various interdisciplinary developments such as super-science, cross-science, evidence-based medicine, translational medicine, and precision medicine. 590 – 592 Today, regulatory science has gained significant attention from major drug regulatory agencies worldwide and has become a strategic frontier discipline of the 21st century.

Based on China’s regulatory science trajectory and key milestones, we divide the scientific development of Chinese drug regulation into four stages:1) Initial Stage (Application of drug analysis technology, 1949–1984); 2) Development Stage (Establishment of drug registration standards, 1985–2014); 3) Acceleration Stage (Introduction of regulatory science concepts, 2015–2018); 4) Leapfrog Stage (Regulatory Science Action Plan, 2019–2023). In April 2019, the NMPA issued the “Notice on the Implementation of China’s Drug Regulatory Science Action Plan,” formally launching regulatory science research. Two batches of 19 key regulatory science projects were organized and implemented (Table S3 and S4 ). Additionally, 14 regulatory science research bases were established, and a total of 337 new regulatory tools, standards, and methods related to drug regulation were developed, providing important technical support for improving the quality and efficiency of China’s drug regulation. Notably, the rise and development of TCM regulatory science have accelerated the creation of an excellent regulatory system for TCM (TCMERS), which is tailored to the characteristics of TCM, rooted in Chinese distinctiveness, and globally advanced. 593 – 596

In July 2023, the NMPA issued the “ Implementation Plan for Comprehensive Strengthening of the Drug Regulatory Science System,” emphasizing the strategic, forward-looking, and systematic development of the regulatory science system. It set new goals for the construction of the drug regulatory science system during the 14 th Five-Year Plan, focusing on pivotal tasks such as “strengthening and upgrading the construction of regulatory science infrastructure platforms,” “improving the regulatory science service support system,” and “breaking through key core technology bottlenecks in critical areas.” Through a series of innovations in regulatory tools, standards, and methods, the plan aims to foster high-level research and efficient translation in drug regulatory science, marking China’s entry into a new phase of comprehensive enhancement in the construction of its drug regulatory science system. 42 , 43

Regulatory measures to promote innovative drugs

In recent years, China’s biopharmaceutical industry has entered a period of rapid innovation and development, supported by favorable policies. Government agencies at various levels have promoted innovation accelerations across multiple stages, including R&D, clinical trials, market access, intellectual property, and medical insurance. 597

Implementation of the marketing authorization holder (MAH) regulation

In 2015, China launched a pilot program for the MAH Regulation. The system was officially included in the revised Drug Administration Law in 2019, empowering innovative entities by allowing them to focus on their core strengths in R&D and manufacturing.

Implementation of International Council for Harmonisation (ICH) guidelines

In 2017, China acceded to the ICH and ascended to membership in the ICH Management Committee in 2018. The implementation of ICH guidelines in China has harmonized its drug registration standards with global benchmarks, reducing the time lag for approval of innovative drugs between China and the United States to near synchronization.

Clinical trial acceleration

The 2019 revision of the Drug Administration Law shifted the management of drug clinical trial institutions from an approval-based system to a record-based system, as outlined in the Regulations on the Management of Drug Clinical Trial Institutions . The transition altered the procedure from a system of explicit application approvals to one of consent, establishing a clear 60-working-day deadline, thereby expanding clinical supplies to accommodate the accommodate demand for drug R&D.

Establishment of drug development communication systems

In 2016, the NMPA issued the Interim Measures for the Administration of Communication and Exchange in Drug Development and Technical Review . In 2020, the Drug Registration Regulation integrated the communication mechanism into the basic drug registration system. Furthermore, in 2021, the Implementation Opinions of the General Office of the State Council on Strengthening Drug Regulatory Capacity increased the required frequency of communication meetings for innovative drugs. Through the improvement of the communication and exchange system, these measures aim to mitigate the risks inherent in innovative drug development while enhancing review efficiency and transparency.

Establishment of a patent compensation system

The 2017 Opinions on Deepening the Reform of the Review and Approval System to Encourage Drug and Medical Device Innovation introduced the patent term compensation system. In the 2021 revision of the Patent Law , this system was officially established to compensate for the time taken for the review and approval of new drug marketing. The compensation is capped at five years, with the total effective patent term not exceeding 14 years post-approval.

Optimization of the financing environment

In July 2019, China launched the Science and Technology Innovation Board (STAR Market), a new board of the stock exchange dedicated to fostering technological advancement and innovation. The biopharmaceutical industry is one of the pivotal sectors of the STAR Market, benefiting from improved liquidity, lower financing costs, and easier access to capital.

Normalization of medical insurance negotiations

In April 2021, the National Healthcare Security Administration (NHSA) and the National Health Commission issued the Guiding Opinions on Establishing and Improving the ‘Dual-Channel’ Management Mechanism for Nationally Negotiated Drugs . This mechanism ensures the supply, clinical use, and payment of negotiated drugs through two channels: designated medical institutions and designated retail pharmacies, with simultaneous integration into the medical insurance payment system. In September 2021, the NHSA and National Health Commission released the Notice on Adapting to the Normalization of National Drug Negotiations and Continuously Promoting the Implementation of Negotiated Drugs . This notice further emphasized the importance of normalizing drug negotiations and improved policies on drug allocation, procurement, and settlement. These measures facilitate the implementation of negotiated drugs and provide a policy window for the early market entry of domestically innovative drugs.

Comprehensive support for innovative drugs

In March 2024, the Government Work Report of the 14th National People’s Congress (NPC) highlighted “innovative drugs” as an emerging industry to be actively cultivated. In July 2024, the State Council approved the Implementation Plan for Full-Chain Support for Innovative Drug Development , providing comprehensive policy support in pricing, medical insurance, commercial insurance, drug allocation, financing, and optimizing review and approval processes.

Optimization of clinical trial approval

In July 2024, the NMPA issued the Pilot Work Plan for Optimizing the Review and Approval Mechanism for Innovative Drug Clinical Trials , aiming to further enhance the clinical trial review and approval process for innovative drugs. The plan strengthens the primary responsibility of drug clinical trial applicants and enhances the ability of stakeholders involved in clinical trials to identify and manage risks. Additionally, it seeks to establish systems and mechanisms that comprehensively improve the quality and efficiency of clinical trials. The goal is to complete the review and approval of innovative drug clinical trial applications within 30 working days, thereby reducing the time required to initiate clinical trials. 597

Accelerated review and approval process for innovative drugs

Breakthrough Therapy Designation

During clinical trials, innovative or modified drugs that are used for treating life-threatening or severely debilitating diseases, for which there are no effective treatments, or that show significant clinical advantages over existing treatments can apply for Breakthrough Therapy designation (BTD) in Phase I or II, usually no later than Phase III. In 2023, 286 applications were submitted for BTD, and 70 were granted, representing a 43% increase compared to 2022. The number of designations since the 2020 Measures for the Administration of Drug Registration was implemented is shown in Fig. 5a . Most of the designations were for oncology drugs (Fig. 5b ). Fig. 5 Overview of accelerated review and approval process for innovative drugs in China from 2020 to 2023. a Number of cases agreed or disagreed for inclusion under the Breakthrough Therapy program from 2020 to 2023. b Distribution of indication areas for drugs agreed for inclusion under Breakthrough Therapy program in the year of 2023. c Number of drugs conditionally approved and transitioned to regular approval from 2020 to 2023. d Distribution of indications for conditionally approved drugs from 2020 to 2023. e Number of drug registration applications under the Prioritized Evaluation and Approval procedure from 2020 to 2023. f Distribution of indications for drug registration applications under the Prioritized Evaluation and Approval procedure from 2020 to 2023. 95 – 99

Conditional Approval

Conditional approval can be granted for drugs that address life-threatening diseases lacking effective treatment, or in scenarios of public health emergencies when clinical trial data indicates effectiveness and predict clinical value. Since 2020, 95 drugs (107 indications) have been conditionally approved, with oncology drugs accounting for 79% (Fig. 5c , d ). The conditional approval will be transitioned to full approval status upon the completion of post-marketing studies.

Prioritized Evaluation and Approval

Drugs with significant clinical value, including those treating rare diseases, pediatric diseases, major infectious diseases, and those listed under the BTD and Conditional Approval programs, are eligible for priority review. The review period for priority review is shortened to 130 days. In 2023, 108 applications (80 products) were accepted for priority review, an increase of 56.9% year-on-year (Fig. 5e ). Oncology drugs accounted for the largest share of approvals (Fig. 5f ).

Breakthroughs in anti-cancer innovative drugs

In the realm of innovative drug development and regulation, anti-cancer drugs, as a key area addressing global health challenges, have received special attention and support. Given the high prevalence and complexity of cancer, the development of anti-cancer drugs faces significant technical challenges and unmet clinical needs. Therefore, regulatory agencies worldwide have implemented more refined and efficient regulatory measures specifically for anti-cancer drugs, in addition to promoting overall innovation in drug development. These measures have not only accelerated the market approval of anti-cancer drugs but also significantly improved their safety and efficacy, making anti-cancer drugs a strategic pioneer in the field of innovative medicines. They have provided patients with substantial health improvements and expanded treatment options.

The CDE of the NMPA has developed and published a series of guidelines to further refine the evaluation system for anti-cancer drugs. As of March 2024, the CDE had issued 503 technical guidelines, of which 61 were related to oncology indications. These guidelines have provided clear technical guidance and standards for pharmaceutical companies, playing a critical role in directing the development of innovative anti-cancer drugs, expediting the introduction of already-approved foreign anti-cancer drugs, and promoting the development and marketing of pediatric oncology drugs.

The 2020 Measures for the Administration of Drug Registration introduced four accelerated pathways: Conditional Approval, Breakthrough Therapy, Priority Review, and Special Approval. For diseases like cancer that pose a serious threat to public health, accelerating the development and approval of new drugs offers hope for survival to patients. As of March 2024, 70 anti-cancer drugs (covering 82 oncology indications) had been conditionally approved in China. 44 , 598 The gradual establishment and refinement of China’s anti-cancer drug evaluation system have benefited from advancements in regulation, which have provided new tools and methods to support drug development. 599

Single-arm trials offering treatment opportunities for patients with no alternatives

In 2020, the CDE issued two guidelines: the Technical Guidelines for Communication Before Key Trials in Single-Arm Trials Supporting Anti-cancer Drug Marketing Approval and the Technical Guidelines for Communication Before Marketing Approval for Single-Arm Trials Supporting Anti-cancer Drug Applications . In 2023, the CDE released the Technical Guidelines for the Applicability of Single-Arm Clinical Trials for Supporting Anti-cancer Drug Applications , systematically explaining the current scientific understanding of the use of single-arm trials for marketing applications. The first drug in China approved based on a single-arm trial was Chidamide (CS055), approved in 2014 for the treatment of relapsed and refractory peripheral T-cell lymphoma (PTCL).

Biomarkers enabling precision medicine

In 2021, the CDE published the Technical Guidelines for the Use of Biomarkers in the Clinical Development of Anti-cancer Drugs , detailing the definition and classification of biomarkers and emphasizing their application in evaluating the efficacy and safety of anti-cancer drugs.

Endpoints reflecting clinical benefit

The 2020 Measures for the Administration of Drug Registration and the accompanying Technical Guidelines for Conditional Approval stipulate that the selection of surrogate endpoints should be based on their ability to predict clinical benefit. For early-stage acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), the CDE issued several guidelines, including the Technical Guidelines for the Detection of Minimal Residual Disease (MRD) in Clinical Trials for Acute Lymphoblastic Leukemia, the Technical Guidelines for the Detection of MRD in Chronic Myeloid Leukemia (CML) Clinical Trials, and the Technical Guidelines for the Application of MRD in Multiple Myeloma (MM) Clinical Trials. When conducting clinical trials for cancer at different stages, considerations for trial endpoints may vary. The CDE issued the Technical Guidelines for Endpoints in Clinical Trials for Advanced NSCLC and the Technical Guidelines for Endpoints in Clinical Trials for Advanced Hepatocellular Carcinoma, detailing considerations for the use of surrogate endpoints at different stages of advanced cancer. According to the Guiding Principles for Anti-cancer Drug Development Based on Clinical Value, applicants are encouraged to use patient-reported outcomes (PRO) tools, such as quality of life and symptom assessments, to better understand how drugs alleviate symptoms and improve the quality of life for cancer patients.

The globalization of China’s anti-cancer drug approvals illustrates both progress and challenges. For example, Sintilimab, a PD-1 inhibitor approved in China, faced rejection by the FDA due to its reliance on data from the ORIENT-11 trial conducted exclusively in China. The FDA raised concerns about the homogeneity of the trial population and the comparator arm, which did not align with U.S. medical standards at the time. 600 , 601 While the trial met its progression-free survival endpoint, the lack of diverse, multiregional clinical trial data limited its applicability to a global population. This case highlights the importance of conducting multiregional clinical trials to ensure Chinese-developed therapies meet international regulatory requirements and gain broader global acceptance. 602 It is also important to note that other China-developed anti-PD-1 inhibitors, such as tislelizumab, have now been approved in the U.S. Tislelizumab, marketed as TEVIMBRA, was approved by the FDA for the first-line treatment of advanced or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma in combination with chemotherapy for patients whose tumors express PD-L1 (≥1). This approval, based on the positive results of the global RATIONALE-305 Phase 3 trial, marks a significant step in BeiGene’s mission to provide transformative therapies for cancer patients globally. 603 The trial demonstrated a 20% reduction in the risk of death, highlighting the international acceptance and potential for Chinese-developed cancer therapies like tislelizumab to succeed in global markets.

Chinese biotechnology companies have increasingly focused on oncology, particularly on immune checkpoint inhibitors (ICPIs), which have made significant contributions both in China and globally. In recent years, ICPIs have emerged as a key area of innovation, with several domestically developed ICPIs achieving regulatory approval and demonstrating clinical efficacy. Between 2005 and 2020, China approved 78 cancer drugs, including a growing number of ICPIs, with nearly half demonstrating overall survival (OS) benefits. 604 , 605 Supported by faster regulatory pathways emphasizing clinical value, Chinese ICPIs are playing an increasingly important role in global oncology drug development, showcasing the country’s growing influence in this field.

Global perspectives on regulatory support for innovative drug development

Globally, the evolution of regulatory frameworks has been pivotal in fostering innovative drug development, with agencies in the United States, Europe, and Japan leading efforts to streamline drug approval processes, integrate new technologies, and address unmet medical needs. The promotion of regulatory in these regions reflects their commitment to modernizing oversight systems and accelerating innovation in the pharmaceutical industry.

The U.S. FDA has long been at the forefront of regulatory innovation. 606 Programs like the BTD, 122 , 123 Accelerated Approval, 8 , 11 , 127 , 130 , 131 , 194 and Priority Review 8 , 91 have substantially reduced the time-to-market for novel therapeutics. As of 2023, the FDA approved over 100 drugs under the BTD program, with a strong focus on oncology, rare diseases, and gene therapies. The implementation of real-world evidence (RWE) in drug evaluations and the expansion of biomarkers for precision medicine have further enhanced the FDA’s ability to support cutting-edge therapies.

In Europe, the EMA has advanced regulatory innovation through its PRIME scheme and Adaptive Pathways program, 86 , 88 , 89 , 607 aimed at accelerating the approval of drugs that address significant clinical gaps. The EMA’s emphasis on harmonizing regulations across member states has facilitated multi-country trials and improved access to innovative medicines.

Japan has embraced unique regulatory mechanisms, such as the Sakigake (Pioneering) designation, 608 – 613 to incentivize domestic innovation and expedite the approval of breakthrough drugs. The use of conditional early approval pathways for regenerative medicine products has been instrumental in advancing therapies. Additionally, Japan’s focus on regulation has led to the establishment of innovative frameworks for real-world evidence and post-marketing surveillance.

International collaboration has emerged as a cornerstone of regulatory progress. The ICH has played a crucial role in aligning regulatory standards across major markets, enabling the global simultaneous development and approval of innovative drugs. Efforts like Project Orbis, spearheaded by the FDA, facilitate concurrent drug reviews among international regulators, significantly reducing delays in patient access to breakthrough therapies.

China’s drug regulatory system is increasingly aligning with global practices, and its future may include participation in international frameworks like Project Orbis, 614 an FDA-led initiative enabling simultaneous submission and review of cancer drugs across multiple countries. Recent discussions between the U.S. and China on streamlining oncology drug development highlight this possibility. If China joins such initiatives, it could significantly enhance global collaboration, reduce approval timelines, and improve access to innovative therapies for patients worldwide. As regulatory improvements continue, China’s integration into global networks could further solidify its role as a key player in the international pharmaceutical landscape.

While China’s regulatory system has advanced rapidly, global agencies offer unique lessons in leveraging harmonization, adaptive pathways, and real-world data. For instance, the widespread use of biomarkers in the FDA’s precision medicine approvals and the EMA’s leadership in multi-country trials underscore the importance of integrating scientific advancements into regulatory processes. Moreover, global regulatory bodies have placed greater emphasis on post-marketing requirements and real-world evidence, areas where China’s system could further evolve to ensure long-term efficacy and safety. Globally, regulatory agencies continue to adapt to emerging scientific and societal challenges, setting benchmarks for efficiency, transparency, and innovation. By studying these global practices, China can refine its own regulatory framework, fostering a collaborative environment that accelerates drug development and enhances global access to life-saving therapies. The integration of international best practices, coupled with China’s own advancements, could significantly bolster global pharmaceutical innovation.

China’s emerging role in global pharmaceutical innovation

China’s pharmaceutical industry has made significant strides in innovative drug development, with an increasing number of domestically developed drugs gaining approval and entering both domestic and international markets. Since 2021 to late 2024, Chinese authorities have approved 113 innovative drugs, contributing to a market scale of ~100 billion yuan (about 13.89 billion U.S. dollars). 615

In comparison to global progress, China’s share of the innovative drug market remains relatively modest. In 2021, the United States accounted for over half of global innovative drug sales, Europe held 16 percent, while China stood at merely 3 percent. 616 Despite this, Chinese pharmaceutical companies are actively expanding their presence in overseas markets. Collaborations with foreign firms and participation in global clinical trials have facilitated the entry of Chinese innovative drugs into international markets, including the United States and Europe. For instance, partnerships and licensing agreements have enabled Chinese-developed drugs to reach a broader patient population globally.

While China has made notable progress in innovative drug development, there remains significant potential for growth in both domestic and international markets. Continued investment in research and development, along with strategic collaborations, will be crucial for China to enhance its position in the global pharmaceutical landscape.

The improvements in research progress, infrastructure including research facilities, laboratories, and manufacturing capabilities, ecosystems such as the collaborative network of government, regulatory bodies, pharmaceutical companies, and academic institutions, and regulatory changes have propelled China’s innovative drug development. Chinese pharmaceutical companies have accelerated their integration into global drug development by conducting clinical trials abroad. Since July 2021, eight original innovative drugs from China have entered international markets, with seven of them being licensed to international partners. In 2024, 465 products under development reached the same development stage domestically and abroad, indicating a trend toward global synchronous development. Additionally, among the 2,623 products that entered clinical development since July 2021, the proportion of me-too products dropped to 35%, compared to 50% in 2021, reflecting the shift in China’s pharmaceutical industry toward drugs with higher clinical value potential.

In October 2023, Junshi Biosciences’ Toripalimab (marketed as LOQTORZI™ in the U.S.) received FDA approval, becoming the first and only FDA-approved drug for the treatment of nasopharyngeal carcinoma. 617 – 626 The approval was supported by robust clinical trial data, including studies conducted in China and internationally, demonstrating its efficacy and safety. Junshi’s collaboration with international partners also played a crucial role in facilitating this approval.

In March 2024, BeiGene’s PD-1 product Tislelizumab (marketed as Baize’an or TEVIMBRA) was approved by the FDA as a monotherapy for adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) who had previously undergone systemic chemotherapy (excluding PD-1/L1 inhibitors). 627 – 636 In July 2024, CStone Pharmaceuticals’ Sugemalimab (marketed as Cejemly®) was approved by the European Commission for first-line treatment in combination with platinum-based chemotherapy for adult patients with metastatic non-small cell lung cancer without EGFR mutations or ALK, ROS1 , or RET genomic alterations. 637 – 642 In June 2024, Chinese biopharmaceutical company Hutchmed’s c-MET kinase inhibitor Glumetinib (SCC244) was approved by Japan’s Ministry of Health, Labor, and Welfare for the treatment of patients with METex14 skipping mutations in locally advanced or metastatic non-small cell lung cancer. 643

An analysis of Chinese innovative drugs undergoing clinical trials in the U.S. from 2007 to 2023 indicates that China is evolving from a major pharmaceutical producer to an increasing participant in global drug development. 644 Between 2007 and 2023, 177 Chinese pharmaceutical companies conducted 691 clinical trials for 350 original innovative drugs, targeting 499 indications in the U.S., including 399 Phase I trials (49%), 269 Phase II trials (39%), and 83 Phase III trials (12%)(Fig. 6a ). 644 Six Chinese innovative drugs have been approved for marketing in the U.S., covering 10 indications, including BeiGene’s Zanubrutinib (2019), Legend Biotech’s Cilta-cel (2022), Ascletis’ Benvitimod (2022), Junshi Biosciences’ Toripalimab (2023), Hutchmed’s Fruquintinib (2023), and Elpiscience’s Agarcetin-α (2023). Of the 350 original innovative drugs, 182 (52%) were NMEs, 162 (46%) were new biologics, and six (2%) were traditional Chinese medicines. Small molecule drugs and monoclonal antibodies accounted for 45% and 22%, respectively; bispecific antibodies for 8%, ADC for 7%, and cell and gene therapies for 5%. Fig. 6 a Clinical trials of Chinese innovative drugs conducted in the U.S. from 2007 to 2023. b Number and growth rate of out-licensing deals of Chinese innovative drugs. 645

Oncology remains the primary focus of Chinese pharmaceutical companies‘ drug development. Of the 691 clinical trials conducted, 358 trials (72%) involved 230 oncology drugs. The top five targets for anti-cancer drugs were PD-1, EGFR, PD-L1, HER2, and Claudin 18.2. Most of the clinical trials for Chinese innovative drugs in the U.S. (82%) were initiated between 2019 and 2023, reflecting a rapid growth. 114 – 117

As reported by Qianwei Ge et al., between 2007 and 2023, 311 clinical stage transitions occurred for 75 drug development projects. 644 The success rate for Phase II trials was 17%, much lower than 41% for Phase I and 36% for Phase III trials. The probability of approval after submission to regulatory agencies was 67%. The success rate for Phase I clinical trials of new biologics was much lower than for new molecular entities (16% vs. 49%), but new biologics had a higher success rate in Phase III (50% vs. 31%). 644

Over the past five years, China’s innovative drug out-licensing has made significant progress, showing several key trends (Fig. 6b ). 1) There has been a notable growth in the number of transactions: in 2023, the number of out-licensing deals for innovative drugs reached 80, a 57% increase compared to 51 deals in 2022, reflecting the increasing international recognition of Chinese innovative drugs. 645 2) The transaction value and structure have been optimized: in 2023, the total transaction value for out-licensing exceeded $46.5 billion, a 69% increase from $27.55 billion in 2022, with a higher proportion of upfront payments indicating growing optimism among international partners about the prospects of Chinese innovative drugs. 646 3) The concentration of deals remains in key sectors such as oncology and immunotherapy, which have bolstered the global influence of Chinese pharmaceutical companies, particularly in the development of innovative therapies targeting cancer and immune-related diseases. 4) Geographically, while Europe and North America remain primary markets for out-licensing, emerging markets in Southeast Asia and Latin America are gaining traction, providing new growth opportunities and furthering the global reach of Chinese innovative drugs.

The Chinese government has encouraged pharmaceutical companies to globalize, especially in innovative drug development. Although the NMPA does not directly manage the process of Chinese innovative drugs entering overseas markets, such as marketing, sales, or approvals, its regulatory activities and policies have significant indirect effects. These effects include setting regulatory standards, guiding drug development practices, facilitating international collaborations, and providing incentives for innovation, which collectively influence the global competitiveness and market access of Chinese drugs. Additionally, the Chinese government has provided ongoing support for the globalization of pharmaceutical companies, particularly through policies that encourage innovation and international expansion.

Conclusion and future prospective

The landscape of innovative drug development is driven by several critical clinical needs, many of which remain unmet despite significant scientific advancements. These clinical needs span a wide range of conditions, from rare and orphan diseases to the more common but complex challenges of cancer, cardiovascular diseases, and neurodegenerative disorders. The increasing prevalence of chronic diseases such as diabetes and obesity, as well as the rise of antimicrobial resistance (AMR), underscores the urgent need for new, effective therapies.

In oncology, for example, while there has been significant progress in immunotherapy and targeted therapies, many cancers still have limited treatment options, especially for advanced stages and metastatic diseases. The clinical need for therapies that can address drug resistance, improve patient survival rates, and reduce side effects is particularly pressing. Similarly, in the field of neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, there is an overwhelming demand for drugs that can modify disease progression, not just alleviate symptoms. Despite substantial investment in research, these diseases remain largely untreatable, highlighting a significant gap in the development of effective therapeutic options.

In addition to these complex conditions, emerging health threats such as the global COVID-19 pandemic have exposed vulnerabilities in existing drug development systems. 354 The urgent need for rapid vaccine and antiviral drug development during the pandemic has underscored the importance of adaptive regulatory frameworks, international collaboration, and the ability to swiftly mobilize clinical trials. The pandemic has also highlighted the need for innovation in vaccine technology, diagnostics, and treatment options that can be rapidly deployed in response to global health crises.

Moreover, the rise of personalized medicine is transforming drug development, as there is a growing need for therapies that are tailored to individual patient profiles. Precision medicine aims to customize healthcare, with the goal of delivering more effective treatments based on genetic, environmental, and lifestyle factors. This approach requires advanced diagnostic tools and an understanding of the molecular mechanisms underlying diseases, pushing the boundaries of regulatory frameworks to accommodate new methods of treatment and testing.

Addressing these clinical needs requires not only innovative scientific research but also a regulatory system that can support the accelerated development and approval of novel therapies. The integration of regulatory support mechanisms that facilitate adaptive clinical trial designs, expedite the approval process for high-need drugs, and promote international cooperation is critical to meeting these challenges. Ensuring that new treatments can be efficiently brought to market is essential to improving patient outcomes and addressing the ongoing gaps in global healthcare.

The global innovative drug development has seen unprecedented advancements over the past decade, driven by cutting-edge technologies, diversified funding sources, and evolving regulatory frameworks. The success of novel platforms such as mRNA technology, CRISPR gene editing, and bispecific antibodies has redefined therapeutic possibilities and accelerated breakthroughs in areas like oncology, rare diseases, and infectious diseases. Nations like the United States and Europe have maintained leadership through robust collaboration between academia, government, and industry, while emerging markets like China are rapidly closing the gap. However, global challenges persist, including high R&D costs, disparities in access to innovation, and the need for harmonized regulatory standards. Strengthening global partnerships and leveraging complementary strengths will be essential to overcoming these challenges, fostering equitable access, and addressing unmet clinical needs across diverse populations. By aligning efforts internationally, the pharmaceutical sector can continue to deliver transformative therapies that improve health outcomes worldwide.

Innovative drug development is a complex and long-term process influenced by various factors such as technology, market demand, regulatory policies, and funding. Companies and research institutions need to closely monitor these trends and continuously adjust their strategies to address future challenges and opportunities in drug development. The pivotal role of collaboration between governmental bodies, academic institutions, and the private sector will be indispensable for propelling innovative drug development forward in China.

The key opportunities for innovative drug development in China encompass the following aspects: Macroeconomic policy: The recently enacted Implementation Plan for Full-Chain Support for Innovative Drug Development will continue to foster innovation in China’s pharmaceutical sector. Future policies are expected to accelerate development by streamlining the drug review and approval process, enhancing intellectual property protection, and offering tax incentives. These policies aim to reduce approval timelines through expedited pathways and rolling reviews, particularly for critical therapies with high unmet medical needs. Intellectual property laws will be strengthened to encourage innovation, with specific incentives for high-tech areas like gene therapy and biologics. Additionally, tax relief will be provided for companies engaged in R&D, including deductions for research expenses. These policies also focus on enhancing clinical trial efficiency by reducing regulatory barriers and promoting international multi-center trials, ensuring that China’s drug development process is globally competitive and aligned with international standards. Technological Innovation: The integration of emerging technologies such as biotechnology, gene editing, and artificial intelligence into drug development is already improving efficiency and success rates. China’s advancements in CGT, protein degraders, and covalent drugs highlight the country’s commitment to adopting and advancing novel paradigms. This progress is aligned with global innovation trends and positions China as a key player in shaping the future of drug development. Clinical demand: China’s vast and diverse population, combined with a broad spectrum of diseases, provides significant clinical resources and market demand for innovative drugs. Areas such as oncology, rare diseases, and chronic illnesses are particularly critical, as unmet medical needs in these fields drive much of the current R&D activity. This clinical demand not only supports drug development but also provides a real-world testing ground for innovative therapies. R&D investment: Increasing attention from both the capital markets and government support is expected to lead to greater investment in drug development. The growing availability of diverse financing channels ensures that sufficient funding is directed toward high-risk, high-reward R&D projects, fostering a robust drug development ecosystem in China. Regulatory science: The exploration and application of regulatory science have significantly improved China’s regulatory environment. Efforts to refine drug evaluation processes, align with international standards, and accelerate the approval of new therapies are enhancing China’s position as a global hub for drug development. International collaboration:

As China’s pharmaceutical sector aligns more closely with international standards, opportunities for global partnerships and joint ventures continue to expand. These collaborations not only provide access to international markets but also enable Chinese companies to contribute to and learn from global innovation efforts, accelerating the pace of drug development.

In summary, driven by macroeconomic policies and regulatory promotion, China’s innovative drug development is poised for significant advancements in small molecules, biologics, and traditional Chinese medicines. Strengthening regulation, expediting the review process, and deepening international cooperation will position China as a major player in global pharmaceutical innovation, contributing to the enhancement of human health and well-being.

Supplementary information

Supplementary Information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Ruirong Tan, Hua Hua

Supplementary information

The online version contains supplementary material available at 10.1038/s41392-025-02267-y.

Acknowledgements

This work was supported by the Key Project of the National Medical Products Administration for the Construction of the Drug Regulatory Science System (RS2024Z003).

Author contributions

J. Zhao and R.T. conceived the main idea and drafted the manuscript. R.T., H.H., S.Z., Z.Y., C.Y., G.H. and J. Zeng conducted literature research, graphing, table and manuscript editing. All authors read and approved the final manuscript.

Competing interests

The authors declare no competing interests.

References

1. Zheng L Wang W Sun Q Targeted drug approvals in 2023: breakthroughs by the FDA and NMPA Signal Transduction Targeted Ther. 2024 9 46 10.1038/s41392-024-01770-y PMC10879080 38378623 Zheng, L., Wang, W. & Sun, Q. Targeted drug approvals in 2023: breakthroughs by the FDA and NMPA. Signal Transduction Targeted Ther. 9 , 46 (2024). 10.1038/s41392-024-01770-y PMC10879080 38378623

2. Shmela M Habbassi M Overview in EMA and FDA approved novel drugs in thE YEARS 2020, 2021 and 2022 Libyan. J. Med. 2024 18 178 192 10.54361/Ljmr18-1.18 Shmela, M. & Habbassi, M. Overview in EMA and FDA approved novel drugs in thE YEARS 2020, 2021 and 2022. Libyan. J. Med. 18 , 178–192 (2024).

3. Scott EC Trends in the approval of cancer therapies by the FDA in the twenty-first century Nat. Rev. Drug Discov. 2023 22 625 640 10.1038/s41573-023-00723-4 37344568 Scott, E. C. et al. Trends in the approval of cancer therapies by the FDA in the twenty-first century. Nat. Rev. Drug Discov. 22 , 625–640 (2023). 37344568 10.1038/s41573-023-00723-4

4. Kinch MS Kraft Z Schwartz T 2023 in review: FDA approvals of new medicines Drug Discov. Today. 2024 29 103966 10.1016/j.drudis.2024.103966 38552777 Kinch, M. S., Kraft, Z. & Schwartz, T. 2023 in review: FDA approvals of new medicines. Drug Discov. Today. 29 , 103966 (2024). 38552777 10.1016/j.drudis.2024.103966

5. Rim MH Barada F Levitsky AM Recent and anticipated novel drug approvals for 2023 and 2024 Am. J. Health Syst. Pharm. 2023 80 1729 1732 10.1093/ajhp/zxad220 37688502 Rim, M. H., Barada, F. & Levitsky, A. M. Recent and anticipated novel drug approvals for 2023 and 2024. Am. J. Health Syst. Pharm. 80 , 1729–1732 (2023). 37688502 10.1093/ajhp/zxad220

6. Hines PA Artificial intelligence in European medicines regulation Nat. Rev. Drug Discov. 2023 22 81 82 10.1038/d41573-022-00190-3 36411368 Hines, P. A. et al. Artificial intelligence in European medicines regulation. Nat. Rev. Drug Discov. 22 , 81–82 (2023). 36411368 10.1038/d41573-022-00190-3

7. Thakkar S Artificial intelligence and real-world data for drug and food safety—a regulatory science perspective Regul. Toxicol. Pharmacol. 2023 140 105388 10.1016/j.yrtph.2023.105388 37061083 Thakkar, S. et al. Artificial intelligence and real-world data for drug and food safety—a regulatory science perspective. Regul. Toxicol. Pharmacol. 140 , 105388 (2023). 37061083 10.1016/j.yrtph.2023.105388

8. Michaeli DT Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy Eur. J. Health. Econ. 2024 25 979 997 10.1007/s10198-023-01639-x 37962724 PMC11283430 Michaeli, D. T. et al. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy. Eur. J. Health. Econ. 25 , 979–997 (2024). 37962724 10.1007/s10198-023-01639-x PMC11283430

9. Wong AK Use of expedited regulatory programs and clinical development times for FDA-approved novel therapeutics JAMA Netw. Open. 2023 6 e2331753 10.1001/jamanetworkopen.2023.31753 37651145 PMC10472182 Wong, A. K. et al. Use of expedited regulatory programs and clinical development times for FDA-approved novel therapeutics. JAMA Netw. Open. 6 , e2331753 (2023). 37651145 10.1001/jamanetworkopen.2023.31753 PMC10472182

10. Brown DG A Drug discovery perspective on FDA expedited development and incentive programs J. Med. Chem. 2024 67 1690 1700 10.1021/acs.jmedchem.3c02165 38233132 Brown, D. G. A Drug discovery perspective on FDA expedited development and incentive programs. J. Med. Chem. 67 , 1690–1700 (2024). 38233132 10.1021/acs.jmedchem.3c02165

11. Benjamin DJ Lythgoe MP Modernising the US FDA’s accelerated approval pathway Lancet Oncol 2023 24 203 205 10.1016/S1470-2045(23)00020-7 36858720 Benjamin, D. J. & Lythgoe, M. P. Modernising the US FDA’s accelerated approval pathway. Lancet Oncol 24 , 203–205 (2023). 36858720 10.1016/S1470-2045(23)00020-7

12. Franco P Regulatory pathways supporting expedited drug development and approval in ICH member countries Ther. Innov. Regul. Sci. 2023 57 484 514 10.1007/s43441-022-00480-3 36463352 PMC9734413 Franco, P. et al. Regulatory pathways supporting expedited drug development and approval in ICH member countries. Ther. Innov. Regul. Sci. 57 , 484–514 (2023). 36463352 10.1007/s43441-022-00480-3 PMC9734413

13. Ghadanian M Schafheutle E Comparison between European Medicines Agency and US Food and Drug Administration in granting accelerated marketing authorizations for Covid-19 medicines and their utilized regulations Ther. Innov. Regul. Sci. 2024 58 79 113 10.1007/s43441-023-00574-6 37861859 PMC10764419 Ghadanian, M. & Schafheutle, E. Comparison between European Medicines Agency and US Food and Drug Administration in granting accelerated marketing authorizations for Covid-19 medicines and their utilized regulations. Ther. Innov. Regul. Sci. 58 , 79–113 (2024). 37861859 10.1007/s43441-023-00574-6 PMC10764419

14. de Claro RA Project Orbis: global collaborative review program Clin. Cancer Res. 2020 26 6412 6416 10.1158/1078-0432.CCR-20-3292 33037016 de Claro, R. A. et al. Project Orbis: global collaborative review program. Clin. Cancer Res. 26 , 6412–6416 (2020). 33037016 10.1158/1078-0432.CCR-20-3292

15. Beca J HPR161 international comparisons of health technology assessment and reimbursement outcomes for oncology drugs with regulatory review through project Orbis Value Health 2023 26 S238 10.1016/j.jval.2023.03.2634 Beca, J. et al. HPR161 international comparisons of health technology assessment and reimbursement outcomes for oncology drugs with regulatory review through project Orbis. Value Health 26 , S238 (2023).

16. Tibau A Kesselheim AS Global cooperation and early access—clinical outcomes matter Lancet Oncol 2024 25 687 688 10.1016/S1470-2045(24)00210-9 38754452 Tibau, A. & Kesselheim, A. S. Global cooperation and early access—clinical outcomes matter. Lancet Oncol 25 , 687–688 (2024). 38754452 10.1016/S1470-2045(24)00210-9

17. Arora S FDA approval summary: pembrolizumab plus lenvatinib for endometrial carcinoma, a collaborative international review under project orbis Clin. Cancer Res. 2020 26 5062 5067 10.1158/1078-0432.CCR-19-3979 32295834 Arora, S. et al. FDA approval summary: pembrolizumab plus lenvatinib for endometrial carcinoma, a collaborative international review under project orbis. Clin. Cancer Res. 26 , 5062–5067 (2020). 32295834 10.1158/1078-0432.CCR-19-3979

18. Koch AL FDA approval summary: osimertinib for adjuvant treatment of surgically resected non–small cell lung cancer, a Collaborative Project Orbis Review Clin. Cancer Res. 2021 27 6638 6643 10.1158/1078-0432.CCR-21-1034 34301748 Koch, A. L. et al. FDA approval summary: osimertinib for adjuvant treatment of surgically resected non–small cell lung cancer, a Collaborative Project Orbis Review. Clin. Cancer Res. 27 , 6638–6643 (2021). 34301748 10.1158/1078-0432.CCR-21-1034

19. Jenei K Gentilini A Haslam A Prasad V Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis Lancet Oncol 2024 25 979 988 10.1016/S1470-2045(24)00286-9 39004098 Jenei, K., Gentilini, A., Haslam, A. & Prasad, V. Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis. Lancet Oncol 25 , 979–988 (2024). 39004098 10.1016/S1470-2045(24)00286-9

20. EMA. EMA to support establishment of the African Medicines Agency , < https://www.ema.europa.eu/en/news/ema-support-establishment-african-medicines-agency > (2024).

21. Ncube BM Dube A Ward K Establishment of the African Medicines Agency: progress, challenges and regulatory readiness J. Pharm. Policy Pract. 2021 14 29 10.1186/s40545-020-00281-9 33685518 PMC7938385 Ncube, B. M., Dube, A. & Ward, K. Establishment of the African Medicines Agency: progress, challenges and regulatory readiness. J. Pharm. Policy Pract. 14 , 29 (2021). 33685518 10.1186/s40545-020-00281-9 PMC7938385

22. Abdulwahab AA The African Medicines Agency and Medicines Regulation: Progress, challenges, and recommendations Health Care Sci 2024 3 350 359 10.1002/hcs2.117 39479274 PMC11520252 Abdulwahab, A. A. et al. The African Medicines Agency and Medicines Regulation: Progress, challenges, and recommendations. Health Care Sci 3 , 350–359 (2024). 39479274 10.1002/hcs2.117 PMC11520252

23. Ogbodum MU African Medicines Agency: How it will change the landscape of medicines in Africa Public Health Chall 2023 2 e96 10.1002/puh2.96 40495871 PMC12039615 Ogbodum, M. U. et al. African Medicines Agency: How it will change the landscape of medicines in Africa. Public Health Chall 2 , e96 (2023). 40495871 10.1002/puh2.96 PMC12039615

24. Hwenda L Sidibe M Makanga M The African Medicines Agency: the key to unlocking clinical research in Africa Lancet Glob. Health. 2022 10 e1088 e1089 10.1016/S2214-109X(22)00243-1 35716676 Hwenda, L., Sidibe, M. & Makanga, M. The African Medicines Agency: the key to unlocking clinical research in Africa. Lancet Glob. Health. 10 , e1088–e1089 (2022). 35716676 10.1016/S2214-109X(22)00243-1

25. Chattu VK Advancing African Medicines Agency through global health diplomacy for an equitable pan-African universal health coverage: a scoping review Int. J. Env. Res. Public Health. 2021 18 11758 10.3390/ijerph182211758 34831511 PMC8621302 Chattu, V. K. et al. Advancing African Medicines Agency through global health diplomacy for an equitable pan-African universal health coverage: a scoping review. Int. J. Env. Res. Public Health. 18 , 11758 (2021). 34831511 10.3390/ijerph182211758 PMC8621302

26. Kong L Li Q Kaitin KI Shao L Innovation in the Chinese pharmaceutical industry Nat. Rev. Drug Discov. 2023 22 12 13 10.1038/d41573-022-00167-2 36303035 Kong, L., Li, Q., Kaitin, K. I. & Shao, L. Innovation in the Chinese pharmaceutical industry. Nat. Rev. Drug Discov. 22 , 12–13 (2023). 36303035 10.1038/d41573-022-00167-2

27. Jia, R., Ma, X., Yang, J. & Zhang, Y. Improving Regulation for Innovation: Evidence from China’s Pharmaceutical Industry (National Bureau of Economic Research, 2023).

28. CHINADAILY. China advances new drug innovations < https://global.chinadaily.com.cn/a/202204/25/WS6265f594a310fd2b29e590ae.html > (2022).

29. Deloitte. Outlook on biopharma innovation trends in China < https://www2.deloitte.com/cn/en/pages/life-sciences-and-healthcare/articles/china-biopharma-innovation-trends.html > (2024).

30. Liu Y Evolution of drug regulations and regulatory innovation for anticancer drugs in China Acta Pharm. Sin. B. 2022 12 4365 4377 10.1016/j.apsb.2022.08.004 36561995 PMC9764065 Liu, Y. et al. Evolution of drug regulations and regulatory innovation for anticancer drugs in China. Acta Pharm. Sin. B. 12 , 4365–4377 (2022). 36561995 10.1016/j.apsb.2022.08.004 PMC9764065

31. Tang W Evolving drug regulatory landscape in China: a clinical pharmacology perspective Clin. Transl. Sci. 2021 14 1222 1230 10.1111/cts.12987 33503308 PMC8301550 Tang, W. et al. Evolving drug regulatory landscape in China: a clinical pharmacology perspective. Clin. Transl. Sci. 14 , 1222–1230 (2021). 33503308 10.1111/cts.12987 PMC8301550

32. Hu Y Retrospection of drug regulatory system reform in china through 1998-2023 Chin. Food Drug Adm. Mag. 2023 03 124 125 Hu, Y. Retrospection of drug regulatory system reform in china through 1998-2023. Chin. Food Drug Adm. Mag. 03 , 124–125 (2023).

33. NMPA. NMPA Held 2023 ICH in China: Progress and Outlook Symposium < https://english.nmpa.gov.cn/2023-09/13/c_963948.htm > (2023).

34. NMPA. NMPA holds symposium on process and prospects of ICH in China < https://english.nmpa.gov.cn/2021-04/10/c_610224.htm#:~:text=China%27s%20drug%20regulatory%20authority%20joined%20the%20ICH%20in,member%20of%20the%20ICH%20Management%20Committee%20in%202018 > (2021).

35. ICH. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) < https://www.ich.org/ > (2024).

36. Lu J Xu L Wei W He W Advanced therapy medicinal products in China: regulation and development MedComm 2023 4 e251 10.1002/mco2.251 37125239 PMC10133728 Lu, J., Xu, L., Wei, W. & He, W. Advanced therapy medicinal products in China: regulation and development. MedComm 4 , e251 (2023). 37125239 10.1002/mco2.251 PMC10133728

37. Zhu Q Expedited program and utilization for anticancer drug approval in China and the United States Chin. J. Oncol. 2024 46 904 910 10.3760/cma.j.cn112152-20231024-00250 39293993 Zhu, Q. et al. Expedited program and utilization for anticancer drug approval in China and the United States. Chin. J. Oncol. 46 , 904–910 (2024). 10.3760/cma.j.cn112152-20231024-00250 39293993

38. The Ministry of Health. The “Major New Drug Development” National Science and Technology Major Project Officially Launched < https://www.gov.cn/gzdt/2008-08/29/content_1082804.htm > (2008).

39. National Medical Products Administration. The NMPA launched the China Drug Regulatory Science Action Plan < http://www.gov.cn/xinwen/2019-05/02/content_5388253.htm > (2019).

40. Tan R Redefining chimeric antigen receptor T-cell (CAR-T) regulation: China’s responses to address secondary cancer risks of CAR-T therapy J. Hematol. Oncol. 2024 17 90 10.1186/s13045-024-01602-0 39380046 PMC11462758 Tan, R. et al. Redefining chimeric antigen receptor T-cell (CAR-T) regulation: China’s responses to address secondary cancer risks of CAR-T therapy. J. Hematol. Oncol. 17 , 90 (2024). 39380046 10.1186/s13045-024-01602-0 PMC11462758

41. Wang S The landscape of cell and gene therapies for solid tumors Cancer Cell 2021 39 7 8 10.1016/j.ccell.2020.12.005 33434513 Wang, S. et al. The landscape of cell and gene therapies for solid tumors. Cancer Cell 39 , 7–8 (2021). 33434513 10.1016/j.ccell.2020.12.005

42. Zhao J Scientific progress of drug regulation and development of drug regulatory science in China Sci. Sin. Vitae. 2024 54 507 524 Zhao, J. et al. Scientific progress of drug regulation and development of drug regulatory science in China. Sci. Sin. Vitae. 54 , 507–524 (2024).

43. Zhao J Prospect for the construction and development of China’s drug regulatory science system Pharmacol. Clin. Chin. Mater. Med. 2024 40 3 17 Zhao, J. Prospect for the construction and development of China’s drug regulatory science system. Pharmacol. Clin. Chin. Mater. Med. 40 , 3–17 (2024).

44. Li G Evolution of innovative drug R&D in China Nat. Rev. Drug Discov. 2022 21 553 554 10.1038/d41573-022-00058-6 35365768 Li, G. et al. Evolution of innovative drug R&D in China. Nat. Rev. Drug Discov. 21 , 553–554 (2022). 35365768 10.1038/d41573-022-00058-6

45. Luo X Clinical benefit, price, and regulatory approval of cancer drugs granted breakthrough therapy designation in China, 2020-2024 JAMA Netw. Open. 2024 7 e2439080 10.1001/jamanetworkopen.2024.39080 39412805 PMC11581593 Luo, X. et al. Clinical benefit, price, and regulatory approval of cancer drugs granted breakthrough therapy designation in China, 2020-2024. JAMA Netw. Open. 7 , e2439080 (2024). 39412805 10.1001/jamanetworkopen.2024.39080 PMC11581593

46. Arciero V Assessment of Food and Drug Administration–and European Medicines Agency–approved systemic oncology therapies and clinically meaningful improvements in quality of life: a systematic review JAMA Netw. Open. 2021 4 e2033004 10.1001/jamanetworkopen.2020.33004 33570573 PMC7879236 Arciero, V. et al. Assessment of Food and Drug Administration–and European Medicines Agency–approved systemic oncology therapies and clinically meaningful improvements in quality of life: a systematic review. JAMA Netw. Open. 4 , e2033004 (2021). 33570573 10.1001/jamanetworkopen.2020.33004 PMC7879236

47. Lythgoe M Time intervals between US Food and Drug Administration (FDA) and European Medicines Agency (EMA) new cancer therapy approvals J. Clin. Oncol. 2021 39 15 10.1200/JCO.2021.39.15_suppl.1575 Lythgoe, M. et al. Time intervals between US Food and Drug Administration (FDA) and European Medicines Agency (EMA) new cancer therapy approvals. J. Clin. Oncol. 39 , 15 (2021).

48. Gnanasakthy A A review of labeling based on patient-reported outcome endpoints for new oncology drugs approved by the European medicines agency (2017–2021) Value Health 2023 26 893 901 10.1016/j.jval.2023.01.017 36746305 Gnanasakthy, A. et al. A review of labeling based on patient-reported outcome endpoints for new oncology drugs approved by the European medicines agency (2017–2021). Value Health 26 , 893–901 (2023). 36746305 10.1016/j.jval.2023.01.017

49. Drug Administration Law of the People’s Republic of China , < https://www.gov.cn/xinwen/2019-08/26/content_5424780.htm > (2019).

50. Opinions on Reforming the Review and Approval System for Drugs and Medical Devices < https://www.gov.cn/zhengce/content/2015-08/18/content_10101.htm > (2015).

51. Drug Registration Management Act , < https://www.gov.cn/gongbao/content/2020/content_5512563.htm > (2020).

52. Notice of the NMPA on the release of chemical drug registration classification and declaration data requirements , < https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20200630180301525.html > (2020).

53. Announcement of the NMPA on Issuing the Classification and Documentation Requirements for the Registration of Biological Products , < https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20200630175301552.html > (2020).

54. Announcement of the National Medical Products Administration on Issuing the “Classification and Documentation Requirements for the Registration of Traditional Chinese Medicines” < https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20200928164311143.html > (2020).

55. FDA. Drug Development and Review Definitions < https://www.fda.gov/drugs/investigational-new-drug-ind-application/drug-development-and-review-definitions > (2015).

56. FDA. Novel Drug Approvals at FDA < https://www.fda.gov/drugs/development-approval-process-drugs/novel-drug-approvals-fda > (2024).

57. FDA. New Molecular Entity (NME) Drug and New Biologic Approvals < https://www.fda.gov/drugs/nda-and-bla-approvals/new-molecular-entity-nme-drug-and-new-biologic-approvals > (2024).

58. Brown DG Wobst HJ A decade of FDA-approved drugs (2010–2019): trends and future directions J. Med. Chem. 2021 64 2312 2338 10.1021/acs.jmedchem.0c01516 33617254 Brown, D. G. & Wobst, H. J. A decade of FDA-approved drugs (2010–2019): trends and future directions. J. Med. Chem. 64 , 2312–2338 (2021). 33617254 10.1021/acs.jmedchem.0c01516

59. Pevarello P Recent drug approvals from the US FDA and EMEA: what the future holds Future Med. Chem. 2009 1 35 48 10.4155/fmc.09.8 21426069 Pevarello, P. Recent drug approvals from the US FDA and EMEA: what the future holds. Future Med. Chem. 1 , 35–48 (2009). 21426069 10.4155/fmc.09.8

60. SSRN. FDA’s Approvable and Related NDA/BLA Actions < https://ssrn.com/abstract=1105509 > (2008).

61. Branch SK Agranat I “New drug” designations for new therapeutic entities: New active substance, new chemical entity, new biological entity, new molecular entity J. Med. Chem. 2014 57 8729 8765 10.1021/jm402001w 25188028 Branch, S. K. & Agranat, I. “New drug” designations for new therapeutic entities: New active substance, new chemical entity, new biological entity, new molecular entity. J. Med. Chem. 57 , 8729–8765 (2014). 25188028 10.1021/jm402001w

62. Griesenauer RH Kinch MS 2016 in review: FDA approvals of new molecular entities Drug Discov. Today. 2017 22 1593 1597 10.1016/j.drudis.2017.06.011 28687460 Griesenauer, R. H. & Kinch, M. S. 2016 in review: FDA approvals of new molecular entities. Drug Discov. Today. 22 , 1593–1597 (2017). 28687460 10.1016/j.drudis.2017.06.011

63. Kinch MS Griesenauer RH 2018 in review: FDA approvals of new molecular entities Drug Discov. Today. 2019 24 1710 1714 10.1016/j.drudis.2019.05.022 31158510 PMC7580227 Kinch, M. S. & Griesenauer, R. H. 2018 in review: FDA approvals of new molecular entities. Drug Discov. Today. 24 , 1710–1714 (2019). 31158510 10.1016/j.drudis.2019.05.022 PMC7580227

64. Kinch MS Griesenauer RH 2017 in review: FDA approvals of new molecular entities Drug Discov. Today. 2018 23 1469 1473 10.1016/j.drudis.2018.05.011 29751111 Kinch, M. S. & Griesenauer, R. H. 2017 in review: FDA approvals of new molecular entities. Drug Discov. Today. 23 , 1469–1473 (2018). 29751111 10.1016/j.drudis.2018.05.011

65. Cross J Postmarketing drug dosage changes of 499 FDA‐approved new molecular entities, 1980–1999 Pharmacoepidemiol. Drug Saf. 2002 11 439 446 10.1002/pds.744 12426927 Cross, J. et al. Postmarketing drug dosage changes of 499 FDA‐approved new molecular entities, 1980–1999. Pharmacoepidemiol. Drug Saf. 11 , 439–446 (2002). 12426927 10.1002/pds.744

66. Kinch MS Haynesworth A Kinch SL Hoyer D An overview of FDA-approved new molecular entities: 1827–2013 Drug Discov. Today. 2014 19 1033 1039 10.1016/j.drudis.2014.03.018 24680947 Kinch, M. S., Haynesworth, A., Kinch, S. L. & Hoyer, D. An overview of FDA-approved new molecular entities: 1827–2013. Drug Discov. Today. 19 , 1033–1039 (2014). 24680947 10.1016/j.drudis.2014.03.018

67. REPROCELL. What you should know about the FDA’s Biological License Application Process < https://www.reprocell.com/blog/what-you-should-know-about-the-fdas-biological-license-application-process > (2024).

68. FDA. Biologics License Applications (BLA) Process (CBER) < https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/biologics-license-applications-bla-process-cber > (2021).

69. FDA. Submitting Biologics Advertising & Promotional Labeling < https://www.fda.gov/vaccines-blood-biologics/labeling-cber-regulated-products/submitting-biologics-advertising-promotional-labeling > (2018).

70. FDA. Biological Approvals by Year < https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/biological-approvals-year > (2024).

71. FDA. Frequently Asked Questions About Therapeutic Biological Products < https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/frequently-asked-questions-about-therapeutic-biological-products > (2024).

72. Hemphill TA Biologics regulation, second-to-market competition, and the use of blockchain technology: an opportunity for the FDA to support responsible biotechnology innovation J. Respons. Innov. 2020 7 689 696 10.1080/23299460.2020.1807669 Hemphill, T. A. Biologics regulation, second-to-market competition, and the use of blockchain technology: an opportunity for the FDA to support responsible biotechnology innovation. J. Respons. Innov. 7 , 689–696 (2020).

73. Chang L-C Mahmood R Qureshi S Breder CD Patterns of use and impact of standardised MedDRA query analyses on the safety evaluation and review of new drug and biologics license applications PLoS One 2017 12 e0178104 10.1371/journal.pone.0178104 28570569 PMC5453490 Chang, L.-C., Mahmood, R., Qureshi, S. & Breder, C. D. Patterns of use and impact of standardised MedDRA query analyses on the safety evaluation and review of new drug and biologics license applications. PLoS One 12 , e0178104 (2017). 28570569 10.1371/journal.pone.0178104 PMC5453490

74. Lau SJ Participation of older adults in clinical trials for new drug applications and biologics license applications from 2010 through 2019 JAMA Netw. Open. 2022 5 e2236149 10.1001/jamanetworkopen.2022.36149 36239939 PMC9568796 Lau, S. J. et al. Participation of older adults in clinical trials for new drug applications and biologics license applications from 2010 through 2019. JAMA Netw. Open. 5 , e2236149 (2022). 36239939 10.1001/jamanetworkopen.2022.36149 PMC9568796

75. Kinch MS An overview of FDA-approved biologics medicines Drug Discov. Today. 2015 20 393 398 10.1016/j.drudis.2014.09.003 25220442 Kinch, M. S. An overview of FDA-approved biologics medicines. Drug Discov. Today. 20 , 393–398 (2015). 25220442 10.1016/j.drudis.2014.09.003

76. Arondekar B Real-world evidence in support of oncology product registration: a systematic review of new drug application and biologics license application approvals from 2015–2020 Clin. Cancer Res. 2022 28 27 35 10.1158/1078-0432.CCR-21-2639 34667027 PMC9401526 Arondekar, B. et al. Real-world evidence in support of oncology product registration: a systematic review of new drug application and biologics license application approvals from 2015–2020. Clin. Cancer Res. 28 , 27–35 (2022). 34667027 10.1158/1078-0432.CCR-21-2639 PMC9401526

77. Rogstad S A retrospective evaluation of the use of mass spectrometry in FDA biologics license applications J. Am. Soc. Mass Spectrom. 2016 28 786 794 10.1007/s13361-016-1531-9 27873217 Rogstad, S. et al. A retrospective evaluation of the use of mass spectrometry in FDA biologics license applications. J. Am. Soc. Mass Spectrom. 28 , 786–794 (2016). 27873217 10.1007/s13361-016-1531-9

78. Purpura CA The role of real‐world evidence in FDA‐approved new drug and biologics license applications Clin. Pharmacol. Ther. 2022 111 135 144 10.1002/cpt.2474 34726771 PMC9299054 Purpura, C. A. et al. The role of real‐world evidence in FDA‐approved new drug and biologics license applications. Clin. Pharmacol. Ther. 111 , 135–144 (2022). 34726771 10.1002/cpt.2474 PMC9299054

79. EMA. Innovative medicine < https://www.ema.europa.eu/en/glossary-terms/innovative-medicine?utm_source=chatgpt.com > (2024).

80. Annemans L Cleemput I Hulstaert F Simoens S Valorising and creating access to innovative medicines in the European Union Front. Pharmacol. 2011 2 57 10.3389/fphar.2011.00057 22013421 PMC3190181 Annemans, L., Cleemput, I., Hulstaert, F. & Simoens, S. Valorising and creating access to innovative medicines in the European Union. Front. Pharmacol. 2 , 57 (2011). 22013421 10.3389/fphar.2011.00057 PMC3190181

81. Motola D An update on the first decade of the European centralized procedure: how many innovative drugs? Br. J. Clin. Pharmacol. 2006 62 610 616 10.1111/j.1365-2125.2006.02700.x 16796703 PMC1885166 Motola, D. et al. An update on the first decade of the European centralized procedure: how many innovative drugs? Br. J. Clin. Pharmacol. 62 , 610–616 (2006). 16796703 10.1111/j.1365-2125.2006.02700.x PMC1885166

82. Bergmann L Access to innovative oncology medicines in Europe Ann. Oncol. 2016 27 353 356 10.1093/annonc/mdv547 26578739 PMC4722892 Bergmann, L. et al. Access to innovative oncology medicines in Europe. Ann. Oncol. 27 , 353–356 (2016). 26578739 10.1093/annonc/mdv547 PMC4722892

83. Vallano A Pontes C Agustí A The challenges of access to innovative medicines with limited evidence in the European Union Front. Pharmacol. 2023 14 1215431 10.3389/fphar.2023.1215431 37719853 PMC10500193 Vallano, A., Pontes, C. & Agustí, A. The challenges of access to innovative medicines with limited evidence in the European Union. Front. Pharmacol. 14 , 1215431 (2023). 37719853 10.3389/fphar.2023.1215431 PMC10500193

84. Enzmann H New trends and challenges in the European regulation of innovative medicines Regul. Toxicol. Pharmacol. 2016 80 314 320 10.1016/j.yrtph.2016.05.033 27237379 Enzmann, H. New trends and challenges in the European regulation of innovative medicines. Regul. Toxicol. Pharmacol. 80 , 314–320 (2016). 27237379 10.1016/j.yrtph.2016.05.033

85. Goldman M The innovative medicines initiative: a European response to the innovation challenge Clin. Pharmacol. Ther. 2012 91 418 425 10.1038/clpt.2011.321 22318619 Goldman, M. The innovative medicines initiative: a European response to the innovation challenge. Clin. Pharmacol. Ther. 91 , 418–425 (2012). 22318619 10.1038/clpt.2011.321

86. Kondo H The current status of Sakigake designation in Japan, PRIME in the European Union, and breakthrough therapy designation in the United States Ther. Innov. Regul. Sci. 2017 51 51 54 10.1177/2168479016662682 30235998 Kondo, H. et al. The current status of Sakigake designation in Japan, PRIME in the European Union, and breakthrough therapy designation in the United States. Ther. Innov. Regul. Sci. 51 , 51–54 (2017). 30235998 10.1177/2168479016662682

87. Joppi R Food and Drug Administration vs European Medicines Agency: review times and clinical evidence on novel drugs at the time of approval Br. J. Clin. Pharmacol. 2020 86 170 174 10.1111/bcp.14130 31657044 PMC6983504 Joppi, R. et al. Food and Drug Administration vs European Medicines Agency: review times and clinical evidence on novel drugs at the time of approval. Br. J. Clin. Pharmacol. 86 , 170–174 (2020). 31657044 10.1111/bcp.14130 PMC6983504

88. Mullard A PRIME time at the EMA Nat. Rev. Drug Discov. 2017 16 226 228 10.1038/nrd.2017.57 28356591 Mullard, A. PRIME time at the EMA. Nat. Rev. Drug Discov. 16 , 226–228 (2017). 28356591 10.1038/nrd.2017.57

89. Antoñanzas F Juárez-Castelló C Rodríguez-Ibeas R EMA Priority Medicines scheme (PRIME): will more paying-for-performance agreements be needed due to immature data? Eur. J. Health Econ. 2018 19 905 907 10.1007/s10198-017-0944-0 29188395 Antoñanzas, F., Juárez-Castelló, C. & Rodríguez-Ibeas, R. EMA Priority Medicines scheme (PRIME): will more paying-for-performance agreements be needed due to immature data? Eur. J. Health Econ. 19 , 905–907 (2018). 29188395 10.1007/s10198-017-0944-0

90. Neez E Hwang TJ Sahoo SA Naci H European Medicines Agency’s priority medicines scheme at 2 years: an evaluation of clinical studies supporting eligible drugs Clin. Pharmacol. Ther. 2020 107 541 552 10.1002/cpt.1669 31591708 Neez, E., Hwang, T. J., Sahoo, S. A. & Naci, H. European Medicines Agency’s priority medicines scheme at 2 years: an evaluation of clinical studies supporting eligible drugs. Clin. Pharmacol. Ther. 107 , 541–552 (2020). 31591708 10.1002/cpt.1669

91. Boucaud-Maitre D Altman J-J Do the EMA accelerated assessment procedure and the FDA priority review ensure a therapeutic added value? 2006–2015: a cohort study Eur. J. Clin. Pharmacol. 2016 72 1275 1281 10.1007/s00228-016-2104-3 27473682 Boucaud-Maitre, D. & Altman, J.-J. Do the EMA accelerated assessment procedure and the FDA priority review ensure a therapeutic added value? 2006–2015: a cohort study. Eur. J. Clin. Pharmacol. 72 , 1275–1281 (2016). 27473682 10.1007/s00228-016-2104-3

92. Parviainen L Early market access for pharmaceuticals in EU: what is the impact of EMA’s accelerated assessment procedure? Value Health 2016 19 A469 10.1016/j.jval.2016.09.710 Parviainen, L. et al. Early market access for pharmaceuticals in EU: what is the impact of EMA’s accelerated assessment procedure? Value Health 19 , A469 (2016).

93. Li X Yang Q Zhou B Empirical analysis on the policies of drug accelerated assessment in the European Union China Pharm 2019 12 443 447 Li, X., Yang, Q. & Zhou, B. Empirical analysis on the policies of drug accelerated assessment in the European Union. China Pharm 12 , 443–447 (2019).

94. EMA. Accelerated assessment < https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/accelerated-assessment > (2021).

95. Center, N. M. P. A. D. E. 2023 Annual Drug Evaluation Report < https://www.cde.org.cn/main/news/viewInfoCommon/9506710a7471174ab169e98b0bbb9e23 > (2024).

96. 2022 Annual Drug Evaluation Report < https://www.cde.org.cn/main/news/viewInfoCommon/849b5a642142fc00738aff200077db11 > (2023).

97. 2021 Annual Drug Evaluation Report < https://www.cde.org.cn/main/news/viewInfoCommon/f92b7bdf775bbf4c4dc3a762f343cdc8 > (2022).

98. 2020 Annual Drug Evaluation Report < https://www.cde.org.cn/main/news/viewInfoCommon/876bb5300cce2d3a5cf4f68c97c8a631 > (2021).

99. 2019 Annual Drug Evaluation Report < https://www.cde.org.cn/main/news/viewInfoCommon/327a9e456913626826bc4cbdfd5354ce > (2020).

100. FDA. IND Receipts < https://www.fda.gov/drugs/ind-activity/ind-receipts?utm_source=chatgpt.com > (2024).

101. CardinalHealth. Key trends in IND applications < https://www.cardinalhealth.com/en/services/manufacturer/biopharmaceutical/drug-development-and-regulatory/resources-for-regulatory-consulting/fda-insights/key-trends-in-ind-applications.html > (2024).

102. Lapteva L Pariser AR Investigational New Drug applications: a 1-year pilot study on rates and reasons for clinical hold J. Investig. Med. 2016 64 376 382 10.1136/jim-2015-000010 26911627 Lapteva, L. & Pariser, A. R. Investigational New Drug applications: a 1-year pilot study on rates and reasons for clinical hold. J. Investig. Med. 64 , 376–382 (2016). 26911627 10.1136/jim-2015-000010

103. Giannuzzi V Altavilla A Ruggieri L Ceci A Clinical trial application in Europe: what will change with the new regulation? Sci. Eng. Ethics. 2016 22 451 466 10.1007/s11948-015-9662-0 26037896 Giannuzzi, V., Altavilla, A., Ruggieri, L. & Ceci, A. Clinical trial application in Europe: what will change with the new regulation? Sci. Eng. Ethics. 22 , 451–466 (2016). 26037896 10.1007/s11948-015-9662-0

104. Eder C Wild C Technology forecast: advanced therapies in late clinical research, EMA approval or clinical application via hospital exemption J. Mark. Access Health Policy. 2019 7 1600939 10.1080/20016689.2019.1600939 31069029 PMC6493298 Eder, C. & Wild, C. Technology forecast: advanced therapies in late clinical research, EMA approval or clinical application via hospital exemption. J. Mark. Access Health Policy. 7 , 1600939 (2019). 31069029 10.1080/20016689.2019.1600939 PMC6493298

105. EMA. Clinical Trials Regulation < https://www.ema.europa.eu/en/human-regulatory-overview/research-development/clinical-trials-human-medicines/clinical-trials-regulation > (2022).

106. NIH. ClinicalTrials.gov < https://clinicaltrials.gov/ > (2023).

107. BIO, P. A very interesting undertaking: international multi-center clinical trials < https://www.pbmcbioshandong.com/hyxw/269.html > (2024).

108. TIMES, F. Europe falls behind China in playing host to clinical drug trials < https://www-ft-com.ezphost.dur.ac.uk/content/3d861acb-8e7d-4157-b845-81124254da8a > (2024).

109. TIMES, F. Europe falling behind US and China in pharma innovation, warns AstraZeneca chief < https://www.ft.com/content/2c0d4917-f837-4aad-be54-6a727800c3e4 > (2024).

110. Pharmaphorum. Europe’s share of clinical trials falling, with China rising < https://pharmaphorum.com/news/europes-share-clinical-trials-falling-china-rising > (2024).

111. VanHelene AD As bleak as it sounds? Analysing trends in oncology clinical trial initiation in the UK from 2010 to 2022 BMJ Oncol. 2024 3 e000410 10.1136/bmjonc-2024-000410 39886121 PMC11347684 VanHelene, A. D. et al. As bleak as it sounds? Analysing trends in oncology clinical trial initiation in the UK from 2010 to 2022. BMJ Oncol. 3 , e000410 (2024). 39886121 10.1136/bmjonc-2024-000410 PMC11347684

112. Lasch F The impact of COVID‐19 on the initiation of clinical trials in Europe and the United States Clin. Pharmacol. Ther. 2022 111 1093 1102 10.1002/cpt.2534 35090044 PMC9015398 Lasch, F. et al. The impact of COVID‐19 on the initiation of clinical trials in Europe and the United States. Clin. Pharmacol. Ther. 111 , 1093–1102 (2022). 35090044 10.1002/cpt.2534 PMC9015398

113. Capone G Accelerating clinical trials in the EU (ACT EU): transforming the EU clinical trials landscape Nat. Rev. Drug Discov. 2024 23 797 798 10.1038/d41573-024-00085-5 38783027 Capone, G. et al. Accelerating clinical trials in the EU (ACT EU): transforming the EU clinical trials landscape. Nat. Rev. Drug Discov. 23 , 797–798 (2024). 38783027 10.1038/d41573-024-00085-5

114. Center for Drug Evaluation, NMPA 2020 Annual report on the progress of clinical trials for new drug registration in China < https://www.cde.org.cn/main/news/viewInfoCommon/d670723dd2f646722097b03cf005e052 > (2021).

115. Center for Drug Evaluation, NMPA 2021 Annual report on the progress of clinical trials for new drug registration in China, < https://www.cde.org.cn/main/news/viewInfoCommon/1839a2c931e1ed43eb4cc7049e189cb0 > (2022).

116. Center for Drug Evaluation, NMPA 2022 Annual report on the progress of clinical trials for new drug registration in China < https://www.cde.org.cn/main/news/viewInfoCommon/46260e34bfe67292bfae1de8863d20fe > (2023).

117. Center for Drug Evaluation, NMPA 2023 Annual report on the progress of clinical trials for new drug registration in China, < https://www.cde.org.cn/main/news/viewInfoCommon/d25e2879906bd2d3ae6c929aece41e34 > (2024).

118. Wang W Sun Q Novel targeted drugs approved by the NMPA and FDA in 2019 Signal Transduct. Target. Ther. 2020 5 65 10.1038/s41392-020-0164-4 32385226 PMC7205905 Wang, W. & Sun, Q. Novel targeted drugs approved by the NMPA and FDA in 2019. Signal Transduct. Target. Ther. 5 , 65 (2020). 32385226 10.1038/s41392-020-0164-4 PMC7205905

119. FDA. Novel Drug Approvals for 2023 , < https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023 > (2024).

120. Ali S Zhou J Highlights on US FDA-approved fluorinated drugs over the past five years (2018–2022) Eur. J. Med. Chem. 2023 256 115476 10.1016/j.ejmech.2023.115476 37207534 PMC10247436 Ali, S. & Zhou, J. Highlights on US FDA-approved fluorinated drugs over the past five years (2018–2022). Eur. J. Med. Chem. 256 , 115476 (2023). 37207534 10.1016/j.ejmech.2023.115476 PMC10247436

121. Michaeli DT Michaeli T Breakthrough therapy cancer drugs and indications with FDA approval: development time, innovation, trials, clinical benefit, epidemiology, and price J. Natl. Compr. Canc. Netw. 2024 22 237110 10.6004/jnccn.2023.7110 38648855 Michaeli, D. T. & Michaeli, T. Breakthrough therapy cancer drugs and indications with FDA approval: development time, innovation, trials, clinical benefit, epidemiology, and price. J. Natl. Compr. Canc. Netw. 22 , 237110 (2024). 10.6004/jnccn.2023.7110 38648855

122. Corrigan‐Curay J Stein P FDA Breakthrough therapy designation–trial design and more–commentary Clin. Pharmacol. Ther. 2021 110 869 870 10.1002/cpt.2378 34389983 Corrigan‐Curay, J. & Stein, P. FDA Breakthrough therapy designation–trial design and more–commentary. Clin. Pharmacol. Ther. 110 , 869–870 (2021). 34389983 10.1002/cpt.2378

123. Chandra A Kao J Miller KL Stern AD Regulatory incentives for innovation: the FDA’s breakthrough therapy designation Rev. Econ. Stat. 2024 2024 1 46 10.1162/rest_a_01434 Chandra, A., Kao, J., Miller, K. L. & Stern, A. D. Regulatory incentives for innovation: the FDA’s breakthrough therapy designation. Rev. Econ. Stat. 2024 , 1–46 (2024).

124. Herink MC Pharmacists’ knowledge and perceptions of FDA approval standards and the breakthrough therapy designation Pharmacy. 2022 10 126 10.3390/pharmacy10050126 36287447 PMC9610476 Herink, M. C. et al. Pharmacists’ knowledge and perceptions of FDA approval standards and the breakthrough therapy designation. Pharmacy. 10 , 126 (2022). 36287447 10.3390/pharmacy10050126 PMC9610476

125. Lingaratnam S Australian access to FDA-approved breakthrough therapy designation medicines: a 10-year review J. Pharm. Policy and Pract. 2024 17 2389120 10.1080/20523211.2024.2389120 39175661 PMC11340226 Lingaratnam, S. et al. Australian access to FDA-approved breakthrough therapy designation medicines: a 10-year review. J. Pharm. Policy and Pract. 17 , 2389120 (2024). 39175661 10.1080/20523211.2024.2389120 PMC11340226

126. Paquin RS Boudewyns V O’Donoghue AC Aikin KJ Physician perceptions of the FDA’s breakthrough therapy designation: an update Oncologist. 2022 27 e85 e88 10.1093/oncolo/oyab021 35305103 PMC8842303 Paquin, R. S., Boudewyns, V., O’Donoghue, A. C. & Aikin, K. J. Physician perceptions of the FDA’s breakthrough therapy designation: an update. Oncologist. 27 , e85–e88 (2022). 35305103 10.1093/oncolo/oyab021 PMC8842303

127. Vokinger, K. N., Kesselheim, A. S., Glaus, C. E. & Hwang, T. J. in JAMA Health Forum . e222685 (American Medical Association). 10.1001/jamahealthforum.2022.2685 PMC9391955 36200635

128. Gyawali B Rome BN Kesselheim AS Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study BMJ. 2021 374 n1959 10.1136/bmj.n1959 34497044 PMC8424519 Gyawali, B., Rome, B. N. & Kesselheim, A. S. Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study. BMJ. 374 , n1959 (2021). 34497044 10.1136/bmj.n1959 PMC8424519

129. Gyawali B Ross JS Kesselheim AS Fulfilling the mandate of the US Food and Drug Administration’s accelerated approval pathway: the need for reforms JAMA Intern. Med. 2021 181 1275 1276 10.1001/jamainternmed.2021.4604 34254981 Gyawali, B., Ross, J. S. & Kesselheim, A. S. Fulfilling the mandate of the US Food and Drug Administration’s accelerated approval pathway: the need for reforms. JAMA Intern. Med. 181 , 1275–1276 (2021). 34254981 10.1001/jamainternmed.2021.4604

130. Cherla A Assessment of coverage in England of cancer drugs qualifying for US Food and Drug Administration accelerated approval JAMA Intern. Med. 2021 181 490 498 10.1001/jamainternmed.2020.8441 33616607 PMC7900925 Cherla, A. et al. Assessment of coverage in England of cancer drugs qualifying for US Food and Drug Administration accelerated approval. JAMA Intern. Med. 181 , 490–498 (2021). 33616607 10.1001/jamainternmed.2020.8441 PMC7900925

131. Wahby S FDA approval summary: accelerated approval of sacituzumab govitecan-hziy for third-line treatment of metastatic triple-negative breast cancer Clin. Cancer Res. 2021 27 1850 1854 10.1158/1078-0432.CCR-20-3119 33168656 Wahby, S. et al. FDA approval summary: accelerated approval of sacituzumab govitecan-hziy for third-line treatment of metastatic triple-negative breast cancer. Clin. Cancer Res. 27 , 1850–1854 (2021). 33168656 10.1158/1078-0432.CCR-20-3119

132. Choi HY Chang J-E Targeted therapy for cancers: from ongoing clinical trials to FDA-approved drugs Int. J. Mol. Sci. 2023 24 13618 10.3390/ijms241713618 37686423 PMC10487969 Choi, H. Y. & Chang, J.-E. Targeted therapy for cancers: from ongoing clinical trials to FDA-approved drugs. Int. J. Mol. Sci. 24 , 13618 (2023). 37686423 10.3390/ijms241713618 PMC10487969

133. Martins AC Oshiro MY Albericio F de la Torre BG Food and Drug Administration (FDA) approvals of biological drugs in 2023 Biomedicines. 2024 12 1992 10.3390/biomedicines12091992 39335511 PMC11428688 Martins, A. C., Oshiro, M. Y., Albericio, F. & de la Torre, B. G. Food and Drug Administration (FDA) approvals of biological drugs in 2023. Biomedicines. 12 , 1992 (2024). 39335511 10.3390/biomedicines12091992 PMC11428688

134. Moon H FDA regulatory considerations for oncology drug development Pharmacol. Res. Perspect. 2024 12 e1254 10.1002/prp2.1254 39075638 PMC11286537 Moon, H. et al. FDA regulatory considerations for oncology drug development. Pharmacol. Res. Perspect. 12 , e1254 (2024). 39075638 10.1002/prp2.1254 PMC11286537

135. Kluetz PG FDA oncology center of excellence project renewal: engaging the oncology community to update product labeling for older oncology drugs Clin. Cancer Res. 2021 27 916 921 10.1158/1078-0432.CCR-20-3213 33257426 Kluetz, P. G. et al. FDA oncology center of excellence project renewal: engaging the oncology community to update product labeling for older oncology drugs. Clin. Cancer Res. 27 , 916–921 (2021). 33257426 10.1158/1078-0432.CCR-20-3213

136. Feinberg BA Use of real-world evidence to support FDA approval of oncology drugs Value Health 2020 23 1358 1365 10.1016/j.jval.2020.06.006 33032780 Feinberg, B. A. et al. Use of real-world evidence to support FDA approval of oncology drugs. Value Health 23 , 1358–1365 (2020). 33032780 10.1016/j.jval.2020.06.006

137. Duke ES Highlights of FDA oncology approvals in 2022: tissue-agnostic indications, dosage optimization, and diversity in drug development Cancer Discov 2022 12 2739 2746 10.1158/2159-8290.CD-22-1185 36458428 Duke, E. S. et al. Highlights of FDA oncology approvals in 2022: tissue-agnostic indications, dosage optimization, and diversity in drug development. Cancer Discov 12 , 2739–2746 (2022). 36458428 10.1158/2159-8290.CD-22-1185

138. Walia A Haslam A Prasad V FDA validation of surrogate endpoints in oncology: 2005–2022 J. Cancer Policy. 2022 34 100364 10.1016/j.jcpo.2022.100364 36155118 Walia, A., Haslam, A. & Prasad, V. FDA validation of surrogate endpoints in oncology: 2005–2022. J. Cancer Policy. 34 , 100364 (2022). 36155118 10.1016/j.jcpo.2022.100364

139. Katz R FDA: evidentiary standards for drug development and approval NeuroRx. 2004 1 307 316 10.1602/neurorx.1.3.307 15717032 PMC534930 Katz, R. FDA: evidentiary standards for drug development and approval. NeuroRx. 1 , 307–316 (2004). 15717032 10.1602/neurorx.1.3.307 PMC534930

140. Papapetropoulos A Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: a year in review Br. J. Pharmacol. 2024 181 1553 1575 10.1111/bph.16337 38519837 Papapetropoulos, A. et al. Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: a year in review. Br. J. Pharmacol. 181 , 1553–1575 (2024). 38519837 10.1111/bph.16337

141. Xia Y Synthetic routes and clinical application of new drugs approved by EMA during 2023 Eur. J. Med. Chem. 2024 277 116762 10.1016/j.ejmech.2024.116762 39151275 Xia, Y. et al. Synthetic routes and clinical application of new drugs approved by EMA during 2023. Eur. J. Med. Chem. 277 , 116762 (2024). 39151275 10.1016/j.ejmech.2024.116762

142. Lythgoe MP From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit Lancet Oncol 2023 24 e150 e160 10.1016/S1470-2045(22)00701-X 36990613 Lythgoe, M. P. et al. From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit. Lancet Oncol 24 , e150–e160 (2023). 36990613 10.1016/S1470-2045(22)00701-X

143. EMA. Human Medicinesin 2024, < https://www.ema.europa.eu/en/documents/report/human-medicines-2024_en.pdf > (2024).

144. Vaz M Silva V Monteiro C Silvestre S Role of aducanumab in the treatment of Alzheimer’s disease: challenges and opportunities Clin. Interv. Aging. 2022 17 797 810 10.2147/CIA.S325026 35611326 PMC9124475 Vaz, M., Silva, V., Monteiro, C. & Silvestre, S. Role of aducanumab in the treatment of Alzheimer’s disease: challenges and opportunities. Clin. Interv. Aging. 17 , 797–810 (2022). 35611326 10.2147/CIA.S325026 PMC9124475

145. Padda, I. S. & Parmar, M. in StatPearls [Internet] (StatPearls Publishing, 2024).

146. Dhillon S Aducanumab: first approval Drugs. 2021 81 1437 1443 10.1007/s40265-021-01569-z 34324167 Dhillon, S. Aducanumab: first approval. Drugs. 81 , 1437–1443 (2021). 34324167 10.1007/s40265-021-01569-z

147. Sevigny J The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease Nature. 2016 537 50 56 10.1038/nature19323 27582220 Sevigny, J. et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. 537 , 50–56 (2016). 27582220 10.1038/nature19323

148. Cummings J Aducanumab: appropriate use recommendations J. Prev. Alzheim. 2021 8 398 410 10.14283/jpad.2021.41 PMC8835345 34585212 Cummings, J. et al. Aducanumab: appropriate use recommendations. J. Prev. Alzheim. 8 , 398–410 (2021). 10.14283/jpad.2021.41 PMC8835345 34585212

149. Walsh S Merrick R Milne R Brayne C Aducanumab for Alzheimer’s disease? BMJ. 2021 374 n1682 10.1136/bmj.n1682 34226181 PMC8258645 Walsh, S., Merrick, R., Milne, R. & Brayne, C. Aducanumab for Alzheimer’s disease? BMJ. 374 , n1682 (2021). 34226181 10.1136/bmj.n1682 PMC8258645

150. Cummings J Lecanemab: appropriate use recommendations J. Prev. Alzheim. 2023 10 362 377 10.14283/jpad.2023.30 PMC10313141 37357276 Cummings, J. et al. Lecanemab: appropriate use recommendations. J. Prev. Alzheim. 10 , 362–377 (2023). 10.14283/jpad.2023.30 PMC10313141 37357276

151. Van Dyck CH Lecanemab in early Alzheimer’s disease N. Engl. J. Med. 2023 388 9 21 10.1056/NEJMoa2212948 36449413 Van Dyck, C. H. et al. Lecanemab in early Alzheimer’s disease. N. Engl. J. Med. 388 , 9–21 (2023). 36449413 10.1056/NEJMoa2212948

152. Swanson CJ A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody Alzheimers Res. Ther. 2021 13 1 14 10.1186/s13195-021-00813-8 33865446 PMC8053280 Swanson, C. J. et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res. Ther. 13 , 1–14 (2021). 33865446 10.1186/s13195-021-00813-8 PMC8053280

153. Chowdhury S Chowdhury NS Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer’s disease: a systematic review Int. J. Immunopath. Ph. 2023 37 03946320231209839 10.1177/03946320231209839 PMC10617290 37902139 Chowdhury, S. & Chowdhury, N. S. Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer’s disease: a systematic review. Int. J. Immunopath. Ph. 37 , 03946320231209839 (2023). 10.1177/03946320231209839 PMC10617290 37902139

154. Walsh S Lecanemab for Alzheimer’s disease BMJ. 2022 379 3010 10.1136/bmj.o3010 36535691 Walsh, S. et al. Lecanemab for Alzheimer’s disease. BMJ. 379 , 3010 (2022). 10.1136/bmj.o3010 36535691

155. Qiao Y Chi Y Zhang Q Ma Y Safety and efficacy of lecanemab for Alzheimer’s disease: a systematic review and meta-analysis of randomized clinical trials Front. Aging Neurosci. 2023 15 1169499 10.3389/fnagi.2023.1169499 37213538 PMC10196238 Qiao, Y., Chi, Y., Zhang, Q. & Ma, Y. Safety and efficacy of lecanemab for Alzheimer’s disease: a systematic review and meta-analysis of randomized clinical trials. Front. Aging Neurosci. 15 , 1169499 (2023). 37213538 10.3389/fnagi.2023.1169499 PMC10196238

156. Lythgoe MP Jenei K Prasad V Regulatory decisions diverge over aducanumab for Alzheimer’s disease BMJ. 2022 376 e069780 10.1136/bmj-2021-069780 35091420 Lythgoe, M. P., Jenei, K. & Prasad, V. Regulatory decisions diverge over aducanumab for Alzheimer’s disease. BMJ. 376 , e069780 (2022). 35091420 10.1136/bmj-2021-069780

157. Mahase E Lecanemab: European drug agency rejects Alzheimer’s drug amid debate over efficacy and safety BMJ. 2024 386 q1692 10.1136/bmj.q1692 39074878 Mahase, E. Lecanemab: European drug agency rejects Alzheimer’s drug amid debate over efficacy and safety. BMJ. 386 , q1692 (2024). 39074878 10.1136/bmj.q1692

158. WHO. WHO Guidelines on Good Reliance Practices: applicability and prospects for implementation , < https://cdn.who.int/media/docs/default-source/health-products-policy-and-standards/7_who-guidelines-on-good-reliance-practices--applicability-and-prospects-for-implementation_samuel-azatyan.pdf?sfvrsn=2e31f8ca_1 > (2023).

159. Lythgoe MP Sullivan R Outsourcing UK regulatory decisions—a double-edged sword? Lancet. 2023 402 24 25 10.1016/S0140-6736(23)01132-7 37393100 Lythgoe, M. P. & Sullivan, R. Outsourcing UK regulatory decisions—a double-edged sword? Lancet. 402 , 24–25 (2023). 37393100 10.1016/S0140-6736(23)01132-7

160. Wu, S. et al. A review of the research report on the high-quality development of China’s pharmaceutical industry (2021–2023). CFDA Mag . 4–17, (2024).

161. Chen Z Chinese innovative drug R&D trends in 2024 Nat. Rev. Drug Discov. 2024 2024 0731 Chen, Z. et al. Chinese innovative drug R&D trends in 2024. Nat. Rev. Drug Discov. 2024 , 0731 (2024).

162. Luscombe E Is being the first ever ‘better’than being the best? Expert Opin. Pharmacother. 2014 15 1 2 10.1517/14656566.2014.906940 24666337 Luscombe, E. Is being the first ever ‘better’than being the best? Expert Opin. Pharmacother. 15 , 1–2 (2014). 24666337 10.1517/14656566.2014.906940

163. Agten, S. & Wu, B. in Biopharma in China: Innovation , Trends and Dealmaking 71–99 (Springer, 2024).

164. Betz UA How many genomics targets can a portfolio afford? Drug Discov. Today. 2005 10 1057 1063 10.1016/S1359-6446(05)03498-7 16055022 Betz, U. A. How many genomics targets can a portfolio afford? Drug Discov. Today. 10 , 1057–1063 (2005). 16055022 10.1016/S1359-6446(05)03498-7

165. Schulze U Ringel M What matters most in commercial success: first-in-class or best-in-class? Nat. Rev. Drug Discov. 2013 12 419 10.1038/nrd4035 23722339 Schulze, U. & Ringel, M. What matters most in commercial success: first-in-class or best-in-class? Nat. Rev. Drug Discov. 12 , 419 (2013). 23722339 10.1038/nrd4035

166. Munos B A forensic analysis of drug targets from 2000 through 2012 Clin. Pharmacol. Ther. 2013 94 407 411 10.1038/clpt.2013.126 23756372 Munos, B. A forensic analysis of drug targets from 2000 through 2012. Clin. Pharmacol. Ther. 94 , 407–411 (2013). 23756372 10.1038/clpt.2013.126

167. Stocks, M. in Introduction to Biological and Small Molecule Drug Research and Development 81–126 (Elsevier, 2013).

168. Nakano T Performance evaluation of leader–follower-based mobile molecular communication networks for target detection applications IEEE Trans. Commun. 2016 65 663 676 10.1109/TCOMM.2016.2628037 Nakano, T. et al. Performance evaluation of leader–follower-based mobile molecular communication networks for target detection applications. IEEE Trans. Commun. 65 , 663–676 (2016).

169. Jiang Y Liu Z Holenz J Yang H Competitive intelligence–based lead generation and fast follower approaches Lead Gen 2016 2016 183 220 10.1002/9783527677047.ch08 Jiang, Y., Liu, Z., Holenz, J. & Yang, H. Competitive intelligence–based lead generation and fast follower approaches. Lead Gen 2016 , 183–220 (2016).

170. Sams-Dodd F Research & market strategy: how choice of drug discovery approach can affect market position Drug Discov. Today. 2007 12 314 318 10.1016/j.drudis.2007.02.014 17395091 Sams-Dodd, F. Research & market strategy: how choice of drug discovery approach can affect market position. Drug Discov. Today. 12 , 314–318 (2007). 17395091 10.1016/j.drudis.2007.02.014

171. Aronson JK Green AR Me‐too pharmaceutical products: history, definitions, examples, and relevance to drug shortages and essential medicines lists Br. J. Clin. Pharmacol. 2020 86 2114 2122 10.1111/bcp.14327 32358800 PMC7576625 Aronson, J. K. & Green, A. R. Me‐too pharmaceutical products: history, definitions, examples, and relevance to drug shortages and essential medicines lists. Br. J. Clin. Pharmacol. 86 , 2114–2122 (2020). 32358800 10.1111/bcp.14327 PMC7576625

172. Régnier S What is the value of ‘me-too’drugs? Health Care Manage. Sci 2013 16 300 313 10.1007/s10729-013-9225-3 23440390 Régnier, S. What is the value of ‘me-too’drugs? Health Care Manage. Sci 16 , 300–313 (2013). 10.1007/s10729-013-9225-3 23440390

173. Pekarsky B Should financial incentives be used to differentially reward ‘me-too’and innovative drugs? Pharmacoeconomics. 2010 28 1 17 10.2165/11318770-000000000-00000 20014872 Pekarsky, B. Should financial incentives be used to differentially reward ‘me-too’and innovative drugs? Pharmacoeconomics. 28 , 1–17 (2010). 20014872 10.2165/11318770-000000000-00000

174. Hollis, A. Me-Too Drugs: Is There a Problem . WHO Report , (2004).

175. Zhou Z Revolutionising cancer immunotherapy: advancements and prospects in non‐viral CAR‐NK cell engineering Cell Prolif 2024 58 e13791 10.1111/cpr.13791 39731215 PMC11969250 Zhou, Z. et al. Revolutionising cancer immunotherapy: advancements and prospects in non‐viral CAR‐NK cell engineering. Cell Prolif 58 , e13791 (2024). 39731215 10.1111/cpr.13791 PMC11969250

176. Wang Y Comparison of seven CD19 CAR designs in engineering NK cells for enhancing anti‐tumour activity Cell Prolif 2024 57 e13683 10.1111/cpr.13683 38830795 PMC11533075 Wang, Y. et al. Comparison of seven CD19 CAR designs in engineering NK cells for enhancing anti‐tumour activity. Cell Prolif 57 , e13683 (2024). 38830795 10.1111/cpr.13683 PMC11533075

177. Citeline. Citeline Pharma R&D Annual Review 2023 < https://www.citeline.com/en/resources/citeline-rd-annual-review-2023 > (2023).

178. VBDATA.CN. 2023 Pharmaceutical R&D Annual Review: with 5402 pipelines, China has become the world’s second largest pharmaceutical research country < https://www.vbdata.cn/1518917850 > (2023).

179. Lyu X The global landscape of approved antibody therapies Antib. Ther. 2022 5 233 257 36213257 10.1093/abt/tbac021 PMC9535261 Lyu, X. et al. The global landscape of approved antibody therapies. Antib. Ther. 5 , 233–257 (2022). 36213257 10.1093/abt/tbac021 PMC9535261

180. Fu Z Antibody drug conjugate: the “biological missile” for targeted cancer therapy Signal Transduct. Target. Ther. 2022 7 93 10.1038/s41392-022-00947-7 35318309 PMC8941077 Fu, Z. et al. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduct. Target. Ther. 7 , 93 (2022). 35318309 10.1038/s41392-022-00947-7 PMC8941077

181. Jin S Emerging new therapeutic antibody derivatives for cancer treatment Signal Transduct. Target. Ther. 2022 7 39 10.1038/s41392-021-00868-x 35132063 PMC8821599 Jin, S. et al. Emerging new therapeutic antibody derivatives for cancer treatment. Signal Transduct. Target. Ther. 7 , 39 (2022). 35132063 10.1038/s41392-021-00868-x PMC8821599

182. Shen L ADCdb: the database of antibody–drug conjugates Nucleic Acids Res 2024 52 D1097 D1109 10.1093/nar/gkad831 37831118 PMC10768060 Shen, L. et al. ADCdb: the database of antibody–drug conjugates. Nucleic Acids Res 52 , D1097–D1109 (2024). 37831118 10.1093/nar/gkad831 PMC10768060

183. Huang, Z., Li, J. & Zhang, M. in New Anti-cancer Drug Development and Evaluation 115–139 (Springer, 2024).

184. Ruan DY Wu HX Meng Q Xu RH Development of antibody‐drug conjugates in cancer: overview and prospects Cancer Commun 2024 44 3 22 10.1002/cac2.12517 PMC10794012 38159059 Ruan, D. Y., Wu, H. X., Meng, Q. & Xu, R. H. Development of antibody‐drug conjugates in cancer: overview and prospects. Cancer Commun 44 , 3–22 (2024). 10.1002/cac2.12517 PMC10794012 38159059

185. Wang V Systematic review on CAR-T cell clinical trials up to 2022: academic center input Cancers. 2023 15 1003 10.3390/cancers15041003 36831349 PMC9954171 Wang, V. et al. Systematic review on CAR-T cell clinical trials up to 2022: academic center input. Cancers. 15 , 1003 (2023). 36831349 10.3390/cancers15041003 PMC9954171

186. Wu W Regulatory oversight of cell therapy in China: government’s efforts in patient access and therapeutic innovation Pharmacol. Res. 2020 158 104889 10.1016/j.phrs.2020.104889 32428666 Wu, W. et al. Regulatory oversight of cell therapy in China: government’s efforts in patient access and therapeutic innovation. Pharmacol. Res. 158 , 104889 (2020). 32428666 10.1016/j.phrs.2020.104889

187. IQVIA. Global pharmaceutical R&D outlook for 2023 < https://www.iqvia.com/-/media/iqvia/pdfs/china/viewpoints/global-trends-in-r-and-d-2023-cn.pdf > (2024).

188. Herink MC Irwin AN Zumach GM FDA breakthrough therapy designation: Evaluating the quality of the evidence behind the drug approvals Pharmacotherapy. 2018 38 967 980 10.1002/phar.2167 30043413 Herink, M. C., Irwin, A. N. & Zumach, G. M. FDA breakthrough therapy designation: Evaluating the quality of the evidence behind the drug approvals. Pharmacotherapy. 38 , 967–980 (2018). 30043413 10.1002/phar.2167

189. Aggarwal S A survey of breakthrough therapy designations Nat. Biotechnol. 2014 32 323 330 10.1038/nbt.2864 24714478 Aggarwal, S. A survey of breakthrough therapy designations. Nat. Biotechnol. 32 , 323–330 (2014). 24714478 10.1038/nbt.2864

190. Poddar A Raggio M Concato J Decisions on non-oncology breakthrough therapy designation requests in 2017–2019 Ther. Innov. Regul. Sci. 2024 58 214 221 10.1007/s43441-023-00589-z 37926768 PMC10764372 Poddar, A., Raggio, M. & Concato, J. Decisions on non-oncology breakthrough therapy designation requests in 2017–2019. Ther. Innov. Regul. Sci. 58 , 214–221 (2024). 37926768 10.1007/s43441-023-00589-z PMC10764372

191. Blumenthal GM Oncology drug approvals: evaluating endpoints and evidence in an era of breakthrough therapies Oncologist. 2017 22 762 767 10.1634/theoncologist.2017-0152 28576856 PMC5507655 Blumenthal, G. M. et al. Oncology drug approvals: evaluating endpoints and evidence in an era of breakthrough therapies. Oncologist. 22 , 762–767 (2017). 28576856 10.1634/theoncologist.2017-0152 PMC5507655

192. Kern KA Trial design and efficacy thresholds for granting breakthrough therapy designation in oncology J. Oncol. Pract. 2016 12 e810 e817 10.1200/JOP.2016.012161 27460496 Kern, K. A. Trial design and efficacy thresholds for granting breakthrough therapy designation in oncology. J. Oncol. Pract. 12 , e810–e817 (2016). 27460496 10.1200/JOP.2016.012161

193. Shea M Impact of breakthrough therapy designation on cancer drug development Nat. Rev. Drug Discov. 2016 15 152 153 10.1038/nrd.2016.19 26931085 Shea, M. et al. Impact of breakthrough therapy designation on cancer drug development. Nat. Rev. Drug Discov. 15 , 152–153 (2016). 26931085 10.1038/nrd.2016.19

194. Yao JC Meric-Bernstam F Lee JJ Eckhardt SG Accelerated approval and breakthrough therapy designation: oncology drug development on speed? Clin. Cancer Res. 2013 19 4305 4308 10.1158/1078-0432.CCR-13-1428 23833307 PMC4167364 Yao, J. C., Meric-Bernstam, F., Lee, J. J. & Eckhardt, S. G. Accelerated approval and breakthrough therapy designation: oncology drug development on speed? Clin. Cancer Res. 19 , 4305–4308 (2013). 23833307 10.1158/1078-0432.CCR-13-1428 PMC4167364

195. Horning SJ Developing standards for breakthrough therapy designation in oncology Clin. Cancer Res. 2013 19 4297 4304 10.1158/1078-0432.CCR-13-0523 23719260 PMC3745545 Horning, S. J. et al. Developing standards for breakthrough therapy designation in oncology. Clin. Cancer Res. 19 , 4297–4304 (2013). 23719260 10.1158/1078-0432.CCR-13-0523 PMC3745545

196. EMA. Brexit: the United Kingdom’s withdrawal from the European Union < https://www.ema.europa.eu/en/about-us/history-ema/brexit-united-kingdoms-withdrawal-european-union > (2019).

197. Lythgoe MP Cancer therapy approval timings, review speed, and publication of pivotal registration trials in the US and Europe, 2010–2019 JAMA Netw. Open. 2022 5 e2216183 10.1001/jamanetworkopen.2022.16183 35687337 PMC9187952 Lythgoe, M. P. et al. Cancer therapy approval timings, review speed, and publication of pivotal registration trials in the US and Europe, 2010–2019. JAMA Netw. Open. 5 , e2216183 (2022). 35687337 10.1001/jamanetworkopen.2022.16183 PMC9187952

198. GreenbergTraurig. China on the move: breaking barriers and accelerating growth: clinical trials, drug approvals, and cross-border data transfers in biotech < https://www.gtlaw.com/en/insights/2024/7/china-on-the-move-breaking-barriers-and-accelerating-growth-clinical-trials?utm_source=chatgpt.com > (2024).

199. Linical. Maximizing clinical trial opportunities in China < https://www.linical.com/articles-research/maximizing-clinical-trial-opportunities-in-china?utm_source=chatgpt.com > (2024).

200. Arena, C. T. The Great Wall: why overseas sponsors are yet to fully tap into China’s clinical trial resources < https://www.clinicaltrialsarena.com/features/china-clinical-trial-challenges-cta-exclusive/ > (2022).

201. Leader, C. Report reflects huge growth of clinical trials in China < https://www.clinicalleader.com/doc/report-reflects-huge-growth-of-clinical-trials-in-china-0001 > (2021).

202. Singh H Pazdur R Importing oncology trials from China: a bridge over troubled waters? Lancet Oncol 2022 23 323 325 10.1016/S1470-2045(22)00071-7 35131039 Singh, H. & Pazdur, R. Importing oncology trials from China: a bridge over troubled waters? Lancet Oncol 23 , 323–325 (2022). 35131039 10.1016/S1470-2045(22)00071-7

203. Zhang, J. Z. In Biotechnology Entrepreneurship 567–582 (Elsevier, 2020).

204. Luo X The price, efficacy, and safety of within-class targeted anticancer medicines between domestic and imported drugs in China: a comparative analysis Lancet. Reg. Health. West. Pac. 2023 32 100670 36785854 10.1016/j.lanwpc.2022.100670 PMC9918802 Luo, X. et al. The price, efficacy, and safety of within-class targeted anticancer medicines between domestic and imported drugs in China: a comparative analysis. Lancet. Reg. Health. West. Pac. 32 , 100670 (2023). 36785854 10.1016/j.lanwpc.2022.100670 PMC9918802

205. Wang S Evolution of early-phase anticancer drug investigations in China JAMA Oncol 2022 8 1692 1694 10.1001/jamaoncol.2022.3856 36074496 PMC9459900 Wang, S. et al. Evolution of early-phase anticancer drug investigations in China. JAMA Oncol 8 , 1692–1694 (2022). 36074496 10.1001/jamaoncol.2022.3856 PMC9459900

206. FDA. PDUFA reauthorization performance goals and procedures fiscal years 2023 through 2027 < https://www.fda.gov/media/151712/download > (2023).

207. FDA. Performance report to congress for the generic drug user fee amendments < https://www.fda.gov/media/151618/download > (2020).

208. Williamson J Spicer AJ Review of the impact of the FDA’s fast track designation on biotechnology companies’ share prices Drug Discov. Today. 2023 28 103771 10.1016/j.drudis.2023.103771 37716502 Williamson, J. & Spicer, A. J. Review of the impact of the FDA’s fast track designation on biotechnology companies’ share prices. Drug Discov. Today. 28 , 103771 (2023). 37716502 10.1016/j.drudis.2023.103771

209. EMA. The evaluation of medicines, step-by-step < https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/evaluation-medicines-step-step?utm_source=chatgpt.com > (2024).

210. EMA. Clinical Trials Information System < https://www.ema.europa.eu/en/human-regulatory-overview/research-development/clinical-trials-human-medicines/clinical-trials-information-system > (2022).

211. Zhu X Chen Y Bridging the new drug access gap between China and the United States and its related policies Front. Pharmacol. 2024 14 1296737 10.3389/fphar.2023.1296737 38259295 PMC10800674 Zhu, X. & Chen, Y. Bridging the new drug access gap between China and the United States and its related policies. Front. Pharmacol. 14 , 1296737 (2024). 38259295 10.3389/fphar.2023.1296737 PMC10800674

212. Wei Y Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001–2020 Lancet. Reg. Health. West. Pac. 2024 45 101055 38590780 10.1016/j.lanwpc.2024.101055 PMC10999698 Wei, Y. et al. Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001–2020. Lancet. Reg. Health. West. Pac. 45 , 101055 (2024). 38590780 10.1016/j.lanwpc.2024.101055 PMC10999698

213. Le AM Torres T New topical therapies for psoriasis Am. J. Clin. Dermatol. 2022 23 13 24 10.1007/s40257-021-00649-w 34705167 Le, A. M. & Torres, T. New topical therapies for psoriasis. Am. J. Clin. Dermatol. 23 , 13–24 (2022). 34705167 10.1007/s40257-021-00649-w

214. Lu ST Kelly KA Feldman SR An overview of benvitimod for the treatment of psoriasis: a narrative review Expert Opin. Pharmacother. 2022 23 327 333 10.1080/14656566.2021.2016699 34937468 Lu, S. T., Kelly, K. A. & Feldman, S. R. An overview of benvitimod for the treatment of psoriasis: a narrative review. Expert Opin. Pharmacother. 23 , 327–333 (2022). 34937468 10.1080/14656566.2021.2016699

215. Chen L Application of benvitimod on psoriasis: a systematic review and meta-analysis of randomized controlled trials. A systematic review of benvitimod on psoriasis Therapies 2022 77 339 347 10.1016/j.therap.2021.09.005 34689959 Chen, L. et al. Application of benvitimod on psoriasis: a systematic review and meta-analysis of randomized controlled trials. A systematic review of benvitimod on psoriasis. Therapies 77 , 339–347 (2022). 10.1016/j.therap.2021.09.005 34689959

216. Zhang J Cai L Zheng M A novel topical treatment for plaque psoriasis: benvitimod/tapinarof J. Am. Acad. Dermatol. 2022 86 e137 e138 10.1016/j.jaad.2021.10.053 34742862 Zhang, J., Cai, L. & Zheng, M. A novel topical treatment for plaque psoriasis: benvitimod/tapinarof. J. Am. Acad. Dermatol. 86 , e137–e138 (2022). 34742862 10.1016/j.jaad.2021.10.053

217. Ehsan M Benvitimod for the treatment of psoriasis: a systematic review and meta‐analysis of randomized controlled trials Dermatol. Ther. 2022 35 e15957 10.1111/dth.15957 36279313 Ehsan, M. et al. Benvitimod for the treatment of psoriasis: a systematic review and meta‐analysis of randomized controlled trials. Dermatol. Ther. 35 , e15957 (2022). 36279313 10.1111/dth.15957

218. Cai L A double-blind, randomized, placebo-and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis Chin. Med. J. 2020 133 2905 2909 10.1097/CM9.0000000000001221 33177393 PMC7752683 Cai, L. et al. A double-blind, randomized, placebo-and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis. Chin. Med. J. 133 , 2905–2909 (2020). 33177393 10.1097/CM9.0000000000001221 PMC7752683

219. Huo Y Efficacy and safety of tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial Circulation. 2022 146 A10111 A10111 10.1161/circ.146.suppl_1.10111 PMC10558773 37808342 Huo, Y. et al. Efficacy and safety of tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial. Circulation. 146 , A10111–A10111 (2022). 10.1016/j.lanwpc.2023.100907 PMC10558773 37808342

220. Cui Y Tafolecimab, a novel potential long-acting PCSK9 monoclonal antibody: efficacy and safety in healthy and hypercholesterolemia subjects Eur. Heart J. 2020 41 ehaa946.3327 10.1093/ehjci/ehaa946.3327 Cui, Y. et al. Tafolecimab, a novel potential long-acting PCSK9 monoclonal antibody: efficacy and safety in healthy and hypercholesterolemia subjects. Eur. Heart J. 41 , ehaa946.3327 (2020).

221. Huo Y Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial Lancet. Reg. Health. West. Pac. 2023 41 100907 37808342 10.1016/j.lanwpc.2023.100907 PMC10558773 Huo, Y. et al. Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial. Lancet. Reg. Health. West. Pac. 41 , 100907 (2023). 37808342 10.1016/j.lanwpc.2023.100907 PMC10558773

222. Qi L Tafolecimab in Chinese patients with hypercholesterolemia (CREDIT-4) a randomized, double-blind, placebo-controlled phase 3 trial JACC: Asia 2023 3 636 645 37614541 10.1016/j.jacasi.2023.04.011 PMC10442872 Qi, L. et al. Tafolecimab in Chinese patients with hypercholesterolemia (CREDIT-4) a randomized, double-blind, placebo-controlled phase 3 trial. JACC: Asia 3 , 636–645 (2023). 37614541 10.1016/j.jacasi.2023.04.011 PMC10442872

223. Keam SJ Tafolecimab: first approval Drugs. 2023 83 1545 1549 10.1007/s40265-023-01952-y 37847461 Keam, S. J. Tafolecimab: first approval. Drugs. 83 , 1545–1549 (2023). 37847461 10.1007/s40265-023-01952-y

224. Chai M Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2) BMC Med 2023 21 77 10.1186/s12916-023-02797-8 36855099 PMC9976471 Chai, M. et al. Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2). BMC Med 21 , 77 (2023). 36855099 10.1186/s12916-023-02797-8 PMC9976471

225. Xu J Efficacy and safety of surufatinib in patients with well-differentiated advanced extrapancreatic neuroendocrine tumors (NETs): results from the randomized phase III study (SANET-ep) Ann. Oncol. 2019 30 v911 10.1093/annonc/mdz394.073 Xu, J. et al. Efficacy and safety of surufatinib in patients with well-differentiated advanced extrapancreatic neuroendocrine tumors (NETs): results from the randomized phase III study (SANET-ep). Ann. Oncol. 30 , v911 (2019).

226. Chen J Surufatinib in Chinese patients with locally advanced or metastatic differentiated thyroid cancer and medullary thyroid cancer: a multicenter, open-label, phase II trial Thyroid. 2020 30 1245 1253 10.1089/thy.2019.0453 32075524 Chen, J. et al. Surufatinib in Chinese patients with locally advanced or metastatic differentiated thyroid cancer and medullary thyroid cancer: a multicenter, open-label, phase II trial. Thyroid. 30 , 1245–1253 (2020). 32075524 10.1089/thy.2019.0453

227. Xu J Surufatinib in advanced well-differentiated neuroendocrine tumors: a multicenter, single-arm, open-label, phase Ib/II trial Clin. Cancer Res. 2019 25 3486 3494 10.1158/1078-0432.CCR-18-2994 30833272 Xu, J. et al. Surufatinib in advanced well-differentiated neuroendocrine tumors: a multicenter, single-arm, open-label, phase Ib/II trial. Clin. Cancer Res. 25 , 3486–3494 (2019). 30833272 10.1158/1078-0432.CCR-18-2994

228. Dasari A Efficacy and safety of surufatinib in United States (US) patients (pts) with neuroendocrine tumors (NETs) J. Clin. Oncol. 2020 38 4610 4610 10.1200/JCO.2020.38.15_suppl.4610 Dasari, A. et al. Efficacy and safety of surufatinib in United States (US) patients (pts) with neuroendocrine tumors (NETs). J. Clin. Oncol. 38 , 4610–4610 (2020).

229. Xu J A single‐arm, multicenter, open‐label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer Cancer. 2021 127 3975 3984 10.1002/cncr.33803 34355801 Xu, J. et al. A single‐arm, multicenter, open‐label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer. Cancer. 127 , 3975–3984 (2021). 34355801 10.1002/cncr.33803

230. Xu J Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study Lancet Oncol 2020 21 1500 1512 10.1016/S1470-2045(20)30496-4 32966811 Xu, J. et al. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 21 , 1500–1512 (2020). 32966811 10.1016/S1470-2045(20)30496-4

231. Syed YY Surufatinib: first approval Drugs. 2021 81 727 732 10.1007/s40265-021-01489-y 33788183 Syed, Y. Y. Surufatinib: first approval. Drugs. 81 , 727–732 (2021). 33788183 10.1007/s40265-021-01489-y

232. Xu J Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs) Ther. Adv. Med. Oncol. 2021 13 17588359211042689 10.1177/17588359211042689 34484432 PMC8411625 Xu, J. Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs). Ther. Adv. Med. Oncol. 13 , 17588359211042689 (2021). 34484432 10.1177/17588359211042689 PMC8411625

233. Koumarianou A Kaltsas G Surufatinib—a novel oral agent for neuroendocrine tumours Nat. Rev. Endocrinol. 2021 17 9 10 10.1038/s41574-020-00439-0 33128026 Koumarianou, A. & Kaltsas, G. Surufatinib—a novel oral agent for neuroendocrine tumours. Nat. Rev. Endocrinol. 17 , 9–10 (2021). 33128026 10.1038/s41574-020-00439-0

234. Xu J Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study Lancet Oncol 2020 21 1489 1499 10.1016/S1470-2045(20)30493-9 32966810 Xu, J. et al. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 21 , 1489–1499 (2020). 32966810 10.1016/S1470-2045(20)30493-9

235. Qian H Effects of food on the pharmacokinetic properties of surufatinib: a phase I, single-dose, randomized, open-label crossover study in healthy subjects Clin. Ther. 2020 42 1778 1786 10.1016/j.clinthera.2020.07.010 32800383 Qian, H. et al. Effects of food on the pharmacokinetic properties of surufatinib: a phase I, single-dose, randomized, open-label crossover study in healthy subjects. Clin. Ther. 42 , 1778–1786 (2020). 32800383 10.1016/j.clinthera.2020.07.010

236. Wang M 987 P Sunvozertinib for NSCLC patients with EGFR exon 20 insertion mutations: preliminary analysis of WU-KONG6, the first pivotal study Ann. Oncol. 2022 33 S1003 S1004 10.1016/j.annonc.2022.07.1114 Wang, M. et al. 987 P Sunvozertinib for NSCLC patients with EGFR exon 20 insertion mutations: preliminary analysis of WU-KONG6, the first pivotal study. Ann. Oncol. 33 , S1003–S1004 (2022).

237. Tucker N Sunvozertinib Yields Tolerability, Efficacy in EGFR + NSCLC Cancer Netw. 2023 2023 NA-NA Tucker, N. Sunvozertinib Yields Tolerability, Efficacy in EGFR + NSCLC. Cancer Netw. 2023 , NA-NA (2023).

238. Yang J-H 1325 P Sunvozertinib as first-line treatment in NSCLC patients with EGFR Exon20 insertion mutations Ann. Oncol. 2023 34 S765 10.1016/j.annonc.2023.09.2358 Yang, J.-H. et al. 1325 P Sunvozertinib as first-line treatment in NSCLC patients with EGFR Exon20 insertion mutations. Ann. Oncol. 34 , S765 (2023).

239. Hayashi H Sunvozertinib: the next candidate of TKI for NSCLC Lancet Respir. Med. 2024 12 185 186 10.1016/S2213-2600(23)00419-8 38101435 Hayashi, H. Sunvozertinib: the next candidate of TKI for NSCLC. Lancet Respir. Med. 12 , 185–186 (2024). 38101435 10.1016/S2213-2600(23)00419-8

240. Dhillon S Sunvozertinib: first approval Drugs. 2023 83 1629 1634 10.1007/s40265-023-01959-5 37962831 Dhillon, S. Sunvozertinib: first approval. Drugs. 83 , 1629–1634 (2023). 37962831 10.1007/s40265-023-01959-5

241. Yang J-H EP08. 02-029 sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations: effect of prior treatment J. Thorac. Oncol. 2022 17 S410 S411 10.1016/j.jtho.2022.07.711 Yang, J.-H. et al. EP08. 02-029 sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations: effect of prior treatment. J. Thorac. Oncol. 17 , S410–S411 (2022).

242. Wang M Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial Lancet Respir. Med. 2024 12 217 224 10.1016/S2213-2600(23)00379-X 38101437 Wang, M. et al. Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial. Lancet Respir. Med. 12 , 217–224 (2024). 38101437 10.1016/S2213-2600(23)00379-X

243. Wang M Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: the first pivotal study results J. Clin. Oncol. 2023 41 9002 9002 10.1200/JCO.2023.41.16_suppl.9002 Wang, M. et al. Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: the first pivotal study results. J. Clin. Oncol. 41 , 9002–9002 (2023).

244. Janne PA Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD (L) 1 treatment failures J. Clin. Oncol. 2022 40 9015 9015 10.1200/JCO.2022.40.16_suppl.9015 Janne, P. A. et al. Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD (L) 1 treatment failures. J. Clin. Oncol. 40 , 9015–9015 (2022).

245. Wang M Sunvozertinib, a selective EGFR inhibitor for previously treated non–small cell lung cancer with EGFR exon 20 insertion mutations Cancer Discov 2022 12 1676 1689 10.1158/2159-8290.CD-21-1615 35404393 PMC9262839 Wang, M. et al. Sunvozertinib, a selective EGFR inhibitor for previously treated non–small cell lung cancer with EGFR exon 20 insertion mutations. Cancer Discov 12 , 1676–1689 (2022). 35404393 10.1158/2159-8290.CD-21-1615 PMC9262839

246. Kong F Traditional Chinese medicines for non-small cell lung cancer: therapies and mechanisms Chin. Herb. Med. 2023 15 509 515 38094015 10.1016/j.chmed.2023.05.004 PMC10715886 Kong, F. et al. Traditional Chinese medicines for non-small cell lung cancer: therapies and mechanisms. Chin. Herb. Med. 15 , 509–515 (2023). 38094015 10.1016/j.chmed.2023.05.004 PMC10715886

247. Wong AHP Impact of CD151 overexpression on prognosis and therapy in non‐small cell lung cancer patients lacking EGFR mutations Cell Prolif 2024 57 e13708 10.1111/cpr.13708 38982031 PMC11503249 Wong, A. H. P. et al. Impact of CD151 overexpression on prognosis and therapy in non‐small cell lung cancer patients lacking EGFR mutations. Cell Prolif 57 , e13708 (2024). 38982031 10.1111/cpr.13708 PMC11503249

248. Campbell N Kalabalik-Hoganson J Frey K Vericiguat: a novel oral soluble guanylate cyclase stimulator for the treatment of heart failure Ann. Pharmacother. 2022 56 600 608 10.1177/10600280211041384 34431706 Campbell, N., Kalabalik-Hoganson, J. & Frey, K. Vericiguat: a novel oral soluble guanylate cyclase stimulator for the treatment of heart failure. Ann. Pharmacother. 56 , 600–608 (2022). 34431706 10.1177/10600280211041384

249. Markham A Pralsetinib: first approval Drugs. 2020 80 1865 1870 10.1007/s40265-020-01427-4 33136236 Markham, A. Pralsetinib: first approval. Drugs. 80 , 1865–1870 (2020). 33136236 10.1007/s40265-020-01427-4

250. Griesinger F Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial Ann. Oncol. 2022 33 1168 1178 10.1016/j.annonc.2022.08.002 35973665 Griesinger, F. et al. Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial. Ann. Oncol. 33 , 1168–1178 (2022). 35973665 10.1016/j.annonc.2022.08.002

251. Gainor JF Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study Lancet Oncol 2021 22 959 969 10.1016/S1470-2045(21)00247-3 34118197 Gainor, J. F. et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol 22 , 959–969 (2021). 34118197 10.1016/S1470-2045(21)00247-3

252. Kim J FDA approval summary: pralsetinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions Clin. Cancer Res. 2021 27 5452 5456 10.1158/1078-0432.CCR-21-0967 34045295 Kim, J. et al. FDA approval summary: pralsetinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions. Clin. Cancer Res. 27 , 5452–5456 (2021). 34045295 10.1158/1078-0432.CCR-21-0967

253. Zhou Q Efficacy and safety of pralsetinib in patients with advanced RET fusion‐positive non–small cell lung cancer Cancer. 2023 129 3239 3251 10.1002/cncr.34897 37282666 Zhou, Q. et al. Efficacy and safety of pralsetinib in patients with advanced RET fusion‐positive non–small cell lung cancer. Cancer. 129 , 3239–3251 (2023). 37282666 10.1002/cncr.34897

254. Subbiah V Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study Lancet Diabetes Endocrinol 2021 9 491 501 10.1016/S2213-8587(21)00120-0 34118198 PMC13224057 Subbiah, V. et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol 9 , 491–501 (2021). 34118198 10.1016/S2213-8587(21)00120-0 PMC13224057

255. Zhu K-W Deuremidevir and simnotrelvir–ritonavir for the treatment of COVID-19 ACS Pharmacol. Transl. Sci. 2023 6 1306 1309 10.1021/acsptsci.3c00134 37705591 PMC10496140 Zhu, K.-W. Deuremidevir and simnotrelvir–ritonavir for the treatment of COVID-19. ACS Pharmacol. Transl. Sci. 6 , 1306–1309 (2023). 37705591 10.1021/acsptsci.3c00134 PMC10496140

256. Cao B Oral Simnotrelvir for adult patients with mild-to-moderate covid-19 N. Engl. J. Med. 2024 390 230 241 10.1056/NEJMoa2301425 38231624 PMC11156186 Cao, B. et al. Oral Simnotrelvir for adult patients with mild-to-moderate covid-19. N. Engl. J. Med. 390 , 230–241 (2024). 38231624 10.1056/NEJMoa2301425 PMC11156186

257. Yang X-M A first-in-human phase 1 study of simnotrelvir, a 3CL-like protease inhibitor for treatment of COVID-19, in healthy adult subjects Eur. J. Pharm. Sci. 2023 191 106598 10.1016/j.ejps.2023.106598 37783378 Yang, X.-M. et al. A first-in-human phase 1 study of simnotrelvir, a 3CL-like protease inhibitor for treatment of COVID-19, in healthy adult subjects. Eur. J. Pharm. Sci. 191 , 106598 (2023). 37783378 10.1016/j.ejps.2023.106598

258. McCarthy MW Simnotrelvir as a potential treatment for COVID-19 Expert Opin. Pharmacother. 2024 25 233 237 10.1080/14656566.2024.2323597 38393345 McCarthy, M. W. Simnotrelvir as a potential treatment for COVID-19. Expert Opin. Pharmacother. 25 , 233–237 (2024). 38393345 10.1080/14656566.2024.2323597

259. Wang F Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial Lancet. Reg. Health. West. Pac. 2023 38 100838 37484496 10.1016/j.lanwpc.2023.100835 PMC10362366 Wang, F. et al. Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial. Lancet. Reg. Health. West. Pac. 38 , 100838 (2023). 37484496 10.1016/j.lanwpc.2023.100835 PMC10362366

260. Jiang X Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir Nat. Commun. 2023 14 6463 10.1038/s41467-023-42102-y 37833261 PMC10575921 Jiang, X. et al. Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir. Nat. Commun. 14 , 6463 (2023). 37833261 10.1038/s41467-023-42102-y PMC10575921

261. Cao Z VV116 versus nirmatrelvir–ritonavir for oral treatment of Covid-19 N. Engl. J. Med. 2023 388 406 417 10.1056/NEJMoa2208822 36577095 PMC9812289 Cao, Z. et al. VV116 versus nirmatrelvir–ritonavir for oral treatment of Covid-19. N. Engl. J. Med. 388 , 406–417 (2023). 36577095 10.1056/NEJMoa2208822 PMC9812289

262. Zhu K-W National Medical Products Administration (NMPA) approves deuremidevir (VV116) and simnotrelvir-ritonavir for mild to moderate COVID-19 in China ACS Pharmacol. Transl. Sci. 2023 6 1306 1309 10.1021/acsptsci.3c00134 37705591 PMC10496140 Zhu, K.-W. National Medical Products Administration (NMPA) approves deuremidevir (VV116) and simnotrelvir-ritonavir for mild to moderate COVID-19 in China. ACS Pharmacol. Transl. Sci. 6 , 1306–1309 (2023). 37705591 10.1021/acsptsci.3c00134 PMC10496140

263. Liu W Remdesivir derivative VV116 is a potential broad-spectrum inhibitor of both human and animal coronaviruses Viruses. 2023 15 2295 10.3390/v15122295 38140536 PMC10748125 Liu, W. et al. Remdesivir derivative VV116 is a potential broad-spectrum inhibitor of both human and animal coronaviruses. Viruses. 15 , 2295 (2023). 38140536 10.3390/v15122295 PMC10748125

264. Juan M Yali P Clinical Research and development of deuremidevir hydrobromide tablets for the treatment of COVID-19 Prog. Pharm. Sci. 2023 47 489 493 Juan, M. & Yali, P. Clinical Research and development of deuremidevir hydrobromide tablets for the treatment of COVID-19. Prog. Pharm. Sci. 47 , 489–493 (2023).

265. Zhan Y Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial Eclinicalmedicine. 2024 67 102359 10.1016/j.eclinm.2023.102359 38188690 PMC10770433 Zhan, Y. et al. Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial. Eclinicalmedicine. 67 , 102359 (2024). 38188690 10.1016/j.eclinm.2023.102359 PMC10770433

266. Wang K Model informed dose regimen optimizing in development of leritrelvir for the treatment of mild or moderate COVID-19 Front. Pharmacol. 2024 15 1449583 10.3389/fphar.2024.1449583 39263567 PMC11387175 Wang, K. et al. Model informed dose regimen optimizing in development of leritrelvir for the treatment of mild or moderate COVID-19. Front. Pharmacol. 15 , 1449583 (2024). 39263567 10.3389/fphar.2024.1449583 PMC11387175

267. Zheng B Small-molecule antivirals treatment for COVID-19: a systematic review and network meta-analysis Int. J. Antimicrob. Agents. 2024 63 107096 10.1016/j.ijantimicag.2024.107096 38244811 Zheng, B. et al. Small-molecule antivirals treatment for COVID-19: a systematic review and network meta-analysis. Int. J. Antimicrob. Agents. 63 , 107096 (2024). 38244811 10.1016/j.ijantimicag.2024.107096

268. Xu Z-l A validated LC-MS/MS method for determination of six Anti-SARS-CoV-2 drugs in plasma and its application for a pharmacokinetic study in rats J. Chromatogr. B. 2024 1235 124038 10.1016/j.jchromb.2024.124038 38341953 Xu, Z.-l et al. A validated LC-MS/MS method for determination of six Anti-SARS-CoV-2 drugs in plasma and its application for a pharmacokinetic study in rats. J. Chromatogr. B. 1235 , 124038 (2024). 10.1016/j.jchromb.2024.124038 38341953

269. Zhang W Efficacy and safety of the 12-week sofosbuvir-coblopasvir regimen in treatment of chronic hepatitis C J. Clin. Hepatobiliary Dis. 2023 39 539 545 Zhang, W. et al. Efficacy and safety of the 12-week sofosbuvir-coblopasvir regimen in treatment of chronic hepatitis C. J. Clin. Hepatobiliary Dis. 39 , 539–545 (2023).

270. Rao H Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosis J. Viral Hepat. 2020 27 45 51 10.1111/jvh.13208 31520460 Rao, H. et al. Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosis. J. Viral Hepat. 27 , 45–51 (2020). 31520460 10.1111/jvh.13208

271. Gao Y Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: a single‐arm, open‐label, phase 3 trial Liver Int 2020 40 2685 2693 10.1111/liv.14633 33047868 PMC7702130 Gao, Y. et al. Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: a single‐arm, open‐label, phase 3 trial. Liver Int 40 , 2685–2693 (2020). 33047868 10.1111/liv.14633 PMC7702130

272. Jinfeng L Tolerance and pharmacokinetics of coblopasvir hydrochloride capsules in patients with hepatitis C virus infection J. Clin. Hepatobiliary Dis. 2021 37 1304 1308 Jinfeng, L. et al. Tolerance and pharmacokinetics of coblopasvir hydrochloride capsules in patients with hepatitis C virus infection. J. Clin. Hepatobiliary Dis. 37 , 1304–1308 (2021).

273. Zhao C Uncovering the mechanism of Tenofovir amibufenamide fumarate punch sticking by combining direct compression experiment and computational simulation Int. J. Pharm. 2024 653 123813 10.1016/j.ijpharm.2024.123813 38272192 Zhao, C. et al. Uncovering the mechanism of Tenofovir amibufenamide fumarate punch sticking by combining direct compression experiment and computational simulation. Int. J. Pharm. 653 , 123813 (2024). 38272192 10.1016/j.ijpharm.2024.123813

274. Ya-ping L Early efficacy of tenofovir amibufenamide (TMF) in the treatment of patients with chronic hepatitis B: a real-word multicenter clinical study Chin. Hepatol. 2023 28 100 Ya-ping, L. et al. Early efficacy of tenofovir amibufenamide (TMF) in the treatment of patients with chronic hepatitis B: a real-word multicenter clinical study. Chin. Hepatol. 28 , 100 (2023).

275. Liu J Effect of food on the pharmacokinetics of tenofovir amibufenamide: a phase I, randomized, open-label, two-period crossover trial in healthy adult subjects Drug Des. Devel. Ther. 2023 17 3061 3072 10.2147/DDDT.S419084 37840641 PMC10572397 Liu, J. et al. Effect of food on the pharmacokinetics of tenofovir amibufenamide: a phase I, randomized, open-label, two-period crossover trial in healthy adult subjects. Drug Des. Devel. Ther. 17 , 3061–3072 (2023). 37840641 10.2147/DDDT.S419084 PMC10572397

276. Meng L-Y Yang C-T Bao J-F Huang J-S Effectiveness and safety of tenofovir amibufenamide in chronic hepatitis B patients World J. Gastroenterol. 2024 30 3261 10.3748/wjg.v30.i26.3261 39086637 PMC11287400 Meng, L.-Y., Yang, C.-T., Bao, J.-F. & Huang, J.-S. Effectiveness and safety of tenofovir amibufenamide in chronic hepatitis B patients. World J. Gastroenterol. 30 , 3261 (2024). 39086637 10.3748/wjg.v30.i26.3261 PMC11287400

277. Peng W-T Tenofovir amibufenamide vs tenofovir alafenamide for treating chronic hepatitis B: a real-world study World J. Gastroenterol. 2023 29 5907 10.3748/wjg.v29.i44.5907 38111506 PMC10725562 Peng, W.-T. et al. Tenofovir amibufenamide vs tenofovir alafenamide for treating chronic hepatitis B: a real-world study. World J. Gastroenterol. 29 , 5907 (2023). 38111506 10.3748/wjg.v29.i44.5907 PMC10725562

278. Liu Z Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B Aliment. Pharmacol. Ther. 2021 54 1134 1149 10.1111/apt.16611 34587302 PMC9292801 Liu, Z. et al. Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B. Aliment. Pharmacol. Ther. 54 , 1134–1149 (2021). 34587302 10.1111/apt.16611 PMC9292801

279. Liu Z 96-week treatment of tenofovir amibufenamide and tenofovir disoproxil fumarate in chronic hepatitis B patients J. Clin. Transl. Hepatol. 2023 11 649 36969889 10.14218/JCTH.2022.00058 PMC10037506 Liu, Z. et al. 96-week treatment of tenofovir amibufenamide and tenofovir disoproxil fumarate in chronic hepatitis B patients. J. Clin. Transl. Hepatol. 11 , 649 (2023). 36969889 10.14218/JCTH.2022.00058 PMC10037506

280. Li L Effectiveness and safety of tenofovir amibufenamide and its comparison with tenofovir alafenamide in patients with chronic hepatitis B: results from a retrospective real-world study Front. Pharmacol. 2023 14 1165990 10.3389/fphar.2023.1165990 37324480 PMC10267382 Li, L. et al. Effectiveness and safety of tenofovir amibufenamide and its comparison with tenofovir alafenamide in patients with chronic hepatitis B: results from a retrospective real-world study. Front. Pharmacol. 14 , 1165990 (2023). 37324480 10.3389/fphar.2023.1165990 PMC10267382

281. Han X Population pharmacokinetics of Ainuovirine and exposure–response analysis in human immunodeficiency virus-infected individuals Chin. Med. J. 2024 10 1097 10.1097/CM9.0000000000002917 PMC11479413 38934053 Han, X. et al. Population pharmacokinetics of Ainuovirine and exposure–response analysis in human immunodeficiency virus-infected individuals. Chin. Med. J. 10 , 1097 (2024). 10.1097/CM9.0000000000002917 PMC11479413 38934053

282. Zhang F Switch to fixed-dose ainuovirine, lamivudine, and tenofovir DF versus elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed people living with HIV-1: the 48-week results of the SPRINT trial, a multi-centre, randomised, double-blind, active-controlled, phase 3, non-inferiority trial Lancet. Reg. Health. West. Pac. 2024 49 101143 39092318 10.1016/j.lanwpc.2024.101143 PMC11293588 Zhang, F. et al. Switch to fixed-dose ainuovirine, lamivudine, and tenofovir DF versus elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed people living with HIV-1: the 48-week results of the SPRINT trial, a multi-centre, randomised, double-blind, active-controlled, phase 3, non-inferiority trial. Lancet. Reg. Health. West. Pac. 49 , 101143 (2024). 39092318 10.1016/j.lanwpc.2024.101143 PMC11293588

283. Xie X Pharmacokinetics and safety of ainuovirine/lamivudine/tenofovir combination tablets in young and elderly patients with human immunodeficiency virus-1 infection Infect. Dis. Ther. 2023 12 2457 2469 10.1007/s40121-023-00877-z 37787861 PMC10600068 Xie, X. et al. Pharmacokinetics and safety of ainuovirine/lamivudine/tenofovir combination tablets in young and elderly patients with human immunodeficiency virus-1 infection. Infect. Dis. Ther. 12 , 2457–2469 (2023). 37787861 10.1007/s40121-023-00877-z PMC10600068

284. Wang C Efficacy and effect on lipid profiles of switching to ainuovirine-based regimen versus continuing efavirenz-based regimen in people with HIV-1: 24-week results from a real-world, retrospective, multi-center cohort study Antimicrob. Agents Chemother. 2024 68 e01668 01623 10.1128/aac.01668-23 38483175 PMC10989015 Wang, C. et al. Efficacy and effect on lipid profiles of switching to ainuovirine-based regimen versus continuing efavirenz-based regimen in people with HIV-1: 24-week results from a real-world, retrospective, multi-center cohort study. Antimicrob. Agents Chemother. 68 , e01668–01623 (2024). 38483175 10.1128/aac.01668-23 PMC10989015

285. Long H Efficacy and effect on lipid profiles of Ainuovirine-based regimen versus Efavirenz-based regimen in treatment-naïve people with HIV-1 at week 24: a real-world, retrospective, multi-center cohort study Biosci. Trends. 2024 18 176 186 10.5582/bst.2024.01070 38684402 Long, H. et al. Efficacy and effect on lipid profiles of Ainuovirine-based regimen versus Efavirenz-based regimen in treatment-naïve people with HIV-1 at week 24: a real-world, retrospective, multi-center cohort study. Biosci. Trends. 18 , 176–186 (2024). 38684402 10.5582/bst.2024.01070

286. Su B Efficacy and safety of ainuovirine versus efavirenz combination therapies with lamivudine/tenofovir disoproxil fumarate for medication of treatment-naïve HIV-1-positive adults: week 48 results of a randomized controlled phase 3 clinical trial followed by an open-label setting until week 96 Lancet. Reg. Health. West. Pac. 2023 36 100769 37547039 10.1016/j.lanwpc.2023.100769 PMC10398592 Su, B. et al. Efficacy and safety of ainuovirine versus efavirenz combination therapies with lamivudine/tenofovir disoproxil fumarate for medication of treatment-naïve HIV-1-positive adults: week 48 results of a randomized controlled phase 3 clinical trial followed by an open-label setting until week 96. Lancet. Reg. Health. West. Pac. 36 , 100769 (2023). 37547039 10.1016/j.lanwpc.2023.100769 PMC10398592

287. Zhang Q Impacts of ainuovirine-based and efavirenz-based antiretroviral therapies on the lipid profile of HIV/AIDS patients in southern China: a real-world study Front. Med. 2024 10 1277059 10.3389/fmed.2023.1277059 PMC10800701 38259850 Zhang, Q. et al. Impacts of ainuovirine-based and efavirenz-based antiretroviral therapies on the lipid profile of HIV/AIDS patients in southern China: a real-world study. Front. Med. 10 , 1277059 (2024). 10.3389/fmed.2023.1277059 PMC10800701 38259850

288. Huang L Pharmacokinetic and bioequivalence evaluation of single‐tablet and separate‐tablet regimens for ainuovirine, lamivudine, and tenofovir disoproxil fumarate in Chinese healthy subjects Clin. Pharmacol. Drug Dev. 2024 13 70 76 10.1002/cpdd.1309 37469278 Huang, L. et al. Pharmacokinetic and bioequivalence evaluation of single‐tablet and separate‐tablet regimens for ainuovirine, lamivudine, and tenofovir disoproxil fumarate in Chinese healthy subjects. Clin. Pharmacol. Drug Dev. 13 , 70–76 (2024). 37469278 10.1002/cpdd.1309

289. Chen R Expert consensus on the clinical application of ormutivimab injection for use against the rabies virus Expert Opin. Drug Saf 2024 23 755 762 10.1080/14740338.2023.2233411 37427985 Chen, R. et al. Expert consensus on the clinical application of ormutivimab injection for use against the rabies virus. Expert Opin. Drug Saf 23 , 755–762 (2024). 37427985 10.1080/14740338.2023.2233411

290. Zhai LL Efficacy of ormutivimab, a novel recombinant human anti-rabies monoclonal antibody, in post-exposure prophylaxis animal models Travel Med. Infect. Dis. 2022 46 102267 10.1016/j.tmaid.2022.102267 35091118 Zhai, L. L. et al. Efficacy of ormutivimab, a novel recombinant human anti-rabies monoclonal antibody, in post-exposure prophylaxis animal models. Travel Med. Infect. Dis. 46 , 102267 (2022). 35091118 10.1016/j.tmaid.2022.102267

291. Zhang J Population pharmacodynamic analyses of human anti-rabies virus monoclonal antibody (Ormutivimab) in healthy adult subjects Vaccines. 2022 10 1218 10.3390/vaccines10081218 36016106 PMC9415024 Zhang, J. et al. Population pharmacodynamic analyses of human anti-rabies virus monoclonal antibody (Ormutivimab) in healthy adult subjects. Vaccines. 10 , 1218 (2022). 36016106 10.3390/vaccines10081218 PMC9415024

292. Li L Neutralizing antibody activity, safety and immunogenicity of human anti-rabies virus monoclonal antibody (Ormutivimab) in Chinese healthy adults: a phase IIb randomized, double-blind, parallel-controlled study Vaccine. 2022 40 6153 6162 10.1016/j.vaccine.2022.09.022 36123259 Li, L. et al. Neutralizing antibody activity, safety and immunogenicity of human anti-rabies virus monoclonal antibody (Ormutivimab) in Chinese healthy adults: a phase IIb randomized, double-blind, parallel-controlled study. Vaccine. 40 , 6153–6162 (2022). 36123259 10.1016/j.vaccine.2022.09.022

293. Liu X Comparing recombinant human rabies monoclonal antibody (ormutivimab) with human rabies immunoglobulin (HRIG) for postexposure prophylaxis: a phase III, randomized, double-blind, non-inferiority trial Int. J. Infect. Dis. 2023 134 53 62 10.1016/j.ijid.2023.05.017 37211270 Liu, X. et al. Comparing recombinant human rabies monoclonal antibody (ormutivimab) with human rabies immunoglobulin (HRIG) for postexposure prophylaxis: a phase III, randomized, double-blind, non-inferiority trial. Int. J. Infect. Dis. 134 , 53–62 (2023). 37211270 10.1016/j.ijid.2023.05.017

294. Crescioli, S. et al. in MAbs . 2297450 (Taylor & Francis).

295. Dhillon S Narlumosbart: First Approval Drugs. 2024 84 105 109 10.1007/s40265-023-01985-3 38112898 Dhillon, S. Narlumosbart: First Approval. Drugs. 84 , 105–109 (2024). 38112898 10.1007/s40265-023-01985-3

296. Yasuda H Discovery of the RANKL/RANK/OPG system J. Bone Miner. Metab. 2021 39 2 11 10.1007/s00774-020-01175-1 33389131 Yasuda, H. Discovery of the RANKL/RANK/OPG system. J. Bone Miner. Metab. 39 , 2–11 (2021). 33389131 10.1007/s00774-020-01175-1

297. Dickinson MJ Glofitamab for relapsed or refractory diffuse large B-cell lymphoma N. Engl. J. Med. 2022 387 2220 2231 10.1056/NEJMoa2206913 36507690 Dickinson, M. J. et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 387 , 2220–2231 (2022). 36507690 10.1056/NEJMoa2206913

298. Hutchings M Glofitamab, a novel, bivalent CD20-targeting T-cell–engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial J. Clin. Oncol. 2021 39 1959 1970 10.1200/JCO.20.03175 33739857 PMC8210975 Hutchings, M. et al. Glofitamab, a novel, bivalent CD20-targeting T-cell–engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. J. Clin. Oncol. 39 , 1959–1970 (2021). 33739857 10.1200/JCO.20.03175 PMC8210975

299. Shirley M Glofitamab: first approval Drugs. 2023 83 935 941 10.1007/s40265-023-01894-5 37285013 PMC10245362 Shirley, M. Glofitamab: first approval. Drugs. 83 , 935–941 (2023). 37285013 10.1007/s40265-023-01894-5 PMC10245362

300. Minson A Dickinson M Glofitamab CD20-TCB bispecific antibody Leuk. Lymphoma. 2021 62 3098 3108 10.1080/10428194.2021.1953016 34263696 Minson, A. & Dickinson, M. Glofitamab CD20-TCB bispecific antibody. Leuk. Lymphoma. 62 , 3098–3108 (2021). 34263696 10.1080/10428194.2021.1953016

301. Hutchings M Glofitamab step-up dosing induces high response rates in patients with hard-to-treat refractory or relapsed non-Hodgkin lymphoma Blood. 2020 136 46 48 10.1182/blood-2020-136044 Hutchings, M. et al. Glofitamab step-up dosing induces high response rates in patients with hard-to-treat refractory or relapsed non-Hodgkin lymphoma. Blood. 136 , 46–48 (2020).

302. Hutchings M Glofitamab (Glofit) in combination with polatuzumab vedotin (Pola): phase Ib/II preliminary data support manageable safety and encouraging efficacy in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) Blood. 2021 138 525 10.1182/blood-2021-148359 Hutchings, M. et al. Glofitamab (Glofit) in combination with polatuzumab vedotin (Pola): phase Ib/II preliminary data support manageable safety and encouraging efficacy in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Blood. 138 , 525 (2021).

303. Townsend W Glofitamab plus immunochemotherapy demonstrates durable efficacy with manageable safety in relapsed/refractory non-Hodgkin lymphoma (R/R NHL): update of a Phase Ib study Hematol. Oncol. 2023 41 595 597 10.1002/hon.3164_446 Townsend, W. et al. Glofitamab plus immunochemotherapy demonstrates durable efficacy with manageable safety in relapsed/refractory non-Hodgkin lymphoma (R/R NHL): update of a Phase Ib study. Hematol. Oncol. 41 , 595–597 (2023).

304. Carlo-Stella C Glofitamab monotherapy induces durable complete remissions and has a manageable safety profile in patients with Richter’s transformation Hematol. Oncol. 2023 41 63 65 10.1002/hon.3163_28 Carlo-Stella, C. et al. Glofitamab monotherapy induces durable complete remissions and has a manageable safety profile in patients with Richter’s transformation. Hematol. Oncol. 41 , 63–65 (2023).

305. Topp MS Glofitamab plus R-CHOP induces high response rates with a manageable safety profile in patients with Previously untreated diffuse large B-Cell lymphoma (DLBCL): a 12-month analysis from a phase ib study Blood. 2023 142 3085 10.1182/blood-2023-174081 Topp, M. S. et al. Glofitamab plus R-CHOP induces high response rates with a manageable safety profile in patients with Previously untreated diffuse large B-Cell lymphoma (DLBCL): a 12-month analysis from a phase ib study. Blood. 142 , 3085 (2023).

306. Morschhauser F Glofitamab as monotherapy and in combination with obinutuzumab induces high complete response rates in patients (pts) with multiple relapsed or refractory (R/R) follicular lymphoma (FL) Blood. 2021 138 128 10.1182/blood-2021-148778 Morschhauser, F. et al. Glofitamab as monotherapy and in combination with obinutuzumab induces high complete response rates in patients (pts) with multiple relapsed or refractory (R/R) follicular lymphoma (FL). Blood. 138 , 128 (2021).

307. Pathak GN Spesolimab: a review of the first IL-36 blocker approved for generalized pustular psoriasis Ann. Pharmacother. 2024 59 174 183 10.1177/10600280241252688 38755971 Pathak, G. N. et al. Spesolimab: a review of the first IL-36 blocker approved for generalized pustular psoriasis. Ann. Pharmacother. 59 , 174–183 (2024). 38755971 10.1177/10600280241252688

308. MPR. Spevigo Gets Expanded Approval for Generalized Pustular Psoriasis https://www.empr.com/home/news/spevigo-gets-expanded-approval-for-generalized-pustular-psoriasis/ > (2025)

309. Palaniappan V Spesolimab: a comprehensive review on the anti‐IL‐36 receptor antibody in dermatology Int. J. Dermatol. 2024 63 88 93 10.1111/ijd.16941 38031264 Palaniappan, V. et al. Spesolimab: a comprehensive review on the anti‐IL‐36 receptor antibody in dermatology. Int. J. Dermatol. 63 , 88–93 (2024). 38031264 10.1111/ijd.16941

310. Nielsen, V. W., Yao, Y., Egeberg, A. & Thomsen, S. F. Spesolimab. Anti-IL-36R monoclonal antibody, treatment of generalized pustular psoriasis, treatment of immune-mediated inflammatory diseases. Drugs Fut . 48 , NA-NA (2023).

311. King B Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial Lancet. 2023 401 1518 1529 10.1016/S0140-6736(23)00222-2 37062298 King, B. et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial. Lancet. 401 , 1518–1529 (2023). 37062298 10.1016/S0140-6736(23)00222-2

312. Ramírez-Marín HA Tosti A Evaluating the therapeutic potential of ritlecitinib for the treatment of alopecia areata Drug Des. Devel. Ther 2023 16 363 374 10.2147/DDDT.S334727 PMC8860347 35210753 Ramírez-Marín, H. A. & Tosti, A. Evaluating the therapeutic potential of ritlecitinib for the treatment of alopecia areata. Drug Des. Devel. Ther 16 , 363–374 (2023). 10.2147/DDDT.S334727 PMC8860347 35210753

313. King B A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results J. Am. Acad. Dermatol. 2021 85 379 387 10.1016/j.jaad.2021.03.050 33757798 King, B. et al. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. J. Am. Acad. Dermatol. 85 , 379–387 (2021). 33757798 10.1016/j.jaad.2021.03.050

314. Guttman-Yassky E Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers J. Allergy Clin. Immunol. 2022 149 1318 1328 10.1016/j.jaci.2021.10.036 34863853 Guttman-Yassky, E. et al. Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers. J. Allergy Clin. Immunol. 149 , 1318–1328 (2022). 34863853 10.1016/j.jaci.2021.10.036

315. Eisman S Sinclair R Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata Expert Opin. Investig. Drugs. 2021 30 1169 1174 10.1080/13543784.2021.2012149 34826225 Eisman, S. & Sinclair, R. Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata. Expert Opin. Investig. Drugs. 30 , 1169–1174 (2021). 34826225 10.1080/13543784.2021.2012149

316. Markati T Fisher G Ramdas S Servais L Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA) Expert Opin. Investig. Drugs. 2022 31 451 461 10.1080/13543784.2022.2056836 35316106 Markati, T., Fisher, G., Ramdas, S. & Servais, L. Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA). Expert Opin. Investig. Drugs. 31 , 451–461 (2022). 35316106 10.1080/13543784.2022.2056836

317. Oskoui M Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA) J. Neurol. 2023 270 2531 2546 10.1007/s00415-023-11560-1 36735057 PMC9897618 Oskoui, M. et al. Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA). J. Neurol. 270 , 2531–2546 (2023). 36735057 10.1007/s00415-023-11560-1 PMC9897618

318. Dhillon S Risdiplam: first approval Drugs. 2020 80 1853 1858 10.1007/s40265-020-01410-z 33044711 Dhillon, S. Risdiplam: first approval. Drugs. 80 , 1853–1858 (2020). 33044711 10.1007/s40265-020-01410-z

319. Mercuri E SUNFISH Part 2: efficacy and safety of risdiplam (RG7916) in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA)(1260) Neurology. 2020 94 1260 10.1212/WNL.94.15_supplement.1260 Mercuri, E. et al. SUNFISH Part 2: efficacy and safety of risdiplam (RG7916) in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA)(1260). Neurology. 94 , 1260 (2020).

320. Paik J Risdiplam: a review in spinal muscular atrophy CNS Drugs 2022 36 401 410 10.1007/s40263-022-00910-8 35284988 Paik, J. Risdiplam: a review in spinal muscular atrophy. CNS Drugs 36 , 401–410 (2022). 35284988 10.1007/s40263-022-00910-8

321. Ratni, H. et al. (ACS Publications, 2018).

322. Behrangi N Fischbach F Kipp M Mechanism of siponimod: anti-inflammatory and neuroprotective mode of action Cells. 2019 8 24 10.3390/cells8010024 30621015 PMC6356776 Behrangi, N., Fischbach, F. & Kipp, M. Mechanism of siponimod: anti-inflammatory and neuroprotective mode of action. Cells. 8 , 24 (2019). 30621015 10.3390/cells8010024 PMC6356776

323. Kappos L Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study Lancet. 2018 391 1263 1273 10.1016/S0140-6736(18)30475-6 29576505 Kappos, L. et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 391 , 1263–1273 (2018). 29576505 10.1016/S0140-6736(18)30475-6

324. Kappos L Safety and efficacy of siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis: dose-blinded, randomized extension of the phase 2 BOLD study JAMA Neurol 2016 73 1089 1098 10.1001/jamaneurol.2016.1451 27380540 Kappos, L. et al. Safety and efficacy of siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis: dose-blinded, randomized extension of the phase 2 BOLD study. JAMA Neurol 73 , 1089–1098 (2016). 27380540 10.1001/jamaneurol.2016.1451

325. Cao, L. et al. Siponimod for multiple sclerosis. Cochrane Database Syst. Rev . (2021). 10.1002/14651858.CD013647.pub2 PMC8592914 34783010

326. Cohan SL The two sides of siponimod: evidence for brain and immune mechanisms in multiple sclerosis CNS Drugs 2022 36 703 719 10.1007/s40263-022-00927-z 35725892 PMC9259525 Cohan, S. L. et al. The two sides of siponimod: evidence for brain and immune mechanisms in multiple sclerosis. CNS Drugs 36 , 703–719 (2022). 35725892 10.1007/s40263-022-00927-z PMC9259525

327. Gold R Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study J. Neurol. 2022 269 5093 5104 10.1007/s00415-022-11166-z 35639197 PMC9363350 Gold, R. et al. Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study. J. Neurol. 269 , 5093–5104 (2022). 35639197 10.1007/s00415-022-11166-z PMC9363350

328. Goodman AD Anadani N Gerwitz L Siponimod in the treatment of multiple sclerosis Expert Opin. Investig. Drugs. 2019 28 1051 1057 10.1080/13543784.2019.1676725 31603362 Goodman, A. D., Anadani, N. & Gerwitz, L. Siponimod in the treatment of multiple sclerosis. Expert Opin. Investig. Drugs. 28 , 1051–1057 (2019). 31603362 10.1080/13543784.2019.1676725

329. Al-Salama ZT Siponimod: first global approval Drugs. 2019 79 1009 1015 10.1007/s40265-019-01140-x 31144287 Al-Salama, Z. T. Siponimod: first global approval. Drugs. 79 , 1009–1015 (2019). 31144287 10.1007/s40265-019-01140-x

330. Kappos, L. et al. Efficacy of siponimod in secondary progressive multiple sclerosis: results of the phase 3 study (CT. 002). Neurology . 88 , CT. 002, (2017).

331. Scott LJ Siponimod: a review in secondary progressive multiple sclerosis CNS Drugs 2020 34 1191 1200 10.1007/s40263-020-00771-z 33108633 PMC7773609 Scott, L. J. Siponimod: a review in secondary progressive multiple sclerosis. CNS Drugs 34 , 1191–1200 (2020). 33108633 10.1007/s40263-020-00771-z PMC7773609

332. Armstrong PW Vericiguat in patients with heart failure and reduced ejection fraction N. Engl. J. Med. 2020 382 1883 1893 10.1056/NEJMoa1915928 32222134 Armstrong, P. W. et al. Vericiguat in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 382 , 1883–1893 (2020). 32222134 10.1056/NEJMoa1915928

333. Gheorghiade M Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial JAMA. 2015 314 2251 2262 10.1001/jama.2015.15734 26547357 Gheorghiade, M. et al. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial. JAMA. 314 , 2251–2262 (2015). 26547357 10.1001/jama.2015.15734

334. Pieske B Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study Eur. Heart J. 2017 38 1119 1127 10.1093/eurheartj/ehw593 28369340 PMC5400074 Pieske, B. et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur. Heart J. 38 , 1119–1127 (2017). 28369340 10.1093/eurheartj/ehw593 PMC5400074

335. Aimo A The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction Heart Fail. Rev. 2022 27 1165 1171 10.1007/s10741-021-10146-1 34291399 PMC9197896 Aimo, A. et al. The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction. Heart Fail. Rev. 27 , 1165–1171 (2022). 34291399 10.1007/s10741-021-10146-1 PMC9197896

336. Armstrong PW Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial JAMA. 2020 324 1512 1521 10.1001/jama.2020.15922 33079152 PMC7576403 Armstrong, P. W. et al. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial. JAMA. 324 , 1512–1521 (2020). 33079152 10.1001/jama.2020.15922 PMC7576403

337. Vannuccini F Campora A Barilli M Palazzuoli A Vericiguat in heart failure: characteristics, scientific evidence and potential clinical applications Biomedicines. 2022 10 2471 10.3390/biomedicines10102471 36289733 PMC9598881 Vannuccini, F., Campora, A., Barilli, M. & Palazzuoli, A. Vericiguat in heart failure: characteristics, scientific evidence and potential clinical applications. Biomedicines. 10 , 2471 (2022). 36289733 10.3390/biomedicines10102471 PMC9598881

338. Markham A Duggan S Vericiguat: first approval Drugs. 2021 81 721 726 10.1007/s40265-021-01496-z 33770393 Markham, A. & Duggan, S. Vericiguat: first approval. Drugs. 81 , 721–726 (2021). 33770393 10.1007/s40265-021-01496-z

339. Lombardi CM Vericiguat for heart failure with reduced ejection fraction Curr. Cardiol. Rep. 2021 23 144 10.1007/s11886-021-01580-6 34410527 PMC8376697 Lombardi, C. M. et al. Vericiguat for heart failure with reduced ejection fraction. Curr. Cardiol. Rep. 23 , 144 (2021). 34410527 10.1007/s11886-021-01580-6 PMC8376697

340. Cai Q Empowering immune responses against cancer by IL-21-driven T cell reprogramming Innov. Life 2025 3 1001127 10.59717/j.xinn-life.2024.100127 Cai, Q. et al. Empowering immune responses against cancer by IL-21-driven T cell reprogramming. Innov. Life 3 , 1001127 (2025).

341. Song Y Relmacabtagene autoleucel CD19 CART therapy for adults with heavily-pretreated relapsed/refractory large B-cell lymphoma in China Blood. 2021 138 3557 10.1182/blood-2021-148358 PMC7897944 33382529 Song, Y. et al. Relmacabtagene autoleucel CD19 CART therapy for adults with heavily-pretreated relapsed/refractory large B-cell lymphoma in China. Blood. 138 , 3557 (2021). 10.1002/cam4.3686 PMC7897944 33382529

342. Zhu J Clinical response of cd19 car-t cells (relmacabtagene autoleucel, relma-cel) in adults with heavily-pre-treated relapsed/refractory (r/r) large b-cell lymphoma in China Blood. 2020 136 39 40 10.1182/blood-2020-136038 Zhu, J. et al. Clinical response of cd19 car-t cells (relmacabtagene autoleucel, relma-cel) in adults with heavily-pre-treated relapsed/refractory (r/r) large b-cell lymphoma in China. Blood. 136 , 39–40 (2020).

343. Ying Z Relmacabtagene autoleucel (relma‐cel) CD19 CAR‐T therapy for adults with heavily pretreated relapsed/refractory large B‐cell lymphoma in China Cancer Med 2021 10 999 1011 10.1002/cam4.3686 33382529 PMC7897944 Ying, Z. et al. Relmacabtagene autoleucel (relma‐cel) CD19 CAR‐T therapy for adults with heavily pretreated relapsed/refractory large B‐cell lymphoma in China. Cancer Med 10 , 999–1011 (2021). 33382529 10.1002/cam4.3686 PMC7897944

344. Ying Z Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkin’s lymphoma: 2-year results of a phase 1 trial Bone Marrow Transplant 2023 58 288 294 10.1038/s41409-022-01888-z 36477110 Ying, Z. et al. Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkin’s lymphoma: 2-year results of a phase 1 trial. Bone Marrow Transplant 58 , 288–294 (2023). 36477110 10.1038/s41409-022-01888-z

345. Ying Z Long-term outcomes of relmacabtagene autoleucel in Chinese patients with relapsed/refractory large B-cell lymphoma: updated results of the RELIANCE study Cytotherapy. 2023 25 521 529 10.1016/j.jcyt.2022.10.011 36842849 Ying, Z. et al. Long-term outcomes of relmacabtagene autoleucel in Chinese patients with relapsed/refractory large B-cell lymphoma: updated results of the RELIANCE study. Cytotherapy. 25 , 521–529 (2023). 36842849 10.1016/j.jcyt.2022.10.011

346. Wang Y Sustained remission and decreased severity of CAR T-cell related adverse events: a pivotal study report of CNCT19 (inaticabtagene autoleucel) treatment in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-Cell ALL) in China Blood. 2022 140 1598 1600 10.1182/blood-2022-165002 Wang, Y. et al. Sustained remission and decreased severity of CAR T-cell related adverse events: a pivotal study report of CNCT19 (inaticabtagene autoleucel) treatment in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-Cell ALL) in China. Blood. 140 , 1598–1600 (2022).

347. Wang Y Inaticabtagene autoleucel ((CNCT19), a CD19-directed chimeric antigen receptor T-cell therapy in adult relapsed or refractory B-cell acute lymphoblastic leukaemia: a multicenter, open-label, single-arm, phase 2 study Lancet 2024 9 836 843 Wang, Y. et al. Inaticabtagene autoleucel ((CNCT19), a CD19-directed chimeric antigen receptor T-cell therapy in adult relapsed or refractory B-cell acute lymphoblastic leukaemia: a multicenter, open-label, single-arm, phase 2 study. Lancet 9 , 836–843 (2024).

348. Keam SJ Equecabtagene autoleucel: first approval Mol. Diagn. Ther. 2023 27 781 787 10.1007/s40291-023-00673-y 37658205 Keam, S. J. Equecabtagene autoleucel: first approval. Mol. Diagn. Ther. 27 , 781–787 (2023). 37658205 10.1007/s40291-023-00673-y

349. Li C Efficacy outcomes and characteristics of patients with multiple myeloma (MM) who achieved sustained minimal residual disease negativity after treatment with equecabtagene autoleucel (Eque-cel, CT103A) in Fumanba-1 Blood. 2023 142 761 10.1182/blood-2023-173427 Li, C. et al. Efficacy outcomes and characteristics of patients with multiple myeloma (MM) who achieved sustained minimal residual disease negativity after treatment with equecabtagene autoleucel (Eque-cel, CT103A) in Fumanba-1. Blood. 142 , 761 (2023).36652635

350. Finance, I. & Newswire, P. in PR Newswire (2024).

351. Administration, N. M. P. National Medical Products Administration353, < https://www.nmpa.gov.cn/ > (2024).

352. Guo C Comparison of antigen-specific B cell responses reveals disparity in immunogenicity and memory B cell formation across COVID-19 vaccine platforms hLife 2024 2 625 640 10.1016/j.hlife.2024.09.002 Guo, C. et al. Comparison of antigen-specific B cell responses reveals disparity in immunogenicity and memory B cell formation across COVID-19 vaccine platforms. hLife 2 , 625–640 (2024).

353. Yan, L. et al. Boosting CAR-T cell therapy with CRISPR technology. hLife , (2024).

354. Jia K New insights for infection mechanism and potential targets of COVID-19: three Chinese patent medicines and three Chinese medicine formulas as promising therapeutic approaches Chin. Herb. Med. 2023 15 157 168 37220535 10.1016/j.chmed.2022.06.014 PMC9993661 Jia, K. et al. New insights for infection mechanism and potential targets of COVID-19: three Chinese patent medicines and three Chinese medicine formulas as promising therapeutic approaches. Chin. Herb. Med. 15 , 157–168 (2023). 37220535 10.1016/j.chmed.2022.06.014 PMC9993661

355. Wang, F.-Z. et al. Kinetics and factors associated with 12-month persistence of neutralizing antibody induced by two inactivated COVID-19 Vaccines. Lancet (2022).

356. World Health Organization, Annexes to the interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm: grading of evidence: evidence to recommendation tables, first issued 07 May 2021, updated 28 October 2021 (World Health Organization, 2021).

357. Ferenci T Sarkadi B RBD-specific antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine BMC Infect. Dis. 2022 22 87 10.1186/s12879-022-07069-z 35073866 PMC8785690 Ferenci, T. & Sarkadi, B. RBD-specific antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine. BMC Infect. Dis. 22 , 87 (2022). 35073866 10.1186/s12879-022-07069-z PMC8785690

358. Wu Z Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial Lancet Infect. Dis. 2021 21 803 812 10.1016/S1473-3099(20)30987-7 33548194 PMC7906628 Wu, Z. et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect. Dis. 21 , 803–812 (2021). 33548194 10.1016/S1473-3099(20)30987-7 PMC7906628

359. Lai KT-W Safety and immunogenicity of a booster vaccination by CoronaVac or BNT162b2 in previously two-dose inactivated virus vaccinated individuals with negative neutralizing antibody Vaccines. 2022 10 556 10.3390/vaccines10040556 35455305 PMC9025305 Lai, K. T.-W. et al. Safety and immunogenicity of a booster vaccination by CoronaVac or BNT162b2 in previously two-dose inactivated virus vaccinated individuals with negative neutralizing antibody. Vaccines. 10 , 556 (2022). 35455305 10.3390/vaccines10040556 PMC9025305

360. Tanriover MD Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey Lancet. 2021 398 213 222 10.1016/S0140-6736(21)01429-X 34246358 PMC8266301 Tanriover, M. D. et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 398 , 213–222 (2021). 34246358 10.1016/S0140-6736(21)01429-X PMC8266301

361. Jin L CoronaVac: a review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2 Hum. Vaccin. Immunother. 2022 18 2096970 10.1080/21645515.2022.2096970 35878789 PMC9746539 Jin, L. et al. CoronaVac: a review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2. Hum. Vaccin. Immunother. 18 , 2096970 (2022). 35878789 10.1080/21645515.2022.2096970 PMC9746539

362. Kennedy RB Efficacy of an adenovirus type 5 vectored SARS-CoV-2 vaccine Lancet. 2022 399 212 10.1016/S0140-6736(21)02834-8 34953524 PMC8700275 Kennedy, R. B. Efficacy of an adenovirus type 5 vectored SARS-CoV-2 vaccine. Lancet. 399 , 212 (2022). 34953524 10.1016/S0140-6736(21)02834-8 PMC8700275

363. Halperin SA Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial Lancet. 2022 399 237 248 10.1016/S0140-6736(21)02753-7 34953526 PMC8700283 Halperin, S. A. et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. Lancet. 399 , 237–248 (2022). 34953526 10.1016/S0140-6736(21)02753-7 PMC8700283

364. Zhu F-C Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial Lancet. 2020 395 1845 1854 10.1016/S0140-6736(20)31208-3 32450106 PMC7255193 Zhu, F.-C. et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 395 , 1845–1854 (2020). 32450106 10.1016/S0140-6736(20)31208-3 PMC7255193

365. Guzmán-López S Clinical and immunologic efficacy of the recombinant adenovirus type-5-vectored (CanSino Bio) Vaccine in University professors during the COVID-19 Delta wave Vaccines. 2022 10 656 10.3390/vaccines10050656 35632412 PMC9143224 Guzmán-López, S. et al. Clinical and immunologic efficacy of the recombinant adenovirus type-5-vectored (CanSino Bio) Vaccine in University professors during the COVID-19 Delta wave. Vaccines. 10 , 656 (2022). 35632412 10.3390/vaccines10050656 PMC9143224

366. Yang S Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials Lancet Infect. Dis. 2021 21 1107 1119 10.1016/S1473-3099(21)00127-4 33773111 PMC7990482 Yang, S. et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect. Dis. 21 , 1107–1119 (2021). 33773111 10.1016/S1473-3099(21)00127-4 PMC7990482

367. Yang S Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials Lancet Infect Dis. 2021 21 1107 1119 10.1016/S1473-3099(21)00127-4 33773111 PMC7990482 Yang, S. et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 21 , 1107–1119 (2021). 33773111 10.1016/S1473-3099(21)00127-4 PMC7990482

368. Chen, F. & Ya, G. In COVID-19 Vaccines-Current State and Perspectives (IntechOpen, 2023).

369. Parreno V Probiotic as adjuvant significantly improves protection of the Lanzhou trivalent rotavirus vaccine against heterologous challenge in a gnotobiotic pig model of human rotavirus infection and disease Vaccines. 2022 10 1529 10.3390/vaccines10091529 36146607 PMC9506166 Parreno, V. et al. Probiotic as adjuvant significantly improves protection of the Lanzhou trivalent rotavirus vaccine against heterologous challenge in a gnotobiotic pig model of human rotavirus infection and disease. Vaccines. 10 , 1529 (2022). 36146607 10.3390/vaccines10091529 PMC9506166

370. Wang Y Application of the cell‐based RT‐qPCR assay (C‐QPA) for potency detection of the novel trivalent rotavirus vaccine in China J. Clin. Lab. Anal. 2023 37 e24989 10.1002/jcla.24989 37975330 PMC10756945 Wang, Y. et al. Application of the cell‐based RT‐qPCR assay (C‐QPA) for potency detection of the novel trivalent rotavirus vaccine in China. J. Clin. Lab. Anal. 37 , e24989 (2023). 37975330 10.1002/jcla.24989 PMC10756945

371. Zhang J The epidemiology of influenza and the associated vaccines development in China: a review Vaccines. 2022 10 1873 10.3390/vaccines10111873 36366381 PMC9692979 Zhang, J. et al. The epidemiology of influenza and the associated vaccines development in China: a review. Vaccines. 10 , 1873 (2022). 36366381 10.3390/vaccines10111873 PMC9692979

372. Geng H Shi CM Health policy, price regulation, and innovation: evidence from China’s vaccine industry J. Dev. Econ. 2024 167 103229 10.1016/j.jdeveco.2023.103229 Geng, H. & Shi, C. M. Health policy, price regulation, and innovation: evidence from China’s vaccine industry. J. Dev. Econ. 167 , 103229 (2024).

373. Meng Z Shan S Zhang R Chinaas COVID-19 vaccination strategy and its impact on the global pandemic Risk Manag. Healthc. Policy 2021 14 4649 4655 10.2147/RMHP.S338701 34815726 PMC8604646 Meng, Z., Shan, S. & Zhang, R. Chinaas COVID-19 vaccination strategy and its impact on the global pandemic. Risk Manag. Healthc. Policy 14 , 4649–4655 (2021). 34815726 10.2147/RMHP.S338701 PMC8604646

374. Blair HA Sotorasib: first approval Drugs. 2021 81 1573 1579 10.1007/s40265-021-01574-2 34357500 PMC8531079 Blair, H. A. Sotorasib: first approval. Drugs. 81 , 1573–1579 (2021). 34357500 10.1007/s40265-021-01574-2 PMC8531079

375. Hong DS KRASG12C inhibition with sotorasib in advanced solid tumors N. Engl. J. Med. 2020 383 1207 1217 10.1056/NEJMoa1917239 32955176 PMC7571518 Hong, D. S. et al. KRASG12C inhibition with sotorasib in advanced solid tumors. N. Engl. J. Med. 383 , 1207–1217 (2020). 32955176 10.1056/NEJMoa1917239 PMC7571518

376. Skoulidis F Sotorasib for lung cancers with KRAS p. G12C mutation N. Engl. J. Med. 2021 384 2371 2381 10.1056/NEJMoa2103695 34096690 PMC9116274 Skoulidis, F. et al. Sotorasib for lung cancers with KRAS p. G12C mutation. N. Engl. J. Med. 384 , 2371–2381 (2021). 34096690 10.1056/NEJMoa2103695 PMC9116274

377. Strickler JH Sotorasib in KRAS p. G12C–mutated advanced pancreatic cancer N. Engl. J. Med. 2023 388 33 43 10.1056/NEJMoa2208470 36546651 PMC10506456 Strickler, J. H. et al. Sotorasib in KRAS p. G12C–mutated advanced pancreatic cancer. N. Engl. J. Med. 388 , 33–43 (2023). 36546651 10.1056/NEJMoa2208470 PMC10506456

378. Nakajima EC FDA approval summary: sotorasib for KRAS G12C-mutated metastatic NSCLC Clin. Cancer Res. 2022 28 1482 1486 10.1158/1078-0432.CCR-21-3074 34903582 PMC9012672 Nakajima, E. C. et al. FDA approval summary: sotorasib for KRAS G12C-mutated metastatic NSCLC. Clin. Cancer Res. 28 , 1482–1486 (2022). 34903582 10.1158/1078-0432.CCR-21-3074 PMC9012672

379. de Langen AJ Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial Lancet 2023 401 733 746 10.1016/S0140-6736(23)00221-0 36764316 de Langen, A. J. et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. Lancet 401 , 733–746 (2023). 36764316 10.1016/S0140-6736(23)00221-0

380. Lanman BA Parsons AT Zech SG Addressing atropisomerism in the development of sotorasib, a covalent inhibitor of KRAS G12C: structural, analytical, and synthetic considerations Acc. Chem. Res. 2022 55 2892 2903 10.1021/acs.accounts.2c00479 36178208 PMC9583618 Lanman, B. A., Parsons, A. T. & Zech, S. G. Addressing atropisomerism in the development of sotorasib, a covalent inhibitor of KRAS G12C: structural, analytical, and synthetic considerations. Acc. Chem. Res. 55 , 2892–2903 (2022). 36178208 10.1021/acs.accounts.2c00479 PMC9583618

381. Sidaway P Sotorasib effective in KRAS-mutant NSCLC Nat. Rev. Clin. Oncol. 2021 18 470 470 34140669 10.1038/s41571-021-00533-w Sidaway, P. Sotorasib effective in KRAS-mutant NSCLC. Nat. Rev. Clin. Oncol. 18 , 470–470 (2021). 34140669 10.1038/s41571-021-00533-w

382. Fraissenon A Sotorasib for vascular malformations associated with KRAS G12C mutation N. Engl. J. Med. 2024 391 334 342 10.1056/NEJMoa2309160 39018528 Fraissenon, A. et al. Sotorasib for vascular malformations associated with KRAS G12C mutation. N. Engl. J. Med. 391 , 334–342 (2024). 39018528 10.1056/NEJMoa2309160

383. Fakih MG Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C N. Engl. J. Med. 2023 389 2125 2139 10.1056/NEJMoa2308795 37870968 Fakih, M. G. et al. Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C. N. Engl. J. Med. 389 , 2125–2139 (2023). 37870968 10.1056/NEJMoa2308795

384. Fakih MG Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial Lancet Oncol. 2022 23 115 124 10.1016/S1470-2045(21)00605-7 34919824 Fakih, M. G. et al. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol. 23 , 115–124 (2022). 34919824 10.1016/S1470-2045(21)00605-7

385. Kuboki Y Sotorasib with panitumumab in chemotherapy-refractory KRAS G12C-mutated colorectal cancer: a phase 1b trial Nat. Med. 2024 30 265 270 10.1038/s41591-023-02717-6 38177853 PMC11135132 Kuboki, Y. et al. Sotorasib with panitumumab in chemotherapy-refractory KRAS G12C-mutated colorectal cancer: a phase 1b trial. Nat. Med. 30 , 265–270 (2024). 38177853 10.1038/s41591-023-02717-6 PMC11135132

386. Lee A Sotorasib: a review in KRAS G12C mutation-positive non-small cell lung cancer Target. Oncol. 2022 17 727 733 10.1007/s11523-022-00922-w 36315377 PMC9715446 Lee, A. Sotorasib: a review in KRAS G12C mutation-positive non-small cell lung cancer. Target. Oncol. 17 , 727–733 (2022). 36315377 10.1007/s11523-022-00922-w PMC9715446

387. Mann JE Sotorasib (Lumakras™) Oncol. Times 2021 43 12 17 Mann, J. E. Sotorasib (Lumakras™). Oncol. Times 43 , 12–17 (2021).

388. Chour A Brief report: severe sotorasib-related hepatotoxicity and non-liver adverse events associated with sequential anti–programmed cell death (Ligand) 1 and sotorasib therapy in KRASG12C-mutant lung cancer J. Thorac. Oncol. 2023 18 1408 1415 10.1016/j.jtho.2023.05.013 37217096 Chour, A. et al. Brief report: severe sotorasib-related hepatotoxicity and non-liver adverse events associated with sequential anti–programmed cell death (Ligand) 1 and sotorasib therapy in KRASG12C-mutant lung cancer. J. Thorac. Oncol. 18 , 1408–1415 (2023). 37217096 10.1016/j.jtho.2023.05.013

389. Rubinson DA Sotorasib is a Pan-RAS G12C inhibitor capable of driving clinical response in NRAS G12C cancers Cancer Discov 2024 14 727 736 10.1158/2159-8290.CD-23-1138 38236605 PMC11061598 Rubinson, D. A. et al. Sotorasib is a Pan-RAS G12C inhibitor capable of driving clinical response in NRAS G12C cancers. Cancer Discov 14 , 727–736 (2024). 38236605 10.1158/2159-8290.CD-23-1138 PMC11061598

390. Koga T KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors, sotorasib and adagrasib, and overcoming strategies: insights from in vitro experiments J. Thorac. Oncol. 2021 16 1321 1332 10.1016/j.jtho.2021.04.015 33971321 Koga, T. et al. KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors, sotorasib and adagrasib, and overcoming strategies: insights from in vitro experiments. J. Thorac. Oncol. 16 , 1321–1332 (2021). 33971321 10.1016/j.jtho.2021.04.015

391. Thummalapalli R Clinical and genomic features of response and toxicity to Sotorasib in a real-world cohort of patients with advanced KRAS g12c-mutant non–small cell lung cancer JCO Precis. Oncol. 2023 7 e2300030 10.1200/PO.23.00030 37384866 PMC10581626 Thummalapalli, R. et al. Clinical and genomic features of response and toxicity to Sotorasib in a real-world cohort of patients with advanced KRAS g12c-mutant non–small cell lung cancer. JCO Precis. Oncol. 7 , e2300030 (2023). 37384866 10.1200/PO.23.00030 PMC10581626

392. Li B PS01. 07 registrational phase 2 trial of sotorasib in KRAS p. G12C mutant NSCLC: first disclosure of the codebreak 100 primary analysis J. Thorac. Oncol. 2021 16 S61 10.1016/j.jtho.2021.01.321 Li, B. et al. PS01. 07 registrational phase 2 trial of sotorasib in KRAS p. G12C mutant NSCLC: first disclosure of the codebreak 100 primary analysis. J. Thorac. Oncol. 16 , S61 (2021).

393. Dy GK Long-term outcomes and molecular correlates of sotorasib efficacy in patients with pretreated KRAS G12C-mutated non–small-cell lung cancer: 2-year analysis of CodeBreaK 100 J. Clin. Oncol. 2023 41 3311 3317 10.1200/JCO.22.02524 37098232 PMC10414711 Dy, G. K. et al. Long-term outcomes and molecular correlates of sotorasib efficacy in patients with pretreated KRAS G12C-mutated non–small-cell lung cancer: 2-year analysis of CodeBreaK 100. J. Clin. Oncol. 41 , 3311–3317 (2023). 37098232 10.1200/JCO.22.02524 PMC10414711

394. Markham A Lurbinectedin: first approval Drugs. 2020 80 1345 1353 10.1007/s40265-020-01374-0 32816202 Markham, A. Lurbinectedin: first approval. Drugs. 80 , 1345–1353 (2020). 32816202 10.1007/s40265-020-01374-0

395. Manzo A Lurbinectedin in small cell lung cancer Front. Oncol. 2022 12 932105 10.3389/fonc.2022.932105 36110944 PMC9469650 Manzo, A. et al. Lurbinectedin in small cell lung cancer. Front. Oncol. 12 , 932105 (2022). 36110944 10.3389/fonc.2022.932105 PMC9469650

396. Trigo J Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial Lancet Oncol. 2020 21 645 654 10.1016/S1470-2045(20)30068-1 32224306 Trigo, J. et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 21 , 645–654 (2020). 32224306 10.1016/S1470-2045(20)30068-1

397. Patel S Petty WJ Sands JM An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer Ther. Adv. Med. Oncol. 2021 13 17588359211020529 10.1177/17588359211020529 34104228 PMC8165873 Patel, S., Petty, W. J. & Sands, J. M. An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer. Ther. Adv. Med. Oncol. 13 , 17588359211020529 (2021). 34104228 10.1177/17588359211020529 PMC8165873

398. Singh S FDA approval summary: lurbinectedin for the treatment of metastatic small cell lung cancer Clin. Cancer Res. 2021 27 2378 2382 10.1158/1078-0432.CCR-20-3901 33288660 PMC9532454 Singh, S. et al. FDA approval summary: lurbinectedin for the treatment of metastatic small cell lung cancer. Clin. Cancer Res. 27 , 2378–2382 (2021). 33288660 10.1158/1078-0432.CCR-20-3901 PMC9532454

399. Belgiovine C Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models Br. J. Cancer. 2017 117 628 638 10.1038/bjc.2017.205 28683469 PMC5572168 Belgiovine, C. et al. Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models. Br. J. Cancer. 117 , 628–638 (2017). 28683469 10.1038/bjc.2017.205 PMC5572168

400. Subbiah V Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment Lung Cancer 2020 150 90 96 10.1016/j.lungcan.2020.10.003 33096421 Subbiah, V. et al. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. Lung Cancer 150 , 90–96 (2020). 33096421 10.1016/j.lungcan.2020.10.003

401. Baena J Lurbinectedin in the treatment of relapsed small cell lung cancer Future Oncol 2021 17 2279 2289 10.2217/fon-2020-1212 33736462 Baena, J. et al. Lurbinectedin in the treatment of relapsed small cell lung cancer. Future Oncol 17 , 2279–2289 (2021). 33736462 10.2217/fon-2020-1212

402. Aix SP Combination lurbinectedin and doxorubicin versus physician’s choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial Lancet Respir. Med. 2023 11 74 86 10.1016/S2213-2600(22)00309-5 36252599 Aix, S. P. et al. Combination lurbinectedin and doxorubicin versus physician’s choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial. Lancet Respir. Med. 11 , 74–86 (2023). 36252599 10.1016/S2213-2600(22)00309-5

403. Povo-Retana A Trabectedin and lurbinectedin modulate the interplay between cells in the tumour microenvironment—progresses in their use in combined cancer therapy Molecules. 2024 29 331 10.3390/molecules29020331 38257245 PMC10820391 Povo-Retana, A. et al. Trabectedin and lurbinectedin modulate the interplay between cells in the tumour microenvironment—progresses in their use in combined cancer therapy. Molecules. 29 , 331 (2024). 38257245 10.3390/molecules29020331 PMC10820391

404. Gadducci A Cosio S Trabectedin and lurbinectedin: mechanisms of action, clinical impact, and future perspectives in uterine and soft tissue sarcoma, ovarian carcinoma, and endometrial carcinoma Front. Oncol. 2022 12 914342 10.3389/fonc.2022.914342 36408147 PMC9671549 Gadducci, A. & Cosio, S. Trabectedin and lurbinectedin: mechanisms of action, clinical impact, and future perspectives in uterine and soft tissue sarcoma, ovarian carcinoma, and endometrial carcinoma. Front. Oncol. 12 , 914342 (2022). 36408147 10.3389/fonc.2022.914342 PMC9671549

405. Longo-Muñoz F Lurbinectedin in patients with pretreated neuroendocrine tumours: results from a phase II basket study Eur. J. Cancer. 2022 172 340 348 10.1016/j.ejca.2022.06.024 35830841 Longo-Muñoz, F. et al. Lurbinectedin in patients with pretreated neuroendocrine tumours: results from a phase II basket study. Eur. J. Cancer. 172 , 340–348 (2022). 35830841 10.1016/j.ejca.2022.06.024

406. Shinn LT Vo KA Reeves DJ Lurbinectedin: a new treatment option for relapsed/refractory small-cell lung cancer Ann. Pharmacother. 2021 55 1172 1179 10.1177/1060028020983014 33348988 Shinn, L. T., Vo, K. A. & Reeves, D. J. Lurbinectedin: a new treatment option for relapsed/refractory small-cell lung cancer. Ann. Pharmacother. 55 , 1172–1179 (2021). 33348988 10.1177/1060028020983014

407. Elez ME First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors Clin. Cancer Res. 2014 20 2205 2214 10.1158/1078-0432.CCR-13-1880 24563480 Elez, M. E. et al. First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors. Clin. Cancer Res. 20 , 2205–2214 (2014). 24563480 10.1158/1078-0432.CCR-13-1880

408. Subbiah V Antitumor activity of lurbinectedin, a selective inhibitor of oncogene transcription, in patients with relapsed Ewing sarcoma: results of a basket phase II study Clin. Cancer Res. 2022 28 2762 2770 10.1158/1078-0432.CCR-22-0696 35486638 PMC9306456 Subbiah, V. et al. Antitumor activity of lurbinectedin, a selective inhibitor of oncogene transcription, in patients with relapsed Ewing sarcoma: results of a basket phase II study. Clin. Cancer Res. 28 , 2762–2770 (2022). 35486638 10.1158/1078-0432.CCR-22-0696 PMC9306456

409. Xie W Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity Oncoimmunology. 2019 8 e1656502 10.1080/2162402X.2019.1656502 31646106 PMC6791417 Xie, W. et al. Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity. Oncoimmunology. 8 , e1656502 (2019). 31646106 10.1080/2162402X.2019.1656502 PMC6791417

410. Calvo E Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study Ann. Oncol. 2017 28 2559 2566 10.1093/annonc/mdx357 28961837 PMC5834091 Calvo, E. et al. Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study. Ann. Oncol. 28 , 2559–2566 (2017). 28961837 10.1093/annonc/mdx357 PMC5834091

411. Schultz CW ATR inhibition augments the efficacy of lurbinectedin in small‐cell lung cancer EMBO Mol. Med. 2023 15 e17313 10.15252/emmm.202217313 37491889 PMC10405061 Schultz, C. W. et al. ATR inhibition augments the efficacy of lurbinectedin in small‐cell lung cancer. EMBO Mol. Med. 15 , e17313 (2023). 37491889 10.15252/emmm.202217313 PMC10405061

412. Allavena P Effects of the anti-tumor agents trabectedin and lurbinectedin on immune cells of the tumor microenvironment Front. Oncol. 2022 12 851790 10.3389/fonc.2022.851790 35299737 PMC8921639 Allavena, P. et al. Effects of the anti-tumor agents trabectedin and lurbinectedin on immune cells of the tumor microenvironment. Front. Oncol. 12 , 851790 (2022). 35299737 10.3389/fonc.2022.851790 PMC8921639

413. Santamaría Nuñez G Lurbinectedin specifically triggers the degradation of phosphorylated RNA polymerase II and the formation of DNA breaks in cancer cells Mol. Cancer Ther. 2016 15 2399 2412 10.1158/1535-7163.MCT-16-0172 27630271 Santamaría Nuñez, G. et al. Lurbinectedin specifically triggers the degradation of phosphorylated RNA polymerase II and the formation of DNA breaks in cancer cells. Mol. Cancer Ther. 15 , 2399–2412 (2016). 27630271 10.1158/1535-7163.MCT-16-0172

414. Lamb YN Inclisiran: first approval Drugs. 2021 81 389 395 10.1007/s40265-021-01473-6 33620677 PMC7900795 Lamb, Y. N. Inclisiran: first approval. Drugs. 81 , 389–395 (2021). 33620677 10.1007/s40265-021-01473-6 PMC7900795

415. Ray KK Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol N. Engl. J. Med. 2017 376 1430 1440 10.1056/NEJMoa1615758 28306389 Ray, K. K. et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N. Engl. J. Med. 376 , 1430–1440 (2017). 28306389 10.1056/NEJMoa1615758

416. Ray KK Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol N. Engl. J. Med. 2020 382 1507 1519 10.1056/NEJMoa1912387 32187462 Ray, K. K. et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N. Engl. J. Med. 382 , 1507–1519 (2020). 32187462 10.1056/NEJMoa1912387

417. Raal FJ Inclisiran for the treatment of heterozygous familial hypercholesterolemia N. Engl. J. Med. 2020 382 1520 1530 10.1056/NEJMoa1913805 32197277 Raal, F. J. et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N. Engl. J. Med. 382 , 1520–1530 (2020). 32197277 10.1056/NEJMoa1913805

418. Ray KK Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial Lancet Diabetes Endocrinol. 2023 11 109 119 10.1016/S2213-8587(22)00353-9 36620965 Ray, K. K. et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol. 11 , 109–119 (2023). 36620965 10.1016/S2213-8587(22)00353-9

419. Ray KK Inclisiran and cardiovascular events: a patient-level analysis of phase III trials Eur. Heart J. 2023 44 129 138 10.1093/eurheartj/ehac594 36331326 PMC9825807 Ray, K. K. et al. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur. Heart J. 44 , 129–138 (2023). 36331326 10.1093/eurheartj/ehac594 PMC9825807

420. Cicero AF Efficacy and safety of inclisiran a newly approved FDA drug: a systematic review and pooled analysis of available clinical studies Am. Heart J. Plus Cardiol. Res. Pract. 2022 13 100127 10.1016/j.ahjo.2022.100127 PMC10978220 38560059 Cicero, A. F. et al. Efficacy and safety of inclisiran a newly approved FDA drug: a systematic review and pooled analysis of available clinical studies. Am. Heart J. Plus Cardiol. Res. Pract. 13 , 100127 (2022). 10.1016/j.ahjo.2022.100127 PMC10978220 38560059

421. Khan SA Naz A Masood MQ Shah R Meta-analysis of inclisiran for the treatment of hypercholesterolemia Am. J. Cardiol. 2020 134 69 73 10.1016/j.amjcard.2020.08.018 32892993 Khan, S. A., Naz, A., Masood, M. Q. & Shah, R. Meta-analysis of inclisiran for the treatment of hypercholesterolemia. Am. J. Cardiol. 134 , 69–73 (2020). 32892993 10.1016/j.amjcard.2020.08.018

422. Dyrbuś K Inclisiran—new hope in the management of lipid disorders? J. Clin. Lipidol. 2020 14 16 27 10.1016/j.jacl.2019.11.001 31879073 Dyrbuś, K. et al. Inclisiran—new hope in the management of lipid disorders? J. Clin. Lipidol. 14 , 16–27 (2020). 31879073 10.1016/j.jacl.2019.11.001

423. Pirillo A Catapano AL Inclisiran: how widely and when should we use it? Curr. Atheroscler. Rep. 2022 24 803 811 10.1007/s11883-022-01056-0 35877035 PMC9474579 Pirillo, A. & Catapano, A. L. Inclisiran: how widely and when should we use it? Curr. Atheroscler. Rep. 24 , 803–811 (2022). 35877035 10.1007/s11883-022-01056-0 PMC9474579

424. German CA Shapiro MD Small interfering RNA therapeutic inclisiran: a new approach to targeting PCSK9 Biodrugs. 2020 34 1 9 10.1007/s40259-019-00399-6 31782112 German, C. A. & Shapiro, M. D. Small interfering RNA therapeutic inclisiran: a new approach to targeting PCSK9. Biodrugs. 34 , 1–9 (2020). 31782112 10.1007/s40259-019-00399-6

425. Ray KK Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: one-year follow-up of the ORION-1 randomized clinical trial JAMA Cardiol 2019 4 1067 1075 10.1001/jamacardio.2019.3502 31553410 PMC6763983 Ray, K. K. et al. Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: one-year follow-up of the ORION-1 randomized clinical trial. JAMA Cardiol 4 , 1067–1075 (2019). 31553410 10.1001/jamacardio.2019.3502 PMC6763983

426. Stoekenbroek RM Kallend D Wijngaard PL Kastelein JJ Inclisiran for the treatment of cardiovascular disease: the ORION clinical development program Future Cardiol. 2018 14 433 442 10.2217/fca-2018-0067 30375244 Stoekenbroek, R. M., Kallend, D., Wijngaard, P. L. & Kastelein, J. J. Inclisiran for the treatment of cardiovascular disease: the ORION clinical development program. Future Cardiol. 14 , 433–442 (2018). 30375244 10.2217/fca-2018-0067

427. Scicchitano P Inclisiran in lipid management: a literature overview and future perspectives Biomed. Pharmacother. 2021 143 112227 10.1016/j.biopha.2021.112227 34563953 Scicchitano, P. et al. Inclisiran in lipid management: a literature overview and future perspectives. Biomed. Pharmacother. 143 , 112227 (2021). 34563953 10.1016/j.biopha.2021.112227

428. Leiter LA Inclisiran lowers LDL-C and PCSK9 irrespective of diabetes status: the ORION-1 randomized clinical trial Diabetes Care 2019 42 173 176 10.2337/dc18-1491 30487231 Leiter, L. A. et al. Inclisiran lowers LDL-C and PCSK9 irrespective of diabetes status: the ORION-1 randomized clinical trial. Diabetes Care 42 , 173–176 (2019). 30487231 10.2337/dc18-1491

429. Nishikido T Ray KK Inclisiran for the treatment of dyslipidemia Expert Opin. Investig. Drugs. 2018 27 287 294 10.1080/13543784.2018.1442435 29451410 Nishikido, T. & Ray, K. K. Inclisiran for the treatment of dyslipidemia. Expert Opin. Investig. Drugs. 27 , 287–294 (2018). 29451410 10.1080/13543784.2018.1442435

430. Wright RS Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis J. Am. Coll. Cardiol. 2021 77 1182 1193 10.1016/j.jacc.2020.12.058 33663735 Wright, R. S. et al. Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis. J. Am. Coll. Cardiol. 77 , 1182–1193 (2021). 33663735 10.1016/j.jacc.2020.12.058

431. Kosmas CE Inclisiran: a new promising agent in the management of hypercholesterolemia Diseases. 2018 6 63 10.3390/diseases6030063 30011788 PMC6163360 Kosmas, C. E. et al. Inclisiran: a new promising agent in the management of hypercholesterolemia. Diseases. 6 , 63 (2018). 30011788 10.3390/diseases6030063 PMC6163360

432. Albosta MS Inclisiran: a new strategy for LDL-C lowering and prevention of atherosclerotic cardiovascular disease Vasc. Health Risk Manag 2023 19 421 431 10.2147/VHRM.S338424 37434791 PMC10332363 Albosta, M. S. et al. Inclisiran: a new strategy for LDL-C lowering and prevention of atherosclerotic cardiovascular disease. Vasc. Health Risk Manag 19 , 421–431 (2023). 37434791 10.2147/VHRM.S338424 PMC10332363

433. Gils T Pretomanid for tuberculosis: a systematic review Clin. Microbiol. Infect. 2022 28 31 42 10.1016/j.cmi.2021.08.007 34400340 Gils, T. et al. Pretomanid for tuberculosis: a systematic review. Clin. Microbiol. Infect. 28 , 31–42 (2022). 34400340 10.1016/j.cmi.2021.08.007

434. Keam SJ Pretomanid: first approval Drugs. 2019 79 1797 1803 10.1007/s40265-019-01207-9 31583606 Keam, S. J. Pretomanid: first approval. Drugs. 79 , 1797–1803 (2019). 31583606 10.1007/s40265-019-01207-9

435. Nguyen TVA Pretomanid resistance: an update on emergence, mechanisms and relevance for clinical practice Int. J. Antimicrob. Agents 2023 62 106953 10.1016/j.ijantimicag.2023.106953 37595848 Nguyen, T. V. A. et al. Pretomanid resistance: an update on emergence, mechanisms and relevance for clinical practice. Int. J. Antimicrob. Agents 62 , 106953 (2023). 37595848 10.1016/j.ijantimicag.2023.106953

436. Conradie F Bedaquiline–pretomanid–linezolid regimens for drug-resistant tuberculosis N. Engl. J. Med. 2022 387 810 823 10.1056/NEJMoa2119430 36053506 PMC9490302 Conradie, F. et al. Bedaquiline–pretomanid–linezolid regimens for drug-resistant tuberculosis. N. Engl. J. Med. 387 , 810–823 (2022). 36053506 10.1056/NEJMoa2119430 PMC9490302

437. Fekadu G Pretomanid development and its clinical roles in treating tuberculosis J. Glob. Antimicrob. Resist. 2022 31 175 184 10.1016/j.jgar.2022.09.001 36087906 Fekadu, G. et al. Pretomanid development and its clinical roles in treating tuberculosis. J. Glob. Antimicrob. Resist. 31 , 175–184 (2022). 36087906 10.1016/j.jgar.2022.09.001

438. Occhineri S Pretomanid for tuberculosis treatment: an update for clinical purposes Curr. Res. Pharmacol. Drug Discov. 2022 3 100128 10.1016/j.crphar.2022.100128 36105740 PMC9461242 Occhineri, S. et al. Pretomanid for tuberculosis treatment: an update for clinical purposes. Curr. Res. Pharmacol. Drug Discov. 3 , 100128 (2022). 36105740 10.1016/j.crphar.2022.100128 PMC9461242

439. Koehler N Pretomanid-resistant tuberculosis J. Infect. 2023 86 520 524 10.1016/j.jinf.2023.01.039 36738862 Koehler, N. et al. Pretomanid-resistant tuberculosis. J. Infect. 86 , 520–524 (2023). 36738862 10.1016/j.jinf.2023.01.039

440. Shirley M Pretomanid in drug-resistant tuberculosis: a profile of its use Drugs Ther. Perspect. 2020 36 273 279 10.1007/s40267-020-00743-9 Shirley, M. Pretomanid in drug-resistant tuberculosis: a profile of its use. Drugs Ther. Perspect. 36 , 273–279 (2020).

441. Deb U Biswas S Pretomanid: the latest USFDA-approved anti-tuberculosis drug Indian J. Tuberc. 2021 68 287 291 10.1016/j.ijtb.2020.09.003 33845969 Deb, U. & Biswas, S. Pretomanid: the latest USFDA-approved anti-tuberculosis drug. Indian J. Tuberc. 68 , 287–291 (2021). 33845969 10.1016/j.ijtb.2020.09.003

442. Dooley KE Assessing pretomanid for tuberculosis (APT), a randomized phase 2 trial of pretomanid-containing regimens for drug-sensitive tuberculosis: 12-week results Am. J. Respir. Crit. Care Med. 2023 207 929 935 10.1164/rccm.202208-1475OC 36455068 PMC12042667 Dooley, K. E. et al. Assessing pretomanid for tuberculosis (APT), a randomized phase 2 trial of pretomanid-containing regimens for drug-sensitive tuberculosis: 12-week results. Am. J. Respir. Crit. Care Med. 207 , 929–935 (2023). 36455068 10.1164/rccm.202208-1475OC PMC12042667

443. Salinger, D. H., Subramoney, V., Everitt, D. & Nedelman, J. R. Population pharmacokinetics of the antituberculosis agent pretomanid. Antimicrob. Agents Chemother . 63 , 10.1128/aac.00907-00919 (2019). 10.1128/AAC.00907-19 PMC6761531 31405856

444. Baptista R Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824) Sci. Rep. 2018 8 5084 10.1038/s41598-018-23110-1 29572459 PMC5865180 Baptista, R. et al. Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824). Sci. Rep. 8 , 5084 (2018). 29572459 10.1038/s41598-018-23110-1 PMC5865180

445. Nedelman, J. R. et al. An exposure-response perspective on the clinical dose of pretomanid. Antimicrob. Agents Chemother . 65 , 10.1128/aac.01121-01120 (2020). 10.1128/AAC.01121-20 PMC7927811 33077660

446. Lyons, M. A. Modeling and simulation of pretomanid pharmacodynamics in pulmonary tuberculosis patients. Antimicrob. Agents Chemother . 63 , 10.1128/aac.00732-00719 (2019). 10.1128/AAC.00732-19 PMC6879235 31570404

447. Mudde SE Delamanid or pretomanid? A Solomonic judgement! J. Antimicrob. Chemother. 2022 77 880 902 10.1093/jac/dkab505 35089314 PMC8969540 Mudde, S. E. et al. Delamanid or pretomanid? A Solomonic judgement! J. Antimicrob. Chemother. 77 , 880–902 (2022). 35089314 10.1093/jac/dkab505 PMC8969540

448. Stancil SL Mirzayev F Abdel-Rahman SM Profiling pretomanid as a therapeutic option for TB infection: evidence to date. Drug Des. Devel. Ther 2021 15 2815 2830 10.2147/DDDT.S281639 34234413 PMC8253981 Stancil, S. L., Mirzayev, F. & Abdel-Rahman, S. M. Profiling pretomanid as a therapeutic option for TB infection: evidence to date. Drug Des. Devel. Ther 15 , 2815–2830 (2021). 34234413 10.2147/DDDT.S281639 PMC8253981

449. Ignatius, E. H. et al. Pretomanid pharmacokinetics in the presence of rifamycins: interim results from a randomized trial among patients with tuberculosis. Antimicrob. Agents Chemother . 65 , 10.1128/aac.01196-01120 (2021). 10.1128/AAC.01196-20 PMC7849006 33229425

450. Timm J Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid PLOS Glob. Public Health 2023 3 e0002283 10.1371/journal.pgph.0002283 37851685 PMC10584172 Timm, J. et al. Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid. PLOS Glob. Public Health 3 , e0002283 (2023). 37851685 10.1371/journal.pgph.0002283 PMC10584172

451. Rahman, A., Chhabra, S. & Parkesh, R. in Drug Discovery Stories 623–645 (Elsevier, 2025).

452. McKenna L Furin J Are pretomanid-containing regimens for tuberculosis a victory or a victory narrative? Lancet Respir. Med. 2019 7 999 1000 10.1016/S2213-2600(19)30363-7 31732486 McKenna, L. & Furin, J. Are pretomanid-containing regimens for tuberculosis a victory or a victory narrative? Lancet Respir. Med. 7 , 999–1000 (2019). 31732486 10.1016/S2213-2600(19)30363-7

453. Dhillon S Tebentafusp: first approval Drugs. 2022 82 703 710 10.1007/s40265-022-01704-4 35364798 Dhillon, S. Tebentafusp: first approval. Drugs. 82 , 703–710 (2022). 35364798 10.1007/s40265-022-01704-4

454. Damato BE Dukes J Goodall H Carvajal RD Tebentafusp: T cell redirection for the treatment of metastatic uveal melanoma Cancers. 2019 11 971 10.3390/cancers11070971 31336704 PMC6679206 Damato, B. E., Dukes, J., Goodall, H. & Carvajal, R. D. Tebentafusp: T cell redirection for the treatment of metastatic uveal melanoma. Cancers. 11 , 971 (2019). 31336704 10.3390/cancers11070971 PMC6679206

455. Nathan P Overall survival benefit with tebentafusp in metastatic uveal melanoma N. Engl. J. Med. 2021 385 1196 1206 10.1056/NEJMoa2103485 34551229 Nathan, P. et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N. Engl. J. Med. 385 , 1196–1206 (2021). 34551229 10.1056/NEJMoa2103485

456. Hassel JC Three-year overall survival with tebentafusp in metastatic uveal melanoma N. Engl. J. Med. 2023 389 2256 2266 10.1056/NEJMoa2304753 37870955 PMC11188986 Hassel, J. C. et al. Three-year overall survival with tebentafusp in metastatic uveal melanoma. N. Engl. J. Med. 389 , 2256–2266 (2023). 37870955 10.1056/NEJMoa2304753 PMC11188986

457. Howlett S Carter TJ Shaw HM Nathan PD Tebentafusp: a first-in-class treatment for metastatic uveal melanoma Ther. Adv. Med. Oncol. 2023 15 17588359231160140 10.1177/17588359231160140 36970111 PMC10031621 Howlett, S., Carter, T. J., Shaw, H. M. & Nathan, P. D. Tebentafusp: a first-in-class treatment for metastatic uveal melanoma. Ther. Adv. Med. Oncol. 15 , 17588359231160140 (2023). 36970111 10.1177/17588359231160140 PMC10031621

458. Middleton MR Tebentafusp, a TCR/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma Clin. Cancer Res. 2020 26 5869 5878 10.1158/1078-0432.CCR-20-1247 32816891 PMC9210997 Middleton, M. R. et al. Tebentafusp, a TCR/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma. Clin. Cancer Res. 26 , 5869–5878 (2020). 32816891 10.1158/1078-0432.CCR-20-1247 PMC9210997

459. Dian Y Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: a systematic review and meta-analysis Hum. Vaccin. Immunother. 2024 20 2374647 10.1080/21645515.2024.2374647 39004419 PMC11249029 Dian, Y. et al. Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: a systematic review and meta-analysis. Hum. Vaccin. Immunother. 20 , 2374647 (2024). 39004419 10.1080/21645515.2024.2374647 PMC11249029

460. Killock D Tebentafusp for uveal melanoma Nat. Rev. Clin. Oncol. 2021 18 747 747 10.1038/s41571-021-00572-3 34625736 Killock, D. Tebentafusp for uveal melanoma. Nat. Rev. Clin. Oncol. 18 , 747–747 (2021). 34625736 10.1038/s41571-021-00572-3

461. Carvajal RD Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial Nat. Med. 2022 28 2364 2373 10.1038/s41591-022-02015-7 36229663 PMC9671803 Carvajal, R. D. et al. Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial. Nat. Med. 28 , 2364–2373 (2022). 36229663 10.1038/s41591-022-02015-7 PMC9671803

462. Carvajal RD Phase I study of safety, tolerability, and efficacy of tebentafusp using a step-up dosing regimen and expansion in patients with metastatic uveal melanoma J. Clin. Oncol. 2022 40 1939 1948 10.1200/JCO.21.01805 35254876 PMC9177239 Carvajal, R. D. et al. Phase I study of safety, tolerability, and efficacy of tebentafusp using a step-up dosing regimen and expansion in patients with metastatic uveal melanoma. J. Clin. Oncol. 40 , 1939–1948 (2022). 35254876 10.1200/JCO.21.01805 PMC9177239

463. Tomsitz D Tebentafusp in patients with metastatic uveal melanoma: a real-life retrospective multicenter study Cancers. 2023 15 3430 10.3390/cancers15133430 37444540 PMC10341126 Tomsitz, D. et al. Tebentafusp in patients with metastatic uveal melanoma: a real-life retrospective multicenter study. Cancers. 15 , 3430 (2023). 37444540 10.3390/cancers15133430 PMC10341126

464. Montazeri K Pattanayak V Sullivan RJ Tebentafusp in the treatment of metastatic uveal melanoma: patient selection and special considerations Drug Des. Devel. Ther 2023 17 333 339 10.2147/DDDT.S368954 36785760 PMC9921510 Montazeri, K., Pattanayak, V. & Sullivan, R. J. Tebentafusp in the treatment of metastatic uveal melanoma: patient selection and special considerations. Drug Des. Devel. Ther 17 , 333–339 (2023). 36785760 10.2147/DDDT.S368954 PMC9921510

465. Olivier T Prasad V Tebentafusp in first-line melanoma trials: an outperforming outlier Transl. Oncol. 2022 20 101408 10.1016/j.tranon.2022.101408 35364557 PMC8968051 Olivier, T. & Prasad, V. Tebentafusp in first-line melanoma trials: an outperforming outlier. Transl. Oncol. 20 , 101408 (2022). 35364557 10.1016/j.tranon.2022.101408 PMC8968051

466. Chen LN Carvajal RD Tebentafusp for the treatment of HLA-A* 02: 01–positive adult patients with unresectable or metastatic uveal melanoma Expert Rev. Anticancer Ther. 2022 22 1017 1027 10.1080/14737140.2022.2124971 36102132 PMC10184536 Chen, L. N. & Carvajal, R. D. Tebentafusp for the treatment of HLA-A* 02: 01–positive adult patients with unresectable or metastatic uveal melanoma. Expert Rev. Anticancer Ther. 22 , 1017–1027 (2022). 36102132 10.1080/14737140.2022.2124971 PMC10184536

467. Liu AW Wei AZ Maniar AB Carvajal RD Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors Expert Opin. Biol. Ther. 2022 22 997 1004 10.1080/14712598.2022.2031970 35060440 Liu, A. W., Wei, A. Z., Maniar, A. B. & Carvajal, R. D. Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors. Expert Opin. Biol. Ther. 22 , 997–1004 (2022). 35060440 10.1080/14712598.2022.2031970

468. Balushi KA Tebentafusp as a promising drug for the treatment of uveal melanoma Curr. Drug Targets 2024 25 149 157 10.2174/0113894501280380231214105255 38115619 Balushi, K. A. et al. Tebentafusp as a promising drug for the treatment of uveal melanoma. Curr. Drug Targets 25 , 149–157 (2024). 38115619 10.2174/0113894501280380231214105255

469. Kozani, P. S., Kozani, P. S. & Sheikhi, A. Tebentafusp: the first FDA-approved monoclonal antibody for cancer treatment in 2022. Trends Med. Sci . 1 , e123546 (2021).

470. Hassel, J. C. et al. Tebentafusp induces a T-cell–driven rash in melanocyte-bearing skin as an adverse event consistent with the mechanism of action. J. Invest. Dermatol . 145, 559–572 (2024). 10.1016/j.jid.2024.03.048 39019150

471. Petzold A Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment Cancer Treat. Rev. 2023 115 102543 10.1016/j.ctrv.2023.102543 36931146 Petzold, A. et al. Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment. Cancer Treat. Rev. 115 , 102543 (2023). 36931146 10.1016/j.ctrv.2023.102543

472. Piulats J Overall survival from Tebentafusp versus Nivolumab plus Ipilimumab in first-line metastatic Uveal Melanoma: a propensity score-weighted analysis Ann. Oncol. 2024 35 317 326 10.1016/j.annonc.2023.11.013 38048850 Piulats, J. et al. Overall survival from Tebentafusp versus Nivolumab plus Ipilimumab in first-line metastatic Uveal Melanoma: a propensity score-weighted analysis. Ann. Oncol. 35 , 317–326 (2024). 38048850 10.1016/j.annonc.2023.11.013

473. Diaz-Manera J Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial Lancet Neurol. 2021 20 1012 1026 10.1016/S1474-4422(21)00241-6 34800399 Diaz-Manera, J. et al. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial. Lancet Neurol. 20 , 1012–1026 (2021). 34800399 10.1016/S1474-4422(21)00241-6

474. Dhillon S Avalglucosidase alfa: first approval Drugs. 2021 81 1803 1809 10.1007/s40265-021-01600-3 34591286 Dhillon, S. Avalglucosidase alfa: first approval. Drugs. 81 , 1803–1809 (2021). 34591286 10.1007/s40265-021-01600-3

475. Pena LD Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: a phase 1, open-label, multicenter, multinational, ascending dose study Neuromuscul. Disord. 2019 29 167 186 10.1016/j.nmd.2018.12.004 30770310 Pena, L. D. et al. Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: a phase 1, open-label, multicenter, multinational, ascending dose study. Neuromuscul. Disord. 29 , 167–186 (2019). 30770310 10.1016/j.nmd.2018.12.004

476. Kishnani PS Efficacy and safety of avalglucosidase alfa in patients with late-onset Pompe disease after 97 weeks: a phase 3 randomized clinical trial JAMA Neurol. 2023 80 558 567 10.1001/jamaneurol.2023.0552 37036722 PMC10087094 Kishnani, P. S. et al. Efficacy and safety of avalglucosidase alfa in patients with late-onset Pompe disease after 97 weeks: a phase 3 randomized clinical trial. JAMA Neurol. 80 , 558–567 (2023). 37036722 10.1001/jamaneurol.2023.0552 PMC10087094

477. Angelini C Evaluating avalglucosidase alfa for the management of late-onset Pompe disease Expert Rev. Neurother. 2024 24 259 266 10.1080/14737175.2024.2306855 38261315 Angelini, C. Evaluating avalglucosidase alfa for the management of late-onset Pompe disease. Expert Rev. Neurother. 24 , 259–266 (2024). 38261315 10.1080/14737175.2024.2306855

478. Kishnani PS Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: the 6-month primary analysis report Genet. Med. 2023 25 100328 10.1016/j.gim.2022.10.010 36542086 Kishnani, P. S. et al. Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: the 6-month primary analysis report. Genet. Med. 25 , 100328 (2023). 36542086 10.1016/j.gim.2022.10.010

479. Dimachkie MM Long-term safety and efficacy of avalglucosidase alfa in patients with late-onset Pompe disease Neurology. 2022 99 e536 e548 10.1212/WNL.0000000000200746 35618441 PMC9421599 Dimachkie, M. M. et al. Long-term safety and efficacy of avalglucosidase alfa in patients with late-onset Pompe disease. Neurology. 99 , e536–e548 (2022). 35618441 10.1212/WNL.0000000000200746 PMC9421599

480. Carter C Boggs T Case LE Kishnani P Real-world outcomes from a series of patients with late onset Pompe disease who switched from alglucosidase alfa to avalglucosidase alfa Front. Genet. 2024 15 1309146 10.3389/fgene.2024.1309146 38313679 PMC10834735 Carter, C., Boggs, T., Case, L. E. & Kishnani, P. Real-world outcomes from a series of patients with late onset Pompe disease who switched from alglucosidase alfa to avalglucosidase alfa. Front. Genet. 15 , 1309146 (2024). 38313679 10.3389/fgene.2024.1309146 PMC10834735

481. Fiumara A Avalglucosidase alfa in infantile-onset Pompe disease: a snapshot of real-world experience in Italy Mol. Genet. Metab. Rep. 2024 40 101126 39161458 10.1016/j.ymgmr.2024.101126 PMC11332206 Fiumara, A. et al. Avalglucosidase alfa in infantile-onset Pompe disease: a snapshot of real-world experience in Italy. Mol. Genet. Metab. Rep. 40 , 101126 (2024). 39161458 10.1016/j.ymgmr.2024.101126 PMC11332206

482. Toscano A Effect of avalglucosidase alfa on disease-specific and general patient-reported outcomes in treatment-naïve adults with late-onset Pompe disease compared with alglucosidase alfa: meaningful change analyses from the Phase 3 COMET trial Mol. Genet. Metab. 2024 141 108121 10.1016/j.ymgme.2023.108121 38184428 Toscano, A. et al. Effect of avalglucosidase alfa on disease-specific and general patient-reported outcomes in treatment-naïve adults with late-onset Pompe disease compared with alglucosidase alfa: meaningful change analyses from the Phase 3 COMET trial. Mol. Genet. Metab. 141 , 108121 (2024). 38184428 10.1016/j.ymgme.2023.108121

483. Kronn D OP016: Mini-COMET: safety and efficacy of≥ 97 weeks’ avalglucosidase alfa in infantile-onset Pompe disease participants previously treated with alglucosidase alfa Genet. Med. 2022 24 S348 S349 10.1016/j.gim.2022.01.566 Kronn, D. et al. OP016: Mini-COMET: safety and efficacy of≥ 97 weeks’ avalglucosidase alfa in infantile-onset Pompe disease participants previously treated with alglucosidase alfa. Genet. Med. 24 , S348–S349 (2022).

484. Mozaffar T Efficacy of avalglucosidase alfa on forced vital capacity percent predicted in treatment-naïve patients with late-onset Pompe disease: a pooled analysis of clinical trials Mol. Genet. Metab. Rep. 2024 40 101109 39035044 10.1016/j.ymgmr.2024.101109 PMC11259910 Mozaffar, T. et al. Efficacy of avalglucosidase alfa on forced vital capacity percent predicted in treatment-naïve patients with late-onset Pompe disease: a pooled analysis of clinical trials. Mol. Genet. Metab. Rep. 40 , 101109 (2024). 39035044 10.1016/j.ymgmr.2024.101109 PMC11259910

485. de Visser, M. & Argov, Z. Vol. 99 , 183–184 (AAN Enterprises, 2022).

486. Tard C Real‐life effectiveness 1 year after switching to avalglucosidase alfa in late‐onset Pompe disease patients worsening on alglucosidase alfa therapy: a French cohort study Eur. J. Neurol 2024 31 e16292 10.1111/ene.16292 38587143 PMC11235864 Tard, C. et al. Real‐life effectiveness 1 year after switching to avalglucosidase alfa in late‐onset Pompe disease patients worsening on alglucosidase alfa therapy: a French cohort study. Eur. J. Neurol 31 , e16292 (2024). 38587143 10.1111/ene.16292 PMC11235864

487. Kishnani P P374 COMET: effects of avalglucosidase alfa and treatment switch from alglucosidase alfa on week 145 QMFT individual item responses Neuromuscul. Disord. 2023 33 S151 S152 10.1016/j.nmd.2023.07.338 Kishnani, P. et al. P374 COMET: effects of avalglucosidase alfa and treatment switch from alglucosidase alfa on week 145 QMFT individual item responses. Neuromuscul. Disord. 33 , S151–S152 (2023).

488. Kushlaf H Efficacy and safety results of the Avalglucosidase alfa phase 3 COMET Trial in late-onset Pompe disease patients (4195) Neurology 2021 96 4195 10.1212/WNL.96.15_supplement.4195 Kushlaf, H. et al. Efficacy and safety results of the Avalglucosidase alfa phase 3 COMET Trial in late-onset Pompe disease patients (4195). Neurology 96 , 4195 (2021).

489. Potters L 660P Safety and efficacy of switching to avalglucosidase alfa in patients with late-onset Pompe disease previously deteriorating on alglucosidase alfa Neuromuscul. Disord 2024 43 S1 10.1016/j.nmd.2024.07.727 Potters, L. et al. 660P Safety and efficacy of switching to avalglucosidase alfa in patients with late-onset Pompe disease previously deteriorating on alglucosidase alfa. Neuromuscul. Disord 43 , S1 (2024).

490. Tiraboschi G Population pharmacokinetic modeling and dosing simulation of avalglucosidase alfa for selecting alternative dosing regimen in pediatric patients with late-onset pompe disease J. Pharmacokinet. Pharmacodyn. 2023 50 461 474 10.1007/s10928-023-09874-8 37535240 PMC10673948 Tiraboschi, G. et al. Population pharmacokinetic modeling and dosing simulation of avalglucosidase alfa for selecting alternative dosing regimen in pediatric patients with late-onset pompe disease. J. Pharmacokinet. Pharmacodyn. 50 , 461–474 (2023). 37535240 10.1007/s10928-023-09874-8 PMC10673948

491. Schoser B P377 Patients in the Pompe registry who switched from alglucosidase alfa to avalglucosidase alfa: real-world experience Neuromuscul. Disord. 2023 33 S152 10.1016/j.nmd.2023.07.341 Schoser, B. et al. P377 Patients in the Pompe registry who switched from alglucosidase alfa to avalglucosidase alfa: real-world experience. Neuromuscul. Disord. 33 , S152 (2023).

492. Raal FJ Evinacumab for homozygous familial hypercholesterolemia N. Engl. J. Med. 2020 383 711 720 10.1056/NEJMoa2004215 32813947 Raal, F. J. et al. Evinacumab for homozygous familial hypercholesterolemia. N. Engl. J. Med. 383 , 711–720 (2020). 32813947 10.1056/NEJMoa2004215

493. Sosnowska B Evinacumab, an ANGPTL3 inhibitor, in the treatment of dyslipidemia J. Clin. Med. 2022 12 168 10.3390/jcm12010168 36614969 PMC9821629 Sosnowska, B. et al. Evinacumab, an ANGPTL3 inhibitor, in the treatment of dyslipidemia. J. Clin. Med. 12 , 168 (2022). 36614969 10.3390/jcm12010168 PMC9821629

494. Rosenson RS Evinacumab in patients with refractory hypercholesterolemia N. Engl. J. Med. 2020 383 2307 2319 10.1056/NEJMoa2031049 33196153 Rosenson, R. S. et al. Evinacumab in patients with refractory hypercholesterolemia. N. Engl. J. Med. 383 , 2307–2319 (2020). 33196153 10.1056/NEJMoa2031049

495. Markham A Evinacumab: first approval Drugs. 2021 81 1101 1105 10.1007/s40265-021-01516-y 34003472 Markham, A. Evinacumab: first approval. Drugs. 81 , 1101–1105 (2021). 34003472 10.1007/s40265-021-01516-y

496. Jin M Efficacy and safety of evinacumab for the treatment of hypercholesterolemia: a meta-analysis J. Cardiovasc. Pharmacol. 2021 78 394 402 10.1097/FJC.0000000000001073 34117182 Jin, M. et al. Efficacy and safety of evinacumab for the treatment of hypercholesterolemia: a meta-analysis. J. Cardiovasc. Pharmacol. 78 , 394–402 (2021). 34117182 10.1097/FJC.0000000000001073

497. Rosenson RS Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial Nat. Med. 2023 29 729 737 10.1038/s41591-023-02222-w 36879129 PMC10033404 Rosenson, R. S. et al. Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial. Nat. Med. 29 , 729–737 (2023). 36879129 10.1038/s41591-023-02222-w PMC10033404

498. Dingman R Evinacumab: m502echanism of action, clinical, and translational science Clin. Transl. Sci. 2024 17 e13836 10.1111/cts.13836 38845393 PMC11157145 Dingman, R. et al. Evinacumab: m502echanism of action, clinical, and translational science. Clin. Transl. Sci. 17 , e13836 (2024). 38845393 10.1111/cts.13836 PMC11157145

499. Rosenson RS Longer-term efficacy and safety of evinacumab in patients with refractory hypercholesterolemia JAMA Cardiol. 2023 8 1070 1076 10.1001/jamacardio.2023.2921 37703006 PMC10500429 Rosenson, R. S. et al. Longer-term efficacy and safety of evinacumab in patients with refractory hypercholesterolemia. JAMA Cardiol. 8 , 1070–1076 (2023). 37703006 10.1001/jamacardio.2023.2921 PMC10500429

500. Warden BA Duell PB Evinacumab for treatment of familial hypercholesterolemia Expert Rev. Cardiovasc. Ther. 2021 19 739 751 10.1080/14779072.2021.1955349 34253139 Warden, B. A. & Duell, P. B. Evinacumab for treatment of familial hypercholesterolemia. Expert Rev. Cardiovasc. Ther. 19 , 739–751 (2021). 34253139 10.1080/14779072.2021.1955349

501. Patel, N., Parmar, M. & Patel, P. Evinacumab (2023). 37983343

502. Pirillo A Catapano AL Evinacumab: a new option in the treatment of homozygous familial hypercholesterolemia Expert Opin. Biol. Ther. 2022 22 813 820 10.1080/14712598.2022.2090242 35698895 Pirillo, A. & Catapano, A. L. Evinacumab: a new option in the treatment of homozygous familial hypercholesterolemia. Expert Opin. Biol. Ther. 22 , 813–820 (2022). 35698895 10.1080/14712598.2022.2090242

503. Raal FJ The long-term efficacy and safety of Evinacumab in patients with homozygous familial hypercholesterolemia JACC Adv. 2023 2 100648 10.1016/j.jacadv.2023.100648 38938723 PMC11198175 Raal, F. J. et al. The long-term efficacy and safety of Evinacumab in patients with homozygous familial hypercholesterolemia. JACC Adv. 2 , 100648 (2023). 38938723 10.1016/j.jacadv.2023.100648 PMC11198175

504. Ahmad Z Inhibition of angiopoietin-like protein 3 with evinacumab in subjects with high and severe hypertriglyceridemia J. Am. Coll. Cardiol. 2021 78 193 195 10.1016/j.jacc.2021.04.091 34238441 Ahmad, Z. et al. Inhibition of angiopoietin-like protein 3 with evinacumab in subjects with high and severe hypertriglyceridemia. J. Am. Coll. Cardiol. 78 , 193–195 (2021). 34238441 10.1016/j.jacc.2021.04.091

505. Wiegman A Evinacumab for pediatric patients with homozygous familial hypercholesterolemia Circulation. 2024 149 343 353 10.1161/CIRCULATIONAHA.123.065529 37860863 PMC10814999 Wiegman, A. et al. Evinacumab for pediatric patients with homozygous familial hypercholesterolemia. Circulation. 149 , 343–353 (2024). 37860863 10.1161/CIRCULATIONAHA.123.065529 PMC10814999

506. White RT Sankey KH Nawarskas JJ Evinacumab-dgnb (Evkeeza-REGN1500), a novel lipid-lowering therapy for homozygous familial hypercholesterolemia Cardiol. Rev. 2024 32 180 185 10.1097/CRD.0000000000000522 37071085 White, R. T., Sankey, K. H. & Nawarskas, J. J. Evinacumab-dgnb (Evkeeza-REGN1500), a novel lipid-lowering therapy for homozygous familial hypercholesterolemia. Cardiol. Rev. 32 , 180–185 (2024). 37071085 10.1097/CRD.0000000000000522

507. Surma, S., Romańczyk, M. & Filipiak, K. J. Evinacumab–The new kid on the block. Is it important for cardiovascular prevention? Int. J. Cardiol. Cardiovasc. Risk Prev . 11 , 200107 (2021). 10.1016/j.ijcrp.2021.200107 PMC8710419 34988554

508. Reeskamp LF ANGPTL3 inhibition with evinacumab results in faster clearance of IDL and LDL apoB in patients with homozygous familial hypercholesterolemia—brief report Arterioscler. Thromb. Vasc. Biol. 2021 41 1753 1759 10.1161/ATVBAHA.120.315204 33691480 PMC8057526 Reeskamp, L. F. et al. ANGPTL3 inhibition with evinacumab results in faster clearance of IDL and LDL apoB in patients with homozygous familial hypercholesterolemia—brief report. Arterioscler. Thromb. Vasc. Biol. 41 , 1753–1759 (2021). 33691480 10.1161/ATVBAHA.120.315204 PMC8057526

509. Asghar AA Khabir Y Hashmi MR Zynteglo: Betibeglogene autotemcel-an innovative therapy for á-thalassemia patients Ann. Med. Surg 2022 82 104624 10.1016/j.amsu.2022.104624 PMC9577626 36268391 Asghar, A. A., Khabir, Y. & Hashmi, M. R. Zynteglo: Betibeglogene autotemcel-an innovative therapy for á-thalassemia patients. Ann. Med. Surg 82 , 104624 (2022). 10.1016/j.amsu.2022.104624 PMC9577626 36268391

510. Schuessler‐Lenz M Enzmann H Vamvakas S Regulators’ advice can make a difference: European Medicines Agency approval of Zynteglo for beta thalassemia Clin. Pharmacol. Ther. 2019 107 492 10.1002/cpt.1639 31705534 PMC7027974 Schuessler‐Lenz, M., Enzmann, H. & Vamvakas, S. Regulators’ advice can make a difference: European Medicines Agency approval of Zynteglo for beta thalassemia. Clin. Pharmacol. Ther. 107 , 492 (2019). 31705534 10.1002/cpt.1639 PMC7027974

511. Gauldie, J. & Verhovsek, M. The applications of zynteglo in treating transfusion dependent beta-thalassemia. Meducator. 45 , 3690 (2024).

512. Malay J Gene therapy: a revolutionary step in treating thalassemia Hematol Rep 2024 16 656 668 10.3390/hematolrep16040064 39449307 PMC11503351 Malay, J. et al. Gene therapy: a revolutionary step in treating thalassemia. Hematol Rep 16 , 656–668 (2024). 39449307 10.3390/hematolrep16040064 PMC11503351

513. Cavero I 19th Annual Meeting of the Safety Pharmacology Society: regulatory and safety perspectives for advanced therapy medicinal products (cellular and gene therapy products) Expert Opin. Drug Saf 2020 19 553 558 10.1080/14740338.2020.1741546 32163309 Cavero, I. et al. 19th Annual Meeting of the Safety Pharmacology Society: regulatory and safety perspectives for advanced therapy medicinal products (cellular and gene therapy products). Expert Opin. Drug Saf 19 , 553–558 (2020). 32163309 10.1080/14740338.2020.1741546

514. Petitpain N Pharmacovigilance of gene therapy medicinal products Rare Dis. Orphan Drugs J 2023 2 25 10.20517/rdodj.2023.19 Petitpain, N. et al. Pharmacovigilance of gene therapy medicinal products. Rare Dis. Orphan Drugs J 2 , 25 (2023).

515. Rós FA A systematic review of clinical trials for gene therapies for β-hemoglobinopathy around the world Cytotherapy. 2023 25 1300 1306 10.1016/j.jcyt.2023.05.006 37318395 Rós, F. A. et al. A systematic review of clinical trials for gene therapies for β-hemoglobinopathy around the world. Cytotherapy. 25 , 1300–1306 (2023). 37318395 10.1016/j.jcyt.2023.05.006

516. Eleftheriou A Juggling between the cost and value of new therapies: does science still serve patient needs? Thalassemia Rep. 2023 13 33 37 10.3390/thalassrep13010004 Eleftheriou, A. et al. Juggling between the cost and value of new therapies: does science still serve patient needs? Thalassemia Rep. 13 , 33–37 (2023).

517. Philippidis A BioMarin’s ROCTAVIAN wins food and drug administration approval as first gene therapy for severe hemophilia A Hum. Gene Ther. 2023 34 665 668 10.1089/hum.2023.29251.bfs 37590493 Philippidis, A. BioMarin’s ROCTAVIAN wins food and drug administration approval as first gene therapy for severe hemophilia A. Hum. Gene Ther. 34 , 665–668 (2023). 37590493 10.1089/hum.2023.29251.bfs

518. Samelson-Jones BJ Small JC George LA Roctavian gene therapy for hemophilia A Blood Adv. 2024 8 5179 5189 10.1182/bloodadvances.2023011847 38991118 PMC11530397 Samelson-Jones, B. J., Small, J. C. & George, L. A. Roctavian gene therapy for hemophilia A. Blood Adv. 8 , 5179–5189 (2024). 38991118 10.1182/bloodadvances.2023011847 PMC11530397

519. Blair HA Valoctocogene roxaparvovec: first approval Drugs. 2022 82 1505 1510 10.1007/s40265-022-01788-y 36214970 Blair, H. A. Valoctocogene roxaparvovec: first approval. Drugs. 82 , 1505–1510 (2022). 36214970 10.1007/s40265-022-01788-y

520. Myshko, D. FDA approves $2.9 million gene therapy for hemophilia A. Formulary Watch (2023).

521. Johnson, V. A slow embrace: hemophilia’s gradual adoption of gene therapy. Victoria (2024).

522. Myshko, D. Alex Jung: it’s time to think differently about specialty drugs. Formulary Watch (2023).

523. Myshko, D. 3 New, and high-cost, gene therapies are expected this year. Formulary Watch (2023).

524. Abramson JS Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study Lancet. 2020 396 839 852 10.1016/S0140-6736(20)31366-0 32888407 Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 396 , 839–852 (2020). 32888407 10.1016/S0140-6736(20)31366-0

525. Iragavarapu C Hildebrandt G Lisocabtagene Maraleucel for the treatment of B-cell lymphoma Expert Opin. Biol. Ther. 2021 21 1151 1156 10.1080/14712598.2021.1933939 34030548 Iragavarapu, C. & Hildebrandt, G. Lisocabtagene Maraleucel for the treatment of B-cell lymphoma. Expert Opin. Biol. Ther. 21 , 1151–1156 (2021). 34030548 10.1080/14712598.2021.1933939

526. Meng J Efficacy and safety of CAR-T cell products axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel for the treatment of hematologic malignancies: a systematic review and meta-analysis Front. Oncol. 2021 11 698607 10.3389/fonc.2021.698607 34381720 PMC8350577 Meng, J. et al. Efficacy and safety of CAR-T cell products axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel for the treatment of hematologic malignancies: a systematic review and meta-analysis. Front. Oncol. 11 , 698607 (2021). 34381720 10.3389/fonc.2021.698607 PMC8350577

527. Sehgal A Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study Lancet Oncol. 2022 23 1066 1077 10.1016/S1470-2045(22)00339-4 35839786 Sehgal, A. et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 23 , 1066–1077 (2022). 35839786 10.1016/S1470-2045(22)00339-4

528. Abramson JS Pivotal safety and efficacy results from transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) large B cell lymphomas Blood 2019 134 241 10.1182/blood-2019-127508 Abramson, J. S. et al. Pivotal safety and efficacy results from transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) large B cell lymphomas. Blood 134 , 241 (2019).

529. Kamdar M Lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, versus standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): results from the randomized phase 3 transform study Blood 2021 138 91 10.1182/blood-2021-147913 Kamdar, M. et al. Lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, versus standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): results from the randomized phase 3 transform study. Blood 138 , 91 (2021).33881503

530. Riedell PA Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis Blood Adv 2024 9 1232 1241 10.1182/bloodadvances.2024014164 PMC11993828 39657136 Riedell, P. A. et al. Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis. Blood Adv 9 , 1232–1241 (2024). 10.1182/bloodadvances.2024014164 PMC11993828 39657136

531. Abramson JS Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study Blood. 2023 141 1675 1684 10.1182/blood.2022018730 36542826 PMC10646768 Abramson, J. S. et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 141 , 1675–1684 (2023). 36542826 10.1182/blood.2022018730 PMC10646768

532. Siddiqi T Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study Lancet 2023 402 641 654 10.1016/S0140-6736(23)01052-8 37295445 PMC11753452 Siddiqi, T. et al. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study. Lancet 402 , 641–654 (2023). 37295445 10.1016/S0140-6736(23)01052-8 PMC11753452

533. St-Pierre F Gordon LI Lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma Future Oncol. 2023 19 19 28 10.2217/fon-2022-0774 36651471 St-Pierre, F. & Gordon, L. I. Lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma. Future Oncol. 19 , 19–28 (2023). 36651471 10.2217/fon-2022-0774

534. Kamdar M Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial Lancet 2022 399 2294 2308 10.1016/S0140-6736(22)00662-6 35717989 Kamdar, M. et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 399 , 2294–2308 (2022). 35717989 10.1016/S0140-6736(22)00662-6

535. Riedell PA Lisocabtagene maraleucel in relapsed/refractory large B-cell lymphoma: real world analysis from the cell therapy consortium Blood 2023 142 617 10.1182/blood-2023-184862 Riedell, P. A. et al. Lisocabtagene maraleucel in relapsed/refractory large B-cell lymphoma: real world analysis from the cell therapy consortium. Blood 142 , 617 (2023).37590027

536. Teoh J Brown LF Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19+ hematologic indications Cytotherapy 2022 24 962 973 10.1016/j.jcyt.2022.03.013 35610089 Teoh, J. & Brown, L. F. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19+ hematologic indications. Cytotherapy 24 , 962–973 (2022). 35610089 10.1016/j.jcyt.2022.03.013

537. Morschhauser, F. et al. Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. Nat. Med . 30, 2199–2207 (2024). 10.1038/s41591-024-02986-9 PMC11333271 38830991

538. Bobillo MSO Real-World (RW) outcomes of lisocabtagene maraleucel (liso-cel) as second-line (2L) therapy in patients (pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): first results from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry Blood. 2024 144 470 10.1182/blood-2024-199723 Bobillo, M. S. O. et al. Real-World (RW) outcomes of lisocabtagene maraleucel (liso-cel) as second-line (2L) therapy in patients (pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): first results from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry. Blood. 144 , 470 (2024).

539. Kharfan-Dabaja MA Lisocabtagene maraleucel in relapsed or refractory diffuse large B cell lymphoma: what is the evidence? Hematol. Oncol. Stem Cell Ther. 2022 15 168 175 10.1016/j.hemonc.2021.09.004 34699774 Kharfan-Dabaja, M. A. et al. Lisocabtagene maraleucel in relapsed or refractory diffuse large B cell lymphoma: what is the evidence? Hematol. Oncol. Stem Cell Ther. 15 , 168–175 (2022). 34699774 10.1016/j.hemonc.2021.09.004

540. Elmacken M FDA approval summary: lisocabtagene maraleucel for second-line treatment of large B-Cell lymphoma Clin. Cancer Res. 2024 30 2309 2316 10.1158/1078-0432.CCR-23-2967 38324398 Elmacken, M. et al. FDA approval summary: lisocabtagene maraleucel for second-line treatment of large B-Cell lymphoma. Clin. Cancer Res. 30 , 2309–2316 (2024). 38324398 10.1158/1078-0432.CCR-23-2967

541. Gordon LI Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study Haematologica 2023 109 857 10.3324/haematol.2023.283162 PMC10905070 37646670 Gordon, L. I. et al. Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study. Haematologica 109 , 857 (2023). 10.3324/haematol.2023.283162 PMC10905070 37646670

542. Siddiqi T Lisocabtagene Maraleucel (liso-cel) in R/R CLL/SLL: 24-month median follow-up of TRANSCEND CLL 004 Blood 2023 142 330 10.1182/blood-2023-179529 Siddiqi, T. et al. Lisocabtagene Maraleucel (liso-cel) in R/R CLL/SLL: 24-month median follow-up of TRANSCEND CLL 004. Blood 142 , 330 (2023).

543. Teoh J Lisocabtagene maraleucel (liso-cel) manufacturing process control and robustness across CD19+ hematological malignancies Blood 2019 134 593 10.1182/blood-2019-127150 Teoh, J. et al. Lisocabtagene maraleucel (liso-cel) manufacturing process control and robustness across CD19+ hematological malignancies. Blood 134 , 593 (2019).

544. Zhang W BCMA-CD19 bispecific CAR-T therapy in refractory chronic inflammatory demyelinating polyneuropathy hLife 2024 2 434 438 10.1016/j.hlife.2024.05.005 Zhang, W. et al. BCMA-CD19 bispecific CAR-T therapy in refractory chronic inflammatory demyelinating polyneuropathy. hLife 2 , 434–438 (2024).

545. Munshi NC Idecabtagene vicleucel in relapsed and refractory multiple myeloma N. Engl. J. Med. 2021 384 705 716 10.1056/NEJMoa2024850 33626253 Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384 , 705–716 (2021). 33626253 10.1056/NEJMoa2024850

546. Anderson LD Jr Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma Future Oncol. 2022 18 277 289 10.2217/fon-2021-1090 34854741 Anderson, L. D. Jr Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma. Future Oncol. 18 , 277–289 (2022). 34854741 10.2217/fon-2021-1090

547. Hansen DK Idecabtagene vicleucel for relapsed/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium J. Clin. Oncol. 2023 41 2087 2097 10.1200/JCO.22.01365 36623248 PMC10082273 Hansen, D. K. et al. Idecabtagene vicleucel for relapsed/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium. J. Clin. Oncol. 41 , 2087–2097 (2023). 36623248 10.1200/JCO.22.01365 PMC10082273

548. Sharma P FDA approval summary: idecabtagene vicleucel for relapsed or refractory multiple myeloma Clin. Cancer Res. 2022 28 1759 1764 10.1158/1078-0432.CCR-21-3803 35046063 PMC9064878 Sharma, P. et al. FDA approval summary: idecabtagene vicleucel for relapsed or refractory multiple myeloma. Clin. Cancer Res. 28 , 1759–1764 (2022). 35046063 10.1158/1078-0432.CCR-21-3803 PMC9064878

549. Robinson A Idecabtagene Vicleucel (Abecma®) Oncol. Times 2021 43 21 10.1097/01.COT.0000753336.18581.7d Robinson, A. Idecabtagene Vicleucel (Abecma®). Oncol. Times 43 , 21 (2021).

550. Oriol A The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma Ther. Adv. Hematol. 2021 12 20406207211019622 10.1177/20406207211019622 34104374 PMC8170343 Oriol, A. et al. The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma. Ther. Adv. Hematol. 12 , 20406207211019622 (2021). 34104374 10.1177/20406207211019622 PMC8170343

551. Lin Y Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial Nat. Med. 2023 29 2286 2294 10.1038/s41591-023-02496-0 37592106 PMC10504071 Lin, Y. et al. Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nat. Med. 29 , 2286–2294 (2023). 37592106 10.1038/s41591-023-02496-0 PMC10504071

552. Lin Y Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in patients with relapsed and refractory multiple myeloma: updated results from phase 1 CRB-401 study Blood 2020 136 26 27 Lin, Y. et al. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in patients with relapsed and refractory multiple myeloma: updated results from phase 1 CRB-401 study. Blood 136 , 26–27 (2020).

553. Usmani SZ KarMMa-4: idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, in high-risk newly diagnosed multiple myeloma Blood 2020 136 18 19 10.1182/blood-2020-139009 Usmani, S. Z. et al. KarMMa-4: idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, in high-risk newly diagnosed multiple myeloma. Blood 136 , 18–19 (2020).

554. Anderson LD Jr OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa Clin. Lymphoma Myeloma Leuk. 2021 21 S17 S18 10.1016/S2152-2650(21)02101-7 Anderson, L. D. Jr et al. OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa. Clin. Lymphoma Myeloma Leuk. 21 , S17–S18 (2021).

555. Delforge M KarMMa-3: a phase 3 study of idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy vs standard regimens in relapsed and refractory multiple myeloma Blood. 2020 136 24 25 10.1182/blood-2020-137156 Delforge, M. et al. KarMMa-3: a phase 3 study of idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy vs standard regimens in relapsed and refractory multiple myeloma. Blood. 136 , 24–25 (2020).32430494

556. Davis J McGann M Shockley A Hashmi H Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie’s choice for patients with relapsed refractory multiple myeloma Expert Rev. Hematol. 2022 15 473 475 10.1080/17474086.2022.2081147 35603733 Davis, J., McGann, M., Shockley, A. & Hashmi, H. Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie’s choice for patients with relapsed refractory multiple myeloma. Expert Rev. Hematol. 15 , 473–475 (2022). 35603733 10.1080/17474086.2022.2081147

557. Raje NS Idecabtagene vicleucel (ide-cel, bb2121) in relapsed and refractory multiple myeloma: analyses of high-risk subgroups in the KarMMa study Blood 2020 136 37 38 10.1182/blood-2020-134319 Raje, N. S. et al. Idecabtagene vicleucel (ide-cel, bb2121) in relapsed and refractory multiple myeloma: analyses of high-risk subgroups in the KarMMa study. Blood 136 , 37–38 (2020).

558. Sidana S Real world outcomes with idecabtagene vicleucel (ide-cel) CAR-T cell therapy for relapsed/refractory multiple myeloma Blood 2023 142 1027 10.1182/blood-2023-181762 Sidana, S. et al. Real world outcomes with idecabtagene vicleucel (ide-cel) CAR-T cell therapy for relapsed/refractory multiple myeloma. Blood 142 , 1027 (2023).

559. Mancuso K Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma Expert Opin. Biol. Ther. 2025 25 27 46 10.1080/14712598.2024.2433518 39651553 Mancuso, K. et al. Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma. Expert Opin. Biol. Ther. 25 , 27–46 (2025). 39651553 10.1080/14712598.2024.2433518

560. Dhodapkar MV Efficacy and safety of idecabtagene vicleucel (ide-cel) in patients with clinical high-risk newly diagnosed multiple myeloma (NDMM) with an inadequate response to frontline autologous stem cell transplantation (ASCT): KarMMa-2 cohort 2c extended follow-up Blood 2023 142 2101 10.1182/blood-2023-173970 Dhodapkar, M. V. et al. Efficacy and safety of idecabtagene vicleucel (ide-cel) in patients with clinical high-risk newly diagnosed multiple myeloma (NDMM) with an inadequate response to frontline autologous stem cell transplantation (ASCT): KarMMa-2 cohort 2c extended follow-up. Blood 142 , 2101 (2023).

561. Maulhardt M Efficacy of idecabtagene vicleucel (ide-cel) in patients with relapsed/refractory multiple myeloma and prior central nervous system manifestation: a retrospective real-world analysis Blood. 2024 144 4759 10.1182/blood-2024-202467 PMC12358732 40832014 Maulhardt, M. et al. Efficacy of idecabtagene vicleucel (ide-cel) in patients with relapsed/refractory multiple myeloma and prior central nervous system manifestation: a retrospective real-world analysis. Blood. 144 , 4759 (2024). 10.1002/hem3.70192 PMC12358732 40832014

562. Minakata D Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma Int. J. Hematol. 2023 117 729 737 10.1007/s12185-023-03538-6 36690910 PMC10121508 Minakata, D. et al. Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma. Int. J. Hematol. 117 , 729–737 (2023). 36690910 10.1007/s12185-023-03538-6 PMC10121508

563. Sidana S Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment Haematologica. 2023 109 777 10.3324/haematol.2023.283940 PMC10905101 37731379 Sidana, S. et al. Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment. Haematologica. 109 , 777 (2023). 10.3324/haematol.2023.283940 PMC10905101 37731379

564. Tartof, S. Y. et al. Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study. Lancet Respir Med. 10 , 689–699 (2022) 10.1016/S2213-2600(22)00101-1 PMC9033225 35468336

565. Abu-Raddad, L. J. et al. Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. J. Travel Med . 28 , taab083 (2021). 10.1093/jtm/taab083 PMC8194836 34050372

566. Guerra-Estévez D Self-reported adverse events within the seven days following the Spikevax®(Moderna) vaccination Farm. Hosp. 2022 46 301 307 36183231 Guerra-Estévez, D. et al. Self-reported adverse events within the seven days following the Spikevax®(Moderna) vaccination. Farm. Hosp. 46 , 301–307 (2022). 36183231

567. Cunningham, H. C., Dunn, J. & Durr, D. An examination of moderna. J. Appl. Bus. Econ . 26 , (2024).

568. Adjobimey T Comparison of IgA, IgG, and neutralizing antibody responses following immunization with Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm’s COVID-19 vaccines Front. Immunol. 2022 13 917905 10.3389/fimmu.2022.917905 35799790 PMC9254618 Adjobimey, T. et al. Comparison of IgA, IgG, and neutralizing antibody responses following immunization with Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm’s COVID-19 vaccines. Front. Immunol. 13 , 917905 (2022). 35799790 10.3389/fimmu.2022.917905 PMC9254618

569. Infectiohn Control Today. Spikevax booster’s efficacy falling behind omicron-targeting booster candidates. https://www.infectioncontroltoday.com/view/spikevax-booster-s-efficacy-falling-behind-omicron-targeting-booster-candidates (2022).

570. Halsey, G. Moderna investigational dual Flu/COVID-19 vaccine shows positive phase 1/2 results. Patient Care . 5 , NA-NA (2023).

571. Knöchel C Hefner G Stiehl T Schmidbauer W Elevated clozapine blood concentrations after second COVID-19 vaccination with Spikevax (COVID-19 vaccine Moderna) J. Clin. Psychopharmacol. 2022 42 317 320 10.1097/JCP.0000000000001522 35091524 PMC9042212 Knöchel, C., Hefner, G., Stiehl, T. & Schmidbauer, W. Elevated clozapine blood concentrations after second COVID-19 vaccination with Spikevax (COVID-19 vaccine Moderna). J. Clin. Psychopharmacol. 42 , 317–320 (2022). 35091524 10.1097/JCP.0000000000001522 PMC9042212

572. Kralickova P Immunogenicity and safety of the spikevax®(Moderna) mRNA SARS-CoV-2 vaccine in patients with primary humoral immunodeficiency Int. Arch. Allergy Immunol. 2022 183 1297 1310 10.1159/000526375 36202084 Kralickova, P. et al. Immunogenicity and safety of the spikevax®(Moderna) mRNA SARS-CoV-2 vaccine in patients with primary humoral immunodeficiency. Int. Arch. Allergy Immunol. 183 , 1297–1310 (2022). 36202084 10.1159/000526375

573. Infection Control Today. Moderna’s vaccine showing robust response against 4 influenza strains. https://www.infectioncontroltoday.com/view/moderna-s-vaccine-showing-robust-response-against-4-influenza-strains (2023).

574. Reynolds L Dewey C Asfour G Little M Vaccine efficacy against SARS-CoV-2 for Pfizer BioNTech, Moderna, and AstraZeneca vaccines: a systematic review Front. Public Health 2023 11 1229716 10.3389/fpubh.2023.1229716 37942238 PMC10628441 Reynolds, L., Dewey, C., Asfour, G. & Little, M. Vaccine efficacy against SARS-CoV-2 for Pfizer BioNTech, Moderna, and AstraZeneca vaccines: a systematic review. Front. Public Health 11 , 1229716 (2023). 37942238 10.3389/fpubh.2023.1229716 PMC10628441

575. Stanisic DI Good MF Malaria vaccines: progress to date Biodrugs. 2023 37 737 756 10.1007/s40259-023-00623-4 37728713 PMC10581939 Stanisic, D. I. & Good, M. F. Malaria vaccines: progress to date. Biodrugs. 37 , 737–756 (2023). 37728713 10.1007/s40259-023-00623-4 PMC10581939

576. Wilby KJ Lau TT Gilchrist SE Ensom MH Mosquirix (RTS, S): a novel vaccine for the prevention of Plasmodium falciparum malaria Ann. Pharmacother. 2012 46 384 393 10.1345/aph.1AQ634 22408046 Wilby, K. J., Lau, T. T., Gilchrist, S. E. & Ensom, M. H. Mosquirix (RTS, S): a novel vaccine for the prevention of Plasmodium falciparum malaria. Ann. Pharmacother. 46 , 384–393 (2012). 22408046 10.1345/aph.1AQ634

577. Keating GM RTS, S/AS01 malaria vaccine (Mosquirix™): a guide to its use Drugs Ther. Perspect. 2016 32 143 148 10.1007/s40267-016-0290-9 Keating, G. M. RTS, S/AS01 malaria vaccine (Mosquirix™): a guide to its use. Drugs Ther. Perspect. 32 , 143–148 (2016).

578. Sahoo JP Mishra P Sahoo S Samal KC Historic moment: WHO approves the world’s first malaria vaccine “Mosquirix or RTS, S/AS01” Biotica Res. Today 2021 3 892 896 Sahoo, J. P., Mishra, P., Sahoo, S. & Samal, K. C. Historic moment: WHO approves the world’s first malaria vaccine “Mosquirix or RTS, S/AS01”. Biotica Res. Today 3 , 892–896 (2021).

579. Syed YY RTS, S/AS01 malaria vaccine (Mosquirix®): a profile of its use Drugs Ther. Perspect. 2022 38 373 381 10.1007/s40267-022-00937-3 36093265 PMC9449949 Syed, Y. Y. RTS, S/AS01 malaria vaccine (Mosquirix®): a profile of its use. Drugs Ther. Perspect. 38 , 373–381 (2022). 36093265 10.1007/s40267-022-00937-3 PMC9449949

580. Nadeem AY Mosquirix™ RTS, S/AS01 vaccine development, immunogenicity, and efficacy Vaccines. 2022 10 713 10.3390/vaccines10050713 35632469 PMC9143879 Nadeem, A. Y. et al. Mosquirix™ RTS, S/AS01 vaccine development, immunogenicity, and efficacy. Vaccines. 10 , 713 (2022). 35632469 10.3390/vaccines10050713 PMC9143879

581. Laurens MB RTS, S/AS01 vaccine (Mosquirix™): an overview Hum. Vaccin. Immunother. 2020 16 480 489 10.1080/21645515.2019.1669415 31545128 PMC7227679 Laurens, M. B. RTS, S/AS01 vaccine (Mosquirix™): an overview. Hum. Vaccin. Immunother. 16 , 480–489 (2020). 31545128 10.1080/21645515.2019.1669415 PMC7227679

582. Vaggelas A Seimetz D Expediting drug development: FDA’s new regenerative medicine advanced therapy designation Ther. Innov. Regul. Sci. 2019 53 364 373 10.1177/2168479018779373 29895180 Vaggelas, A. & Seimetz, D. Expediting drug development: FDA’s new regenerative medicine advanced therapy designation. Ther. Innov. Regul. Sci. 53 , 364–373 (2019). 29895180 10.1177/2168479018779373

583. Food & Drug Law Institue. FDA sharpens its focus on regenerative medicine regulation. https://www.fdli.org/2017/08/fda-sharpens-focus-regenerative-medicine-regulation (2017).

584. Mendicino M Current state of US Food and Drug Administration regulation for cellular and gene therapy products: potential cures on the horizon Cytotherapy. 2019 21 699 724 10.1016/j.jcyt.2019.04.002 31196820 Mendicino, M. et al. Current state of US Food and Drug Administration regulation for cellular and gene therapy products: potential cures on the horizon. Cytotherapy. 21 , 699–724 (2019). 31196820 10.1016/j.jcyt.2019.04.002

585. Lythgoe MP Middleton P Comparison of COVID-19 vaccine approvals at the US Food and Drug administration, European Medicines Agency, and health Canada JAMA Netw. Open 2021 4 e2114531 e2114531 10.1001/jamanetworkopen.2021.14531 34170306 PMC8233699 Lythgoe, M. P. & Middleton, P. Comparison of COVID-19 vaccine approvals at the US Food and Drug administration, European Medicines Agency, and health Canada. JAMA Netw. Open 4 , e2114531–e2114531 (2021). 34170306 10.1001/jamanetworkopen.2021.14531 PMC8233699

586. Fortner A Schumacher D First COVID-19 vaccines receiving the US FDA and EMA emergency use authorization Discoveries 2021 9 e122 10.15190/d.2021.1 33969180 PMC8101362 Fortner, A. & Schumacher, D. First COVID-19 vaccines receiving the US FDA and EMA emergency use authorization. Discoveries 9 , e122 (2021). 33969180 10.15190/d.2021.1 PMC8101362

587. Ballentine, C. Sulfanilamide disaster. FDA Consum . 5 , NA-NA (1981).

588. Woolf, A. D. in History of Modern Clinical Toxicology 139–148 (Elsevier, 2022).

589. Moghissi A Regulatory science education: the need for generalization J. Regul. Sci. 2020 8 1 7 Moghissi, A. et al. Regulatory science education: the need for generalization. J. Regul. Sci. 8 , 1–7 (2020).

590. Hamburg MA Sharfstein JM The FDA as a public health agency N. Engl. J. Med. 2009 360 2493 2495 10.1056/NEJMp0903764 19470577 Hamburg, M. A. & Sharfstein, J. M. The FDA as a public health agency. N. Engl. J. Med. 360 , 2493–2495 (2009). 19470577 10.1056/NEJMp0903764

591. Moghissi AA Calderone RA McBride DK Jaeger L Innovation in regulatory science: metrics for evaluation of regulatory science claims based on best available regulatory science J. Regul. Sci. 2017 5 50 58 Moghissi, A. A., Calderone, R. A., McBride, D. K. & Jaeger, L. Innovation in regulatory science: metrics for evaluation of regulatory science claims based on best available regulatory science. J. Regul. Sci. 5 , 50–58 (2017).

592. Lee M Ly H Möller CC Ringel MS Innovation in regulatory science is meeting evolution of clinical evidence generation Clin. Pharmacol. Ther. 2019 105 886 898 10.1002/cpt.1354 30636288 PMC6593618 Lee, M., Ly, H., Möller, C. C. & Ringel, M. S. Innovation in regulatory science is meeting evolution of clinical evidence generation. Clin. Pharmacol. Ther. 105 , 886–898 (2019). 30636288 10.1002/cpt.1354 PMC6593618

593. Zhao J Strategies and prospects for the construction of an excellent regulatory system for traditional Chinese medicine CFDA Mag 2024 2 4 15 Zhao, J. Strategies and prospects for the construction of an excellent regulatory system for traditional Chinese medicine. CFDA Mag 2 , 4–15 (2024).

594. Zhao J Regulatory science of traditional Chinese medicine: contribute to a higher level of scientific supervision of traditional Chinese medicine J. Chin. Pharm. Sci. 2023 58 749 761 Zhao, J. Regulatory science of traditional Chinese medicine: contribute to a higher level of scientific supervision of traditional Chinese medicine. J. Chin. Pharm. Sci. 58 , 749–761 (2023).

595. Zhao J Huang L Regulatory science of traditional Chinese medicine: an emerging convergence science in development Bull. Natl. Nat. Sci. Found. China 2024 38 396 405 Zhao, J. & Huang, L. Regulatory science of traditional Chinese medicine: an emerging convergence science in development. Bull. Natl. Nat. Sci. Found. China 38 , 396–405 (2024).

596. Yao R He C Xiao P ‘Food and medicine Continuum’in the East and West: old tradition and current regulation Chin. Herb. Med. 2023 15 6 14 36875443 10.1016/j.chmed.2022.12.002 PMC9975626 Yao, R., He, C. & Xiao, P. ‘Food and medicine Continuum’in the East and West: old tradition and current regulation. Chin. Herb. Med. 15 , 6–14 (2023). 36875443 10.1016/j.chmed.2022.12.002 PMC9975626

597. NMPA, T. Notice on the Issuance of the Pilot Program for Optimizing the Review and Approval of Clinical Trials for Innovative Drugs by the National Medical Products Administration < https://www.gov.cn/zhengce/zhengceku/202408/content_6965736.htm > (2024).

598. Zhou S Yang Z Song Y Huang G Reform and development of evaluation and approval of innovative drugs in China: a case study of anti-tumor drugs CFDA Mag. 2024 06 4 15 Zhou, S., Yang, Z., Song, Y. & Huang, G. Reform and development of evaluation and approval of innovative drugs in China: a case study of anti-tumor drugs. CFDA Mag. 06 , 4–15 (2024).

599. Huang X Cao X Innovative drugs bring continuous benefits to cancer patients Innov. Life 2023 1 100043 10.59717/j.xinn-life.2023.100043 Huang, X. & Cao, X. Innovative drugs bring continuous benefits to cancer patients. Innov. Life 1 , 100043 (2023).

600. Benjamin DJ Prasad V Lythgoe MP FDA decisions on new oncological drugs Lancet Oncol. 2022 23 585 586 10.1016/S1470-2045(22)00135-8 35489341 Benjamin, D. J., Prasad, V. & Lythgoe, M. P. FDA decisions on new oncological drugs. Lancet Oncol. 23 , 585–586 (2022). 35489341 10.1016/S1470-2045(22)00135-8

601. Li G FDA decisions on new oncological drugs Lancet Oncol 2022 23 583 585 10.1016/S1470-2045(22)00136-X 35489340 Li, G. et al. FDA decisions on new oncological drugs. Lancet Oncol 23 , 583–585 (2022). 35489340 10.1016/S1470-2045(22)00136-X

602. Lythgoe MP Sullivan R Approved anti-PD-1 monoclonal antibodies in China: a bridge too far for US approval Eur. J. Cancer 2022 169 103 105 10.1016/j.ejca.2022.03.030 35533585 Lythgoe, M. P. & Sullivan, R. Approved anti-PD-1 monoclonal antibodies in China: a bridge too far for US approval. Eur. J. Cancer 169 , 103–105 (2022). 35533585 10.1016/j.ejca.2022.03.030

603. BeiGene. TEVIMBRA approved in U.S. for first-line treatment of gastric and gastroesophageal junction cancers in combination with chemotherapy , < https://ir.beigene.com/news/tevimbra-approved-in-u-s-for-first-line-treatment-of-gastric-and-gastroesophageal-junction-cancers-in-combination/cedb475b-fcfe-47a4-8afe-8a501d9cf849/ > (2024).

604. Lythgoe MP The rise of immuno-oncology in China: a challenge to western dominance? Lancet Oncol. 2023 24 439 441 10.1016/S1470-2045(23)00026-8 37142369 Lythgoe, M. P. et al. The rise of immuno-oncology in China: a challenge to western dominance? Lancet Oncol. 24 , 439–441 (2023). 37142369 10.1016/S1470-2045(23)00026-8

605. Zhang, Y. et al. Overall survival benefits of cancer drugs approved in China from 2005 to 2020. JAMA Netw. Open 5 , e2225973–e2225973 (2022). 10.1001/jamanetworkopen.2022.25973 PMC9366546 35947385

606. FDA. Fast track, breakthrough therapy, accelerated approval, priority review, < https://www.fda.gov/patients/learn-about-drug-and-device-approvals/fast-track-breakthrough-therapy-accelerated-approval-priority-review > (2023). 10.1007/s10198-023-01639-x PMC11283430 37962724

607. Piachaud-Moustakis, B. Improvements to EMA’s PRIME designation scheme. Pharm. Tech. Euro. 35 , 7–8 (2023).

608. Ozaki A Japan’s drug regulation framework: aiming for better health or bigger profits? Int. J. Health Policy Manag. 2020 10 47 10.34172/ijhpm.2020.56 PMC7947705 32610799 Ozaki, A. et al. Japan’s drug regulation framework: aiming for better health or bigger profits? Int. J. Health Policy Manag. 10 , 47 (2020). 10.34172/ijhpm.2020.56 PMC7947705 32610799

609. Kajiwara E Shikano M Considerations and regulatory challenges for innovative medicines in expedited approval programs: breakthrough therapy and Sakigake designation Ther. Innov. Regul. Sci. 2020 54 814 820 10.1007/s43441-019-00019-z 32557300 Kajiwara, E. & Shikano, M. Considerations and regulatory challenges for innovative medicines in expedited approval programs: breakthrough therapy and Sakigake designation. Ther. Innov. Regul. Sci. 54 , 814–820 (2020). 32557300 10.1007/s43441-019-00019-z

610. Muensterman ET Luo Y Parker JM Breakthrough therapy, PRIME and Sakigake: a comparison between neuroscience and oncology in obtaining preferred regulatory status Ther. Innov. Regul. Sci. 2020 54 658 666 10.1007/s43441-019-00100-7 33301147 Muensterman, E. T., Luo, Y. & Parker, J. M. Breakthrough therapy, PRIME and Sakigake: a comparison between neuroscience and oncology in obtaining preferred regulatory status. Ther. Innov. Regul. Sci. 54 , 658–666 (2020). 33301147 10.1007/s43441-019-00100-7

611. Maruyama Y Regulatory issues: PMDA–review of sakigake designation products: oncolytic virus therapy with delytact injection (Teserpaturev) for Malignant glioma Oncologist 2023 28 664 670 10.1093/oncolo/oyad041 36917020 PMC10400161 Maruyama, Y. et al. Regulatory issues: PMDA–review of sakigake designation products: oncolytic virus therapy with delytact injection (Teserpaturev) for Malignant glioma. Oncologist 28 , 664–670 (2023). 36917020 10.1093/oncolo/oyad041 PMC10400161

612. Nagasaka, M. & Ou, S.-h. I. ORIENT-31 as the Sakigake “Charging Samurai” born of IMpower150 but will MARIPOSA-2 IMPRESS in the “Meiji Modernization” of post-3G EGFR TKI progression? Lung Cancer. 13 , 13–21 (2022). 10.2147/LCTT.S355503 PMC8976558 35378922

613. Tanaka M Achievements and challenges of the Sakigake designation system in Japan Br. J. Clin. Pharmacol. 2021 87 4027 4035 10.1111/bcp.14807 33694268 Tanaka, M. et al. Achievements and challenges of the Sakigake designation system in Japan. Br. J. Clin. Pharmacol. 87 , 4027–4035 (2021). 33694268 10.1111/bcp.14807

614. Forbes. U.S., China advance discussions on pact to accelerate cancer drug trials < https://www.forbes.com/sites/russellflannery/2022/12/17/us-china-advance-discussions-on-pact-to-accelerate-cancer-drug-trials/ > (2022).

615. Xinhua. Chinese-made innovative drugs hit 100-billion-yuan market scale: report < https://english.news.cn/20241116/5001bddba977483b9b50a2046bcb788b/c.html?utm_source=chatgpt.com > (2024).

616. CHINADAILY. Chinese-made new drugs big hit overseas < https://global.chinadaily.com.cn/a/202407/24/WS66a062c7a31095c51c50fa01.html?utm_source=chatgpt.com > (2024).

617. Ma J Phase I study of the anti-BTLA antibody tifcemalimab as a single agent or in combination with toripalimab in relapsed/refractory lymphomas Blood 2022 140 3716 3717 10.1182/blood-2022-157497 Ma, J. et al. Phase I study of the anti-BTLA antibody tifcemalimab as a single agent or in combination with toripalimab in relapsed/refractory lymphomas. Blood 140 , 3716–3717 (2022).

618. Keam SJ Toripalimab: first global approval Drugs 2019 79 573 578 10.1007/s40265-019-01076-2 30805896 Keam, S. J. Toripalimab: first global approval. Drugs 79 , 573–578 (2019). 30805896 10.1007/s40265-019-01076-2

619. Wang J Final progression-free survival, interim overall survival, and biomarker analyses of CHOICE-01: a phase III study of toripalimab versus placebo in combination with first-line chemotherapy for advanced NSCLC without EGFR/ALK mutations J. Clin. Oncol. 2022 40 362936 362936 10.1200/JCO.2022.40.36_suppl.362936 Wang, J. et al. Final progression-free survival, interim overall survival, and biomarker analyses of CHOICE-01: a phase III study of toripalimab versus placebo in combination with first-line chemotherapy for advanced NSCLC without EGFR/ALK mutations. J. Clin. Oncol. 40 , 362936–362936 (2022).

620. Jiang Z TORCHLIGHT: a randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel (nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC) J. Hematol. Oncol. 2023 41 LBA1013 Jiang, Z. et al. TORCHLIGHT: a randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel (nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC). J. Hematol. Oncol. 41 , LBA1013 (2023).

621. Ren C Clinical response and biomarker analysis of a phase II basket trial of toripalimab, a PD-1 mAb in combination with standard chemotherapy as a first-line treatment for patients with solid tumors J. Clin. Oncol. 2020 38 e15083 e15083 10.1200/JCO.2020.38.15_suppl.e15083 Ren, C. et al. Clinical response and biomarker analysis of a phase II basket trial of toripalimab, a PD-1 mAb in combination with standard chemotherapy as a first-line treatment for patients with solid tumors. J. Clin. Oncol. 38 , e15083–e15083 (2020).

622. Wang J Final overall survival and biomarker analyses of CHOICE-01: a double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations J. Clin. Oncol. 2023 41 9003 9003 10.1200/JCO.2023.41.16_suppl.9003 Wang, J. et al. Final overall survival and biomarker analyses of CHOICE-01: a double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations. J. Clin. Oncol. 41 , 9003–9003 (2023).

623. Ren S A multi-center phase II study of toripalimab with chemotherapy in patients with EGFR mutant advanced NSCLC patients resistant to EGFR TKIs: efficacy and biomarker analysis J. Clin. Oncol. 2020 38 e21618 e21618 10.1200/JCO.2020.38.15_suppl.e21618 Ren, S. et al. A multi-center phase II study of toripalimab with chemotherapy in patients with EGFR mutant advanced NSCLC patients resistant to EGFR TKIs: efficacy and biomarker analysis. J. Clin. Oncol. 38 , e21618–e21618 (2020).

624. Wang J Final progression-free survival, interim overall survival, and biomarker analyses of CHOICE-01: a phase 3 study of toripalimab versus placebo in combination with first-line chemotherapy for advanced NSCLC without EGFR/ALK mutations J. Clin. Oncol. 2022 40 9028 9028 10.1200/JCO.2022.40.16_suppl.9028 Wang, J. et al. Final progression-free survival, interim overall survival, and biomarker analyses of CHOICE-01: a phase 3 study of toripalimab versus placebo in combination with first-line chemotherapy for advanced NSCLC without EGFR/ALK mutations. J. Clin. Oncol. 40 , 9028–9028 (2022).

625. Xu, R.-h. et al. JUPITER-02: randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC). J. Clin. Oncol . 39 , LBA2-LBA2 (2021).

626. Mai H-Q Abstract CT226: final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma Cancer Res. 2022 82 CT226 CT226 10.1158/1538-7445.AM2022-CT226 Mai, H.-Q. et al. Abstract CT226: final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma. Cancer Res. 82 , CT226–CT226 (2022).

627. Gao B 1284P Sitravatinib+ tislelizumab in patients with anti-PD-(L) 1 refractory/resistant metastatic NSCLC Ann. Oncol. 2021 32 S998 10.1016/j.annonc.2021.08.1886 Gao, B. et al. 1284P Sitravatinib+ tislelizumab in patients with anti-PD-(L) 1 refractory/resistant metastatic NSCLC. Ann. Oncol. 32 , S998 (2021).

628. Ye D Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma Cancer Sci. 2021 112 305 313 10.1111/cas.14681 33047430 PMC7780053 Ye, D. et al. Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma. Cancer Sci. 112 , 305–313 (2021). 33047430 10.1111/cas.14681 PMC7780053

629. Wang J 1264P Updated analysis of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment of advanced squamous non-small cell lung cancer (SQ NSCLC) Ann. Oncol. 2020 31 S817 10.1016/j.annonc.2020.08.1578 Wang, J. et al. 1264P Updated analysis of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment of advanced squamous non-small cell lung cancer (SQ NSCLC). Ann. Oncol. 31 , S817 (2020).

630. Yang Y 121O rationale 309: a randomized, global, double-blind, phase III trial of tislelizumab (TIS) vs placebo, plus gemcitabine+ cisplatin (GP), as first-line treatment for recurrent/metastatic nasopharyngeal cancer (RM-NPC) Ann. Oncol. 2021 32 S1430 10.1016/j.annonc.2021.10.140 Yang, Y. et al. 121O rationale 309: a randomized, global, double-blind, phase III trial of tislelizumab (TIS) vs placebo, plus gemcitabine+ cisplatin (GP), as first-line treatment for recurrent/metastatic nasopharyngeal cancer (RM-NPC). Ann. Oncol. 32 , S1430 (2021).

631. Liu S-Y Wu Y-L Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC) Expert Opin. Investig. Drugs 2020 29 1355 1364 10.1080/13543784.2020.1833857 33044117 Liu, S.-Y. & Wu, Y.-L. Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC). Expert Opin. Investig. Drugs 29 , 1355–1364 (2020). 33044117 10.1080/13543784.2020.1833857

632. Lee A Keam SJ Tislelizumab: first approval Drugs. 2020 80 617 624 10.1007/s40265-020-01286-z 32185681 Lee, A. & Keam, S. J. Tislelizumab: first approval. Drugs. 80 , 617–624 (2020). 32185681 10.1007/s40265-020-01286-z

633. Sandhu S Tislelizumab, an anti-PD-1 antibody, in patients with urothelial carcinoma (UC): results from an ongoing phase I/II study Ann. Oncol. 2018 29 x28 10.1093/annonc/mdy487.007 Sandhu, S. et al. Tislelizumab, an anti-PD-1 antibody, in patients with urothelial carcinoma (UC): results from an ongoing phase I/II study. Ann. Oncol. 29 , x28 (2018).

634. Barlow P P2. 04-33 single-agent tislelizumab, an anti-PD-1 antibody: results from a phase 1 expansion cohort in NSCLC patients J. Thorac. Oncol. 2019 14 S721 10.1016/j.jtho.2019.08.1538 Barlow, P. et al. P2. 04-33 single-agent tislelizumab, an anti-PD-1 antibody: results from a phase 1 expansion cohort in NSCLC patients. J. Thorac. Oncol. 14 , S721 (2019).

635. Ducreux M O-1 Results from a global phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with unresectable hepatocellular carcinoma Ann. Oncol. 2021 32 S217 10.1016/j.annonc.2021.05.005 Ducreux, M. et al. O-1 Results from a global phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with unresectable hepatocellular carcinoma. Ann. Oncol. 32 , S217 (2021).

636. Deva S A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors Ann. Oncol. 2018 29 x24 x25 10.1093/annonc/mdy487.042 Deva, S. et al. A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors. Ann. Oncol. 29 , x24–x25 (2018).

637. Gong, J. et al. Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial. Cancer Immunol. Immunother . 71 ,1897–1908 (2022). 10.1007/s00262-021-03102-3 PMC9293819 34984540

638. Huang H GEMSTONE-201: preplanned primary analysis of a multicenter, single-arm, phase 2 study of sugemalimab (suge) in patients (pts) with relapsed or refractory extranodal natural killer/T cell lymphoma (R/R ENKTL) J. Clin. Oncol. 2022 40 7501 7501 10.1200/JCO.2022.40.16_suppl.7501 Huang, H. et al. GEMSTONE-201: preplanned primary analysis of a multicenter, single-arm, phase 2 study of sugemalimab (suge) in patients (pts) with relapsed or refractory extranodal natural killer/T cell lymphoma (R/R ENKTL). J. Clin. Oncol. 40 , 7501–7501 (2022).

639. Huang H Sugemalimab monotherapy for patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (GEMSTONE-201): results from a single-arm, multicenter, phase II study J. Clin. Oncol. 2023 41 3032 3041 10.1200/JCO.22.02367 36996373 PMC10414714 Huang, H. et al. Sugemalimab monotherapy for patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (GEMSTONE-201): results from a single-arm, multicenter, phase II study. J. Clin. Oncol. 41 , 3032–3041 (2023). 36996373 10.1200/JCO.22.02367 PMC10414714

640. Zhou C Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial Lancet Oncol 2022 23 220 233 10.1016/S1470-2045(21)00650-1 35038432 Zhou, C. et al. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial. Lancet Oncol 23 , 220–233 (2022). 35038432 10.1016/S1470-2045(21)00650-1

641. Zhou Q Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial Lancet Oncol 2022 23 209 219 10.1016/S1470-2045(21)00630-6 35038429 Zhou, Q. et al. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 23 , 209–219 (2022). 35038429 10.1016/S1470-2045(21)00630-6

642. Dhillon S Duggan S Sugemalimab: first approval Drugs. 2022 82 593 599 10.1007/s40265-022-01693-4 35298827 Dhillon, S. & Duggan, S. Sugemalimab: first approval. Drugs. 82 , 593–599 (2022). 35298827 10.1007/s40265-022-01693-4

643. Ai J Preclinical evaluation of SCC244 (Glumetinib), a novel, potent, and highly selective inhibitor of c-Met in MET-dependent cancer models Mol. Cancer Ther. 2018 17 751 762 10.1158/1535-7163.MCT-17-0368 29237805 Ai, J. et al. Preclinical evaluation of SCC244 (Glumetinib), a novel, potent, and highly selective inhibitor of c-Met in MET-dependent cancer models. Mol. Cancer Ther. 17 , 751–762 (2018). 29237805 10.1158/1535-7163.MCT-17-0368

644. Ge Q Zhang X Kaitin KI Shao L Development of Chinese innovative drugs in the USA Nat. Rev. Drug Discov. 2024 23 421 423 10.1038/d41573-024-00079-3 38720006 Ge, Q., Zhang, X., Kaitin, K. I. & Shao, L. Development of Chinese innovative drugs in the USA. Nat. Rev. Drug Discov. 23 , 421–423 (2024). 38720006 10.1038/d41573-024-00079-3

645. BD, M. 2023 China Pharmaceutical Licensing BD Transaction Annual Report < https://www.yaopower.com/static/public/2024-03/f7d863c0c5439a364c9df91d839f6084.pdf > (2024).

646. Network, C. F. a. D. Domestic innovative drugs set off a going global wave < http://m.cnpharm.com/c/2024-04-03/1041294.shtml > (2024).